<?xml version="1.0"?>
<rdf:RDF xmlns="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#"
     xml:base="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg"
     xmlns:owl="http://www.w3.org/2002/07/owl#"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:xml="http://www.w3.org/XML/1998/namespace"
     xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
     xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
     xmlns:ontologia_tfg="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#">
    <owl:Ontology rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg"/>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Annotation properties
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#code -->

    <owl:AnnotationProperty rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#code">
        <rdfs:comment>CODE</rdfs:comment>
    </owl:AnnotationProperty>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#conceptInSubset -->

    <owl:AnnotationProperty rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#conceptInSubset">
        <rdfs:comment>CONCEPT_IN_SUBSET</rdfs:comment>
    </owl:AnnotationProperty>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#definition -->

    <owl:AnnotationProperty rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#definition">
        <rdfs:label>DEF</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#name -->

    <owl:AnnotationProperty rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#name">
        <rdfs:label>Preferred_Name</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#semanticType -->

    <owl:AnnotationProperty rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#semanticType">
        <rdfs:label>SEM_TYPE</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#synonym -->

    <owl:AnnotationProperty rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#synonym">
        <rdfs:label>SYN</rdfs:label>
    </owl:AnnotationProperty>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Classes
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C102875 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C102875">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67502"/>
        <code>C102875</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation of nanoparticles encapsulating the hydrochloride salt form of the anthracycline antibiotic doxorubicin, with potential antitumor activity. Upon intravenous administration, doxorubicin intercalates DNA, interferes with the activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells.</definition>
        <name>Nanoparticle-encapsulated Doxorubicin Hydrochloride</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>BA-003</synonym>
        <synonym>Doxorubicin Transdrug</synonym>
        <synonym>Livatag</synonym>
        <synonym>Nanoparticle-encapsulated Doxorubicin Hydrochloride</synonym>
        <rdfs:label>Nanoparticle-encapsulated Doxorubicin Hydrochloride</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C105613 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C105613">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1557"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2150"/>
        <code>C105613</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.</definition>
        <name>Gemcitabine Hydrochloride Emulsion</name>
        <semanticType>Nucleic Acid, Nucleoside, or Nucleotide</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>D07001-F4</synonym>
        <synonym>Gemcitabine Hydrochloride Emulsion</synonym>
        <rdfs:label>Gemcitabine Hydrochloride Emulsion</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C111688 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C111688">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1752"/>
        <code>C111688</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.</definition>
        <name>Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101</name>
        <semanticType>Immunologic Factor</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101</synonym>
        <synonym>PDS0101</synonym>
        <synonym>mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine</synonym>
        <rdfs:label>Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C112883 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C112883">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20401"/>
        <code>C112883</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any monoclonal antibody directed against the cell surface glycoprotein CD3.</definition>
        <name>Anti-CD3 Monoclonal Antibody</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <synonym>Anti-CD3 Monoclonal Antibody</synonym>
        <rdfs:label>Anti-CD3 Monoclonal Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C113175 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C113175">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1450"/>
        <code>C113175</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>Polymeric micellar nanoparticles containing diaminocyclohexane platinum (DACH-platin or DACH-Pt) with potential antineoplastic activity. DACH-platin micelle NC-4016 is prepared through the formation of a polymer-metal complex between DACH-platin and the polyethylene glycol-poly (glutamic acid) block copolymer, PEG-P(Glu). DACH-platin, an active metabolite of the platinum-based antineoplastic agent oxaliplatin, is highly hydrophobic and toxic when administered systemically. The use of polymeric micelles incorporating DACH-platin may both increase cell permeability and enhance the retention of the agent. This allows an extended half-life in the blood circulation and a selective and high accumulation of DACH-platin at tumor sites. This results in increased anticancer efficacy while reducing side effects due to DACH-platin toxicity. Upon intravenous administration and internalization by tumor cells, DACH-platin binds to and causes both inter- and intra-strand cross-links in DNA, forming platinum adducts and triggering tumor cell apoptosis.</definition>
        <name>DACH-Platin Micelle NC-4016</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>DACH-Platin Micelle NC-4016</synonym>
        <synonym>DACH-Pt/m NC-4016</synonym>
        <synonym>Dach-Platin Micelle NC-4016</synonym>
        <synonym>Diaminocyclohexane Platinum Micelle NC-4016</synonym>
        <synonym>NC-4016</synonym>
        <rdfs:label>DACH-Platin Micelle NC-4016</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C115104 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C115104">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1966"/>
        <code>C115104</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides, with potential use as a tumor-selective fluorescent imaging agent. Upon intradermal administration of the fluorescent cRGDY PEG-Cy5.5 C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon intraoperative fluorescence imaging, alphaVbeta3-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.</definition>
        <name>Fluorescent cRGDY PEG-Cy5.5 C Dots</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Fluorescent cRGDY PEG-Cy5.5 C Dots</synonym>
        <synonym>cRGDY-PEG-Cy5.5-C Dots</synonym>
        <rdfs:label>Fluorescent cRGDY PEG-Cy5.5 C Dots</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C115108 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C115108">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C115108</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.</definition>
        <name>MYC-targeting siRNA DCR-MYC</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>DCR-M1711</synonym>
        <synonym>DCR-MYC</synonym>
        <synonym>MYC-targeting siRNA DCR-MYC</synonym>
        <rdfs:label>MYC-targeting siRNA DCR-MYC</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C115986 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C115986">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1937"/>
        <code>C115986</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation containing carbon, with both a mean size of 150 nm, and potential use as a stain for lymph node draining. Upon injection of the carbon nanoparticles at the tumor site, these nanoparticles travel to regional lymph nodes and stain the lymph nodes black due to the presence of the carbon. This may allow for a more precise surgical removal of tumor-draining lymph nodes.</definition>
        <name>Carbon Nanoparticle-based Formulation</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>CNP</synonym>
        <synonym>Carbon Nanoparticle-based Formulation</synonym>
        <synonym>Carbon Nanoparticles</synonym>
        <rdfs:label>Carbon Nanoparticle-based Formulation</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C116792 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C116792">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C116792</code>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR) encapsulated in lipids, which has potential use in the treatment of TTR-mediated amyloidosis (ATTR). Upon intravenous administration of patisiran, the lipid formulation promotes the uptake by cells. The siRNAs bind to TTR mRNAs, which may result in the inhibition of both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.</definition>
        <name>Patisiran</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ALN-18328</synonym>
        <synonym>ALN-TTR02</synonym>
        <synonym>PATISIRAN</synonym>
        <synonym>Patisiran</synonym>
        <synonym>RNAi Therapeutic-targeting Transthyretin ALN-TTR02</synonym>
        <rdfs:label>Patisiran</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C116869 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C116869">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C116869</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor&apos;s vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel&apos;s efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.</definition>
        <name>Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>MNK-010</synonym>
        <synonym>MP-3549-1</synonym>
        <synonym>Pegylated Liposomal Docetaxel Prodrug MNK-010</synonym>
        <synonym>Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010</synonym>
        <rdfs:label>Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C116890 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C116890">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1904"/>
        <code>C116890</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle albumin-bound formulation of a thiocolchicine dimer, an inhibitor of both microtubule and topoisomerase I (TOP1), with antineoplastic and vascular disrupting activities. Upon administration of nanoparticle albumin-bound thiocolchicine dimer nab-5404, this agent binds to tubulin and inhibits its polymerization, which blocks mitotic spindle formation and leads to cell cycle arrest and tumor endothelial cell apoptosis. This disrupts the tumor vasculature and leads to tumor necrosis. In addition, nab-5404 binds to topoisomerase I (TOPI) and inhibits its activity. This results in the inhibition of the repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. The nanoparticle albumin-based formulation permits the albumin-mediated endocytosis of the thiocolchicine dimer by tumor cells and endothelial cells.</definition>
        <name>Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ABI-011</synonym>
        <synonym>IDN 5404</synonym>
        <synonym>IDN-5404</synonym>
        <synonym>NTB-011</synonym>
        <synonym>Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404</synonym>
        <synonym>nab-5404</synonym>
        <synonym>nab-Thiocolchicine Dimer</synonym>
        <rdfs:label>Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C117733 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C117733">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C26170"/>
        <code>C117733</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>Orally available, nanobubble-based, electrokinetically modified water (EMW) composed of reverse osmosis water where the minerals calcium chloride, magnesium chloride, and potassium bicarbonate have been added and with an increased oxygen concentration compared to normal water. Upon consumption, the EMW may have a beneficial effect on fatigue. This water may protect muscle cells against damage and may improve skeletal muscle function. The water is pretreated with strong, controlled turbulence to create charge-stabilized nanostructures.</definition>
        <name>Electrokinetically Modified Water</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>EMW</synonym>
        <synonym>Electro-kinetically Altered Beverage</synonym>
        <synonym>Electrokinetically Modified Water</synonym>
        <rdfs:label>Electrokinetically Modified Water</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C118648 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C118648">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C118648</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based suspension containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intraperitoneal administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division. The nanoparticle-based formulation is devoid of toxic solvents, such as cremophor; therefore, this agent has fewer side effects than the standard, solvent-based paclitaxel formulation.</definition>
        <name>Nanoparticle-based Paclitaxel Suspension</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Nanoparticle-based Paclitaxel Suspension</synonym>
        <synonym>Nanotax</synonym>
        <rdfs:label>Nanoparticle-based Paclitaxel Suspension</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C121214 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C121214">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163952"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2189"/>
        <code>C121214</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation composed of a microRNA 16 (miR-16) mimic, a double-stranded, 23 base pair, synthetic RNA molecule, encapsulated in nonliving bacterial minicells and coated with anti-epidermal growth factor receptor (EGFR) antibodies, with potential antineoplastic activity. Upon intravenous administration and subsequent transfection, nanocell-encapsulated miR-16-based microRNA mimic targets EGFR-expressing tumor cells and facilitates the restoration of expression of the miR-16 family. This leads to the downregulation of the expression of tumor promoting genes and the inhibition of tumor cell growth. In addition, restoration of miR-16 expression sensitizes the tumor cell to certain chemotherapeutic agents. miR-16, a family of microRNAs, is critical to the regulation of gene expression and appears to have a tumor suppressor function; its expression is downregulated in various cancer cell types.</definition>
        <name>Nanocell-encapsulated miR-16-based microRNA Mimic</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Nanocell-encapsulated miR-16-based microRNA Mimic</synonym>
        <synonym>TargomiRs</synonym>
        <rdfs:label>Nanocell-encapsulated miR-16-based microRNA Mimic</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C121539 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C121539">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C121539</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation containing the poorly water-soluble, second-generation taxane analog docetaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel-loaded nanopharmaceutical CRLX301, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor&apos;s vasculature, while avoiding normal, healthy tissue. In turn, CRLX301 is taken up by the tumor cell via macropinocytosis. Subsequently, docetaxel is slowly released into the cytoplasm where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This prevents mitosis and results in cell death. Compared to the administration of docetaxel alone, this formulation is able to increase docetaxel&apos;s efficacy while avoiding systemic exposure, which minimizes its toxicity.</definition>
        <name>Docetaxel-loaded Nanopharmaceutical CRLX301</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CRLX301</synonym>
        <synonym>Docetaxel-loaded Nanopharmaceutical CRLX301</synonym>
        <rdfs:label>Docetaxel-loaded Nanopharmaceutical CRLX301</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C121961 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C121961">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C121961</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A polymeric nanoparticle (PNP) formulation containing the poorly water-soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel nanoparticle CPC634, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor&apos;s vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site, binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel&apos;s efficacy while avoiding systemic exposure, which minimizes its toxicity.</definition>
        <name>Docetaxel Nanoparticle CPC634</name>
        <semanticType>Organic Chemical</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CPC 634</synonym>
        <synonym>CPC-634</synonym>
        <synonym>CPC634</synonym>
        <synonym>CriPec (R) Docetaxel</synonym>
        <synonym>Docetaxel Nanoparticle CPC634</synonym>
        <synonym>Docetaxel containing CriPec (R) Nanoparticles</synonym>
        <synonym>Docetaxel-containing CriPec (R) Nanoparticles CPC634</synonym>
        <synonym>Nanoparticle-encapsulated Docetaxel CPC634</synonym>
        <rdfs:label>Docetaxel Nanoparticle CPC634</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C12218 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C12218">
        <owl:disjointWith rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1908"/>
        <owl:disjointWith rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20181"/>
        <owl:disjointWith rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43431"/>
        <code>C12218</code>
        <definition>A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified.</definition>
        <name>Chemotherapy Regimen or Agent Combination</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Chemotherapy Regimen or Agent Combination</synonym>
        <synonym>Combination Chemotherapy Regimen</synonym>
        <rdfs:label>Chemotherapy Regimen or Agent Combination</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C124053 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C124053">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C697"/>
        <code>C124053</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation containing the alkyl ester of bendamustine, a bifunctional mechlorethamine derivative, encapsulated in human serum albumin (HSA), with potential alkylating and antineoplastic activities. Upon administration of the alkyl ester bendamustine-containing nanoparticle formulation RXDX-107, the nanoparticle formulation permits high concentrations of the alkyl ester of bendamustine be localized at the tumor site. The modified bendamustine alkylates and crosslinks macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis.</definition>
        <name>Bendamustine-containing Nanoparticle-based Formulation RXDX-107</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>BENDAMUSTINE DODECYL ESTER</synonym>
        <synonym>Bendamustine-containing Nanoparticle-based Formulation RXDX-107</synonym>
        <synonym>CEP-40125</synonym>
        <synonym>RXDX 107</synonym>
        <synonym>RXDX-107</synonym>
        <rdfs:label>Bendamustine-containing Nanoparticle-based Formulation RXDX-107</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C126800 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C126800">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C126800</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid-based nanoparticle formulation composed of liposomes encapsulating a small oligonucleotide encoding a small activating RNA (saRNA) targeting the CCAAT enhancer binding protein alpha (CEBPA; C/EBP-a) gene, with potential antineoplastic activity. Although the exact mechanism of action through which saRNAs exert their effect(s) is still largely being investigated, it appears that, upon administration, the CEBPA-targeting saRNA MTL-CEBPA liposome targets and binds to a specific DNA regulatory target region, most likely the promoter region, for the CEBPA gene. This restores CEBPA gene transcription, and increases both CEBPA mRNA levels and protein expression. This in turn activates the expression of tumor suppressor genes and may halt proliferation of susceptible tumor cells. Specifically, upregulation of CEBPA in liver cells abrogates liver cancer cell proliferation, thereby prevents liver failure and normalizes liver function. CEBPA, a transcription factor that plays a key role in the regulation of the expression of genes with many functions, including those involved in cellular proliferation, metastasis and normal hepatocyte function, is found in many tissues, including liver cells, adipose tissue and myeloid cells. CEBPA is downregulated in certain types of cancer cells, such as liver cancer cells. saRNA is a short, double-stranded RNA that is structurally related to siRNAs; saRNA is most likely to bind to a target site on the promoter of the CEBPA gene and upregulates its gene expression.</definition>
        <name>CEBPA-targeting saRNA MTL-CEBPA Liposome</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CEBPA-targeting saRNA MTL-CEBPA Liposome</synonym>
        <synonym>MTL-501</synonym>
        <synonym>MTL-CEBPA</synonym>
        <rdfs:label>CEBPA-targeting saRNA MTL-CEBPA Liposome</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C128132 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C128132">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2124"/>
        <code>C128132</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides labeled with the positron-emitting radioisotope iodine I 124 via a tyrosine linker, with potential use in positron emission tomography (PET)/spiral computed tomography (CT) imaging. Upon intravenous administration of the radiolabeled iodine I 124-cRGDY-PEG-C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon PET/CT imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.</definition>
        <name>Iodine I 124-cRGDY-PEG-C Dots</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>124I-cRGDY-PEG-C Dots</synonym>
        <synonym>124I-cRGDY-PEG-dots</synonym>
        <synonym>124I-cRGDY-PEG-ylated Dots</synonym>
        <synonym>124I-cRGDY-PEG-ylated-C Dots</synonym>
        <synonym>I-124 cRGDY-PEG-C Dots</synonym>
        <synonym>I-124 cRGDY-PEG-dots</synonym>
        <synonym>Iodine I 124-cRGDY-PEG-C Dots</synonym>
        <synonym>Iodine I 124-cRGDY-PEG-dots</synonym>
        <rdfs:label>Iodine I 124-cRGDY-PEG-C Dots</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1283 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1283">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C1283</code>
        <name>Recombinant Cytokine</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Cytokines</synonym>
        <synonym>Recombinant Cytokine</synonym>
        <rdfs:label>Recombinant Cytokine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1291 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1291">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <code>C1291</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>Antisense Oligonucleotides, short synthetic segments of DNA or RNA, designed with a sequence complimentary to a specific mRNA that target and bind with mRNA, causing inhibition of translation or overexpression of the protein encoded by the mRNA.</definition>
        <name>Antisense Oligonucleotides</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <semanticType>Nucleic Acid, Nucleoside, or Nucleotide</semanticType>
        <synonym>AS ODNs</synonym>
        <synonym>Antisense Agents</synonym>
        <synonym>Antisense Oligonucleotides</synonym>
        <synonym>Gene Expression Inhibitor</synonym>
        <synonym>antisense agent</synonym>
        <synonym>antisense oligonucleotide</synonym>
        <rdfs:label>Antisense Oligonucleotides</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129651 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129651">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62358"/>
        <code>C129651</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A nanoparticle formulation composed of a polysiloxane-based inorganic matrix bound to cyclic chelates composed of the chelating agent DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently bound to the paramagnetic contrast enhancer gadolinium (Gd), a high-Z material, with potential use in enhancing diagnostic images upon magnetic resonance imaging (MRI) and potential radiosensitizing activity. Upon intravenous administration of polysiloxane matrix-gadolinium chelates-based nanoparticles, the nanoparticles extravasate to tumor sites due to the unique, hyperpermeable environment of the tumor vasculature. In addition, the small nanoparticles allow for deep penetration into the tumor, where they subsequently accumulate. Upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues are enhanced compared to unenhanced MRI. The ultra-small nanoparticles, less than 5 nm in diameter, allow for rapid renal clearance and reduced toxicity. Due to their magnetic properties, these nanoparticles make tumor cells more sensitive to radiation therapy.</definition>
        <name>Polysiloxane/Gadolinium Chelates-based Nanoparticles</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <semanticType>Organic Chemical</semanticType>
        <synonym>AGuIX</synonym>
        <synonym>AGuIX-NP</synonym>
        <synonym>Gadolinium-Based Nanoparticle</synonym>
        <synonym>Polysiloxane Matrix-gadolinium Chelates-based Nanoparticles</synonym>
        <synonym>Polysiloxane/Gadolinium Chelates-based Nanoparticles</synonym>
        <synonym>Polysiloxane/Gadolinium-DOTA Chelates-based Nanoparticles</synonym>
        <rdfs:label>Polysiloxane/Gadolinium Chelates-based Nanoparticles</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129819 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129819">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1446"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C129819</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>Any radiopharmaceutical agent that targets cancer cells and exerts an antineoplastic effect through radiotoxicity.</definition>
        <name>Antineoplastic Radiopharmaceutical Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-cancer Radiopharmaceutical</synonym>
        <synonym>Antineoplastic Radiopharmaceutical</synonym>
        <synonym>Antineoplastic Radiopharmaceutical Agent</synonym>
        <rdfs:label>Antineoplastic Radiopharmaceutical Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C129820</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>Any agent that is capable of modulating the immune system in order to exert antineoplastic effects. Antineoplastic immunomodulating agents either activate the immune system, restore certain immune system activators or abrogate immunosuppression.</definition>
        <name>Antineoplastic Immunomodulating Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-cancer Immunotherapeutic</synonym>
        <synonym>Antineoplastic BRM</synonym>
        <synonym>Antineoplastic Biological Response Modifier</synonym>
        <synonym>Antineoplastic Immunomodulating Agent</synonym>
        <synonym>Antineoplastic Immunotherapeutic</synonym>
        <rdfs:label>Antineoplastic Immunomodulating Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <code>C129821</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>Any agent that has a biological nature, such as agents containing living organisms, derived from living organisms, or comprised of ex vivo synthesized analogs of substances derived from living organisms, and that exerts antineoplastic activity.</definition>
        <name>Antineoplastic Biological Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-cancer Biological Agent</synonym>
        <synonym>Anticancer Biological</synonym>
        <synonym>Antineoplastic Biological</synonym>
        <synonym>Antineoplastic Biological Agent</synonym>
        <synonym>Antineoplastic Biotherapeutic</synonym>
        <rdfs:label>Antineoplastic Biological Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129822 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129822">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C129822</code>
        <definition>Any type of antibody that exerts antineoplastic activity.</definition>
        <name>Antineoplastic Antibody</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-cancer Antibody</synonym>
        <synonym>Anticancer Antibody</synonym>
        <synonym>Antineoplastic Ab</synonym>
        <synonym>Antineoplastic Antibody</synonym>
        <rdfs:label>Antineoplastic Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129824 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129824">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2189"/>
        <code>C129824</code>
        <definition>Any agent that inhibits the activity of any protein that is involved in cancer-specific pathways. An antineoplastic protein inhibitor is a specific cancer cell-targeting agent.</definition>
        <name>Antineoplastic Protein Inhibitor</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-cancer Protein Inhibitor</synonym>
        <synonym>Antineoplastic Protein Antagonist</synonym>
        <synonym>Antineoplastic Protein Inhibitor</synonym>
        <rdfs:label>Antineoplastic Protein Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129825 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129825">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129824"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C471"/>
        <code>C129825</code>
        <definition>Any agent that specifically inhibits a particular enzyme that is overexpressed and/or mutated in cancer cell pathways. Antineoplastic enzyme inhibitors specifically target tumor cells by targeting enzymes that are not normally expressed or are minimally expressed in normal, healthy tissues.</definition>
        <name>Antineoplastic Enzyme Inhibitor</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-cancer Enzyme Inhibitor</synonym>
        <synonym>Antineoplastic Enzyme Inhibitor</synonym>
        <rdfs:label>Antineoplastic Enzyme Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129839 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129839">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C129839</code>
        <definition>Any agent that directly targets the apoptotic pathway and has an antineoplastic effect.</definition>
        <name>Apoptotic Pathway-targeting Antineoplastic Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Apoptotic Pathway-targeting Antineoplastic Agent</synonym>
        <synonym>Apoptotic Pathway-targeting Cancer Therapeutic</synonym>
        <rdfs:label>Apoptotic Pathway-targeting Antineoplastic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131213 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131213">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C131213</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.</definition>
        <name>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>AR160</synonym>
        <synonym>Abraxane Coated with Rituximab 160nm Nanoparticle</synonym>
        <synonym>Abraxane coated with Rituximab</synonym>
        <synonym>Abraxane/Rituxan 160 Complex</synonym>
        <synonym>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160</synonym>
        <rdfs:label>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131368 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131368">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C131368</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A spherical nucleic acid (SNA) gold nanoparticle formulation composed of small interfering RNAs (siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence and conjugated to gold nanoparticles, with potential antineoplastic activity. Upon administration of SNA NU-0129, the siRNA prevents the translation of the BCL2L12 gene. Inhibiting the expression of BCL2L12 by NU-0129 induces tumor cell apoptosis. Bcl2L12, a protein belonging to the Bcl-2 protein family, is overexpressed in glioblastoma multiforme (GBM) and plays a role in tumor cell progression and tumor cell resistance to apoptosis. NU-0129 is able to cross the blood brain barrier (BBB).</definition>
        <name>Spherical Nucleic Acid Nanoparticle NU-0129</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>NU-0129</synonym>
        <synonym>SNA Gold Nanoparticle NU-0129</synonym>
        <synonym>SNA NU-0129</synonym>
        <synonym>Spherical Nucleic Acid Nanoparticle NU-0129</synonym>
        <rdfs:label>Spherical Nucleic Acid Nanoparticle NU-0129</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131434 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131434">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129839"/>
        <code>C131434</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid-based nanoparticle formulation composed of the apoptosis-inducing sphingolipid ceramide encapsulated within nanoliposomes, with potential apoptotic and antineoplastic activities. Upon administration, ceramide nanoliposomes accumulate in the tumor environment, due to the unique properties of the tumor vasculature, and easily enter tumor cells. This delivers ceramide inside the tumor cells, where ceramide induces apoptosis. Although the process is not completely understood, ceramide-dependent apoptosis most likely results from the downregulation of nutrient transporter proteins, which prevents cellular access to extracellular nutrients and causes tumor cell starvation. This selectively destroys tumor cells. Ceramide alone is insoluble and has a very short half-life; therefore, the nanoliposome formulation increases its solubility and half-life. Ceramide plays a key role in the regulation of autophagy, apoptosis, survival and proliferation. Serving as a tumor suppressor lipid, the expression of ceramide is inversely correlated with tumor cell growth, survival and metastasis.</definition>
        <name>Ceramide Nanoliposome</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CNL</synonym>
        <synonym>Ceramide Nanoliposome</synonym>
        <synonym>KN 001</synonym>
        <synonym>KN-001</synonym>
        <synonym>KN-01</synonym>
        <synonym>Nanoliposomal Ceramide</synonym>
        <rdfs:label>Ceramide Nanoliposome</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131825 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C131825">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177174"/>
        <code>C131825</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.</definition>
        <name>Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3</synonym>
        <synonym>M-VM3</synonym>
        <synonym>Mobilan</synonym>
        <rdfs:label>Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C133878 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C133878">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20401"/>
        <code>C133878</code>
        <definition>Any monoclonal antibody directed against epidermal growth factor receptor (EGFR).</definition>
        <name>Anti-EGFR Monoclonal Antibody</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <synonym>Anti-EGFR MoAb</synonym>
        <synonym>Anti-EGFR Monoclonal Antibody</synonym>
        <rdfs:label>Anti-EGFR Monoclonal Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C136981 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C136981">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C136981</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel&apos;s half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel&apos;s efficacy while lowering its systemic toxicity.</definition>
        <name>Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310</synonym>
        <synonym>Anti-EphA2 Antibody-targeted Nanoliposome MM-310</synonym>
        <synonym>Anti-EphA2 Docetaxel-based Nanoliposome MM-310</synonym>
        <synonym>EphA2-targeted Docetaxel Nanoliposome MM-310</synonym>
        <synonym>MM 310</synonym>
        <synonym>MM-310</synonym>
        <synonym>MM310</synonym>
        <rdfs:label>Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C137951 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C137951">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1420"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1512"/>
        <code>C137951</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.</definition>
        <name>Belzupacap Sarotalocan</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>AU-011</synonym>
        <synonym>BELZUPACAP SAROTALOCAN</synonym>
        <synonym>Belzupacap Sarotalocan</synonym>
        <synonym>HPV-NP AU-011</synonym>
        <synonym>Human Papillomavirus Virus-like Particles Conjugated with IR700 Dye AU-011</synonym>
        <synonym>Light-activated AU-011</synonym>
        <synonym>VNC AU-011</synonym>
        <synonym>Viral Nanoparticle Conjugates AU-011</synonym>
        <rdfs:label>Belzupacap Sarotalocan</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C139003 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C139003">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1594"/>
        <code>C139003</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.</definition>
        <name>Micellar Nanoparticle-encapsulated Epirubicin</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Epirubicin-incorporating Micelle</synonym>
        <synonym>K-912</synonym>
        <synonym>Micellar Nanoparticle-encapsulated Epirubicin</synonym>
        <synonym>NC-6300</synonym>
        <synonym>Nanoparticle Epirubicin</synonym>
        <rdfs:label>Micellar Nanoparticle-encapsulated Epirubicin</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1404 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1404">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C471"/>
        <code>C1404</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any substance that inhibits protein kinase, an enzyme that catalyzes the addition of a phosphate group to a protein and is active in many diverse signaling pathways.</definition>
        <name>Protein Kinase Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Protein Kinase Inhibitor</synonym>
        <rdfs:label>Protein Kinase Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1420 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1420">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C1420</code>
        <definition>Any pharmaceutical that is administered as an inactive precursor that can be converted to its pharmacologically active form through exposure to ultraviolet radiation or sunlight.</definition>
        <name>Photosensitizing Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Photosensitizer</synonym>
        <synonym>Photosensitizers</synonym>
        <synonym>Photosensitizing Agent</synonym>
        <synonym>photosensitizer</synonym>
        <synonym>photosensitizing agent</synonym>
        <rdfs:label>Photosensitizing Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C142078 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C142078">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C208191"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C142078</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A preparation of allogeneic or autologous cells that is meant to be administered to a patient and may have an immunotherapeutic effect.</definition>
        <name>Adoptive Cell Therapy Agent</name>
        <semanticType>Classification</semanticType>
        <synonym>ACT Agent</synonym>
        <synonym>Adoptive Cell Therapy Agent</synonym>
        <synonym>Adoptive Cell Transfer Agent</synonym>
        <synonym>Adoptive Cell-based Agent</synonym>
        <synonym>Adoptive Cellular Therapy Agent</synonym>
        <synonym>Adoptive Immunotherapy</synonym>
        <synonym>Cellular Immunotherapy Agent</synonym>
        <rdfs:label>Adoptive Cell Therapy Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C142137 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C142137">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <code>C142137</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A proprietary formulation consisting of a lipid nanoparticle encapsulating a synthetic messenger RNA (mRNA) encoding the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), with potential immunomodulatory and antitumor activities. Although the mechanism of action has not been completely characterized, following intratumoral injection of lipid nanoparticle encapsulated OX40L mRNA-2416, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the OX40L mRNA into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes. Altogether, this may enhance an immune response that promotes the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.</definition>
        <name>Lipid Nanoparticle Encapsulated OX40L mRNA-2416</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Lipid Nanoparticle Encapsulated OX40L mRNA-2416</synonym>
        <synonym>Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L</synonym>
        <synonym>mRNA 2416</synonym>
        <synonym>mRNA-2416</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulated OX40L mRNA-2416</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1446 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1446">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C1446</code>
        <conceptInSubset>BRIDG Class Terminology</conceptInSubset>
        <conceptInSubset>BRIDG Terminology</conceptInSubset>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>An agent that contains a radioactive isotope and is used for diagnostic or therapeutic purposes.</definition>
        <name>Radiopharmaceutical Compound</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Radioactive Pharmaceutical</synonym>
        <synonym>Radiochemical</synonym>
        <synonym>Radiopharmaceutical</synonym>
        <synonym>Radiopharmaceutical Compound</synonym>
        <synonym>Radiopharmaceuticals</synonym>
        <synonym>radioactive drug</synonym>
        <synonym>radiopharmaceutical</synonym>
        <rdfs:label>Radiopharmaceutical Compound</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1450 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1450">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1590"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2163"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C798"/>
        <code>C1450</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <definition>A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.</definition>
        <name>Platinum Compound</name>
        <semanticType>Chemical Viewed Structurally</semanticType>
        <synonym>Platinum Agents</synonym>
        <synonym>Platinum Compound</synonym>
        <synonym>Platinum-Based Chemotherapeutic Agent</synonym>
        <rdfs:label>Platinum Compound</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1454 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1454">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C1454</code>
        <name>Bispecific Antibody</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Bispecific Antibodies</synonym>
        <synonym>Bispecific Antibody</synonym>
        <synonym>bispecific antibody</synonym>
        <synonym>bsAb</synonym>
        <rdfs:label>Bispecific Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C146821 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C146821">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C146821</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A topical ointment composed of the water-insoluble taxane paclitaxel that has been processed to form uncoated nanoparticles, with potential antineoplastic activity. Upon topical administration of nanoparticle paclitaxel ointment SOR007 to the affected area, and following epithelial and dermal penetration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The nanoparticles in the nanoparticle paclitaxel ointment are produced through a specific proprietary submicron particle production.</definition>
        <name>Nanoparticle Paclitaxel Ointment SOR007</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>NanoPac Ointment</synonym>
        <synonym>Nanopartcle Paclitaxel SOR007</synonym>
        <synonym>Nanoparticle Paclitaxel Ointment SOR007</synonym>
        <synonym>SOR007</synonym>
        <synonym>SOR007 Ointment</synonym>
        <synonym>Topical Nanoparticle Paclitaxel Ointment</synonym>
        <synonym>Uncoated Nanoparticle Paclitaxel Ointment</synonym>
        <rdfs:label>Nanoparticle Paclitaxel Ointment SOR007</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C147562 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C147562">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2201"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C574"/>
        <code>C147562</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A proprietary, biodegradable, poly (lactic-co-glycolic acid) (PLGA) nanoparticle-based formulation composed of synthetic vaccine particles (SVP) encapsulating the macrolide antibiotic rapamycin (SVP-R), with immunosuppressant and drug-protective activities. Upon administration of SVP-R, the SVP moiety is selectively and preferentially taken up through endocytosis by antigen-presenting cells (APCs), located in the spleen and lymph nodes, specifically dendritic cells (DCs). Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, prevents DC maturation, induces tolerogenic DCs, induces regulatory T-cells (Tregs), blocks activation of effector T-cells, induces B-cell tolerance, reduces B-cell activation, and prevents antibody formation, thereby inducing immune tolerance. When co-administered with a biological immunogenic drug known to induce the production of anti-drug antibodies (ADA), SVP-R is able to prevent ADA formation, which prevents the unwanted neutralizing effects of ADAs, increases efficacy of the biological drug, and permits sustained therapeutic activity and repeated administration of the biological drug. In the presence of a specific target antigen, SVP-R is able to prevent an antigen-specific immune response and induces antigen-specific immune tolerance. Compared to the administration of free rapamycin, SVP-R induces long-lasting immunological tolerance.</definition>
        <name>Synthetic Vaccine Particles-Rapamycin</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>SEL 110</synonym>
        <synonym>SEL-110</synonym>
        <synonym>SEL110</synonym>
        <synonym>SVP-R</synonym>
        <synonym>SVP-Rapa</synonym>
        <synonym>SVP-Rapamycin</synonym>
        <synonym>Synthetic Vaccine Particles-Rapamycin</synonym>
        <rdfs:label>Synthetic Vaccine Particles-Rapamycin</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148280 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148280">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C798"/>
        <code>C148280</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.</definition>
        <name>MOF Compound RiMO-301</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>MOF Compound RiMO-301</synonym>
        <synonym>RiMO-301</synonym>
        <rdfs:label>MOF Compound RiMO-301</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148511 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148511">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1904"/>
        <code>C148511</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation consisting of polymeric micelles, composed of triblock copolymers, loaded with the bioactive hydrophobic irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38), with potential antineoplastic activity. Upon administration, nanoparticle SN-38-encapsulated micelle formulation IT141 diffuses into the tumor site and the SN-38 moiety binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication, and apoptosis. Compared to SN-38 alone, this formulation increases the water solubility of SN-38 and allows the delivery of higher doses of SN-38. IT-141 also has a much longer circulation time and reduces toxicity to normal, healthy tissues.</definition>
        <name>Nanoparticle SN-38-encapsulated Micelle Formulation IT-141</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>IT-141</synonym>
        <synonym>IT141</synonym>
        <synonym>Nanoparticle SN-38 Formulation IT141</synonym>
        <synonym>Nanoparticle SN-38-encapsulated Micelle Formulation IT-141</synonym>
        <rdfs:label>Nanoparticle SN-38-encapsulated Micelle Formulation IT-141</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148522 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148522">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663"/>
        <code>C148522</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based cancer vaccine composed of a neutralized bacteriophage Lambda construct that is genetically engineered to contain peptide fragments of human aspartyl/asparaginyl beta-hydroxylase (HAAH; ASPH) on its surface and are fused to the C-terminus of the head protein of phage lambda gpD, with potential immunostimulating and antineoplastic activities. HAAH lambda phage vaccine SNS-301 also contains DNA fragments representing the phage CpG motif that activate the MHC class II pathway. Upon intradermal administration of the HAAH lambda phage vaccine SNS-301, the bacteriophage exposes the immune system to HAAH, producing a HAAH-specific antibody response, and may activate the immune system to induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against HAAH-expressing tumor cells. HAAH is a transmembrane protein and highly conserved enzyme that catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of substrate proteins. HAAH is normally expressed in fetal development and is upregulated in a variety of cancer cell types, while its expression is nearly absent in healthy, normal cells. HAAH plays a key role in cancer cell growth, cell motility and invasiveness. Its expression is associated with a poor prognosis.</definition>
        <name>HAAH Lambda phage Vaccine SNS-301</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Bacteriophage Cancer Vaccine SNS-301</synonym>
        <synonym>HAAH Lambda phage Vaccine SNS-301</synonym>
        <synonym>HAAH-1/2/3 Lambda Phage Vaccine SNS-301</synonym>
        <synonym>Nanoparticle HAAH Vaccine SNS-301</synonym>
        <synonym>PAN 301-1</synonym>
        <synonym>PAN-301-1</synonym>
        <synonym>SNS 301</synonym>
        <synonym>SNS-301</synonym>
        <synonym>SNS301</synonym>
        <rdfs:label>HAAH Lambda phage Vaccine SNS-301</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148531 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148531">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C148531</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.</definition>
        <name>Paclitaxel Polymeric Micelle Formulation NANT-008</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Cynviloq</synonym>
        <synonym>Genexol-PM</synonym>
        <synonym>IG-001</synonym>
        <synonym>Micellar Nanoparticle-encapsulated NANT-008</synonym>
        <synonym>NANT 008</synonym>
        <synonym>NANT-008</synonym>
        <synonym>NANT008</synonym>
        <synonym>Nant-paclitaxel</synonym>
        <synonym>Paclitaxel Polymeric Micelle Formulation NANT-008</synonym>
        <synonym>Paclitaxel-loaded Micellar Diblock Copolymer NANT-008</synonym>
        <synonym>Paclitaxel-loaded Polymeric Micelle NANT-008</synonym>
        <rdfs:label>Paclitaxel Polymeric Micelle Formulation NANT-008</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148635 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C148635">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C148635</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel&apos;s solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.</definition>
        <name>PEOX-based Polymer Encapsulated Paclitaxel FID-007</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>FID 007</synonym>
        <synonym>FID-007</synonym>
        <synonym>FID007</synonym>
        <synonym>Nanoencapsulated Paclitaxel FID-007</synonym>
        <synonym>PEOX-based Polymer Encapsulated Paclitaxel FID-007</synonym>
        <synonym>Paclitaxel in Polyethyloxazoline Polymer</synonym>
        <rdfs:label>PEOX-based Polymer Encapsulated Paclitaxel FID-007</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C150508 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C150508">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C275"/>
        <code>C150508</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle formulation containing the poorly water-soluble naturally-occurring flavonoid luteolin encapsulated within a water-soluble polymer, with potential anti-oxidant, anti-inflammatory, apoptosis-inducing and chemopreventive activities. Upon administration of the polymer-encapsulated luteolin nanoparticle, luteolin scavenges free radicals, protects cells from reactive oxygen species (ROS)-induced damage and induces direct tumor cell cycle arrest and apoptosis in tumor cells. This inhibits tumor cell proliferation and suppresses metastasis. Compared to luteolin alone, encapsulation increases the delivery of luteolin to the tumor cells by protecting the drug against clearance and degradation, increases blood circulation time and enhances delivery into the tumor through the leaky vasculature.</definition>
        <name>Polymer-encapsulated Luteolin Nanoparticle</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>3&apos;,4&apos;,5,7-Tetrahydroxyflavone-encapsulated Polymer Nanoparticles</synonym>
        <synonym>Nano-luteolin</synonym>
        <synonym>Nanoluteolin</synonym>
        <synonym>Nanoparticle-based Luteolin</synonym>
        <synonym>Polymer-encapsulated Luteolin Nanoparticle</synonym>
        <rdfs:label>Polymer-encapsulated Luteolin Nanoparticle</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C150717 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C150717">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129825"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1946"/>
        <code>C150717</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity.</definition>
        <name>Panobinostat Nanoparticle Formulation MTX110</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>MTX 110</synonym>
        <synonym>MTX-110</synonym>
        <synonym>MTX110</synonym>
        <synonym>Panobinostat Nanoparticle Formulation MTX110</synonym>
        <rdfs:label>Panobinostat Nanoparticle Formulation MTX110</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1511 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1511">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1512"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2124"/>
        <code>C1511</code>
        <definition>Monoclonal antibodies (MoAb) conjugated with radioisotopes, i.e., I-131, Y-90, T-99, or In-111. Using radioimmunoconjugates in radiotherapy or radioimaging has the advantage of targeting cells carrying specific antigens, thereby limiting toxic effects on normal cells. Tumor eradication can be achieved by either the antibody-mediated immune response or by only the cytotoxic activity of the radiation.</definition>
        <name>Radioimmunoconjugate</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Radioimmunoconjugate</synonym>
        <synonym>Radiolabeled Antibodies</synonym>
        <rdfs:label>Radioimmunoconjugate</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1512 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1512">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C1512</code>
        <definition>An agent that consists of an immune substance, such as a monoclonal antibody, antigen or an immunoglobulin, and covalently bound to other molecule(s), usually either a toxin, a radioisotope, or a cytotoxic agent. Immunoconjugates allow for specific delivery of certain substances to specific cells or tissues for diagnostic or therapeutic purposes.</definition>
        <name>Immunoconjugate</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Icon</synonym>
        <synonym>Immunoconjugate</synonym>
        <rdfs:label>Immunoconjugate</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C153425 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C153425">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1450"/>
        <code>C153425</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A preparation of platinum acetylacetonate supported by sol-gel technology functionalized titania, with potential antineoplastic activity. Upon intravenous administration, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the nanoparticle formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.</definition>
        <name>Platinum Acetylacetonate-Titanium Dioxide Nanoparticles</name>
        <semanticType>Inorganic Chemical</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>NPt</synonym>
        <synonym>NPt Nanomaterial</synonym>
        <synonym>NPt Nanoparticles</synonym>
        <synonym>NPt-Ca</synonym>
        <synonym>Platinum Acetylacetonate-Titanium Dioxide Nanoparticles</synonym>
        <synonym>Sol-gel NPt Nanomaterial</synonym>
        <synonym>Sol-gel NPt Nanoparticles</synonym>
        <rdfs:label>Platinum Acetylacetonate-Titanium Dioxide Nanoparticles</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C15415 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C15415">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C94625"/>
        <code>C15415</code>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <name>Hyperthermia Treatment</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Clinical Hyperthermia</synonym>
        <synonym>Diathermy</synonym>
        <synonym>Hyperthermia</synonym>
        <synonym>Hyperthermia Therapy</synonym>
        <synonym>Hyperthermia Treatment</synonym>
        <synonym>diathermy</synonym>
        <synonym>hyperthermia therapy</synonym>
        <rdfs:label>Hyperthermia Treatment</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C154569 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C154569">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67502"/>
        <code>C154569</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A water-soluble, nano-sized formulation composed of nanoparticles encapsulating the poorly water-soluble curcumin, a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI), and the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of the curcumin/doxorubicin-encapsulating nanoparticle IMX-110, the curcumin moiety targets and inhibits the activation of STAT3 and NF-kB and prevents STAT3- and NF-kB-mediated signaling pathways, both of which are activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, tumor resistance to apoptosis, metastasis and immune evasion. The doxorubicin moiety intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and curcumin, by inhibiting NFkB and STAT3 activity, may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells. Chemotherapeutic agents, such as doxorubicin, upregulate the expression of NF-kB in tumor cells which generates chemotherapy-resistant tumor cells.</definition>
        <name>Doxorubicin-loaded EGFR-targeting Nanocells</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110</synonym>
        <synonym>IMX 110</synonym>
        <synonym>IMX-110</synonym>
        <synonym>IMX110</synonym>
        <synonym>Stat3/NF-kB/poly-tyrosine Kinase Inhibitor/Doxorubicin-encapsulating Nanoparticle IMX-110</synonym>
        <rdfs:label>Doxorubicin-loaded EGFR-targeting Nanocells</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1557 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1557">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C272"/>
        <code>C1557</code>
        <definition>An antimetabolite that affects the metabolism and utilization of pyrimidines.</definition>
        <name>Pyrimidine Antagonist</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Pyrimidine Antagonist</synonym>
        <rdfs:label>Pyrimidine Antagonist</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C15670 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C15670">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C15415"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20985"/>
        <code>C15670</code>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <name>Thermal Ablation Therapy</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Thermal Ablation Therapy</synonym>
        <synonym>thermal ablation</synonym>
        <rdfs:label>Thermal Ablation Therapy</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C156739 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C156739">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1511"/>
        <code>C156739</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A radioconjugate composed of a tumor-selective fluorescent imaging agent containing silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, cyanine 5 (Cy5), and surrounded by polyethylene glycol (PEG) chains attached to cyclic arginine-glycine-aspartic acid-tyrosine) (cyclo-(Arg-Gly-Asp-Tyr; cRGDY) peptides (C&apos; dots; Cornell prime dots; cRGDY-PEG-C&apos; dots), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon intradermal administration of the zirconium Zr 89 cRGDY PEG-Cy5-C&apos; dots, the cRGDY moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of integrin-expressing tumor cells as well as the visualization of the distribution, uptake and removal within tumor tissues. The fluorescence imaging agent is used to visualize alphaVbeta3-expressing tumor cells and assess the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.</definition>
        <name>Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C&apos; Dots</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>89Zr-DFO-cRGDY-PEG-Cy5-C&apos; Dot Nanoparticles</synonym>
        <synonym>89Zr-DFO-cRGDY-PEG-Cy5-C&apos; Dot Particles</synonym>
        <synonym>89Zr-DFO-cRGDY-PEG-Cy5-C&apos; Dots</synonym>
        <synonym>Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C&apos; Dots</synonym>
        <synonym>Zr 89-DFO-cRGDY PEG-Cy5-C&apos; Dots</synonym>
        <rdfs:label>Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C&apos; Dots</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C156880 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C156880">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C74526"/>
        <code>C156880</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>Any agent that inhibits heat shock protein (Hsp) 90.</definition>
        <name>HSP90 Inhibitor</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>HSP90 Inhibitor</synonym>
        <synonym>Heat Shock Protein 90 Inhibitor</synonym>
        <synonym>Hsp 90 Inhibitor</synonym>
        <rdfs:label>HSP90 Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C156926 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C156926">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C181141"/>
        <code>C156926</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient&apos;s tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of sapecmeran autogene, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient&apos;s cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.</definition>
        <name>Sapecmeran Autogene</name>
        <semanticType>Immunologic Factor</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Boosting Cancer Vaccine GRT-R902</synonym>
        <synonym>GRT R902</synonym>
        <synonym>GRT-R902</synonym>
        <synonym>GRTR902</synonym>
        <synonym>SAPECMERAN AUTOGENE</synonym>
        <synonym>Sapecmeran Autogene</synonym>
        <synonym>mRNA-based TSNA Boosting Vaccine GRT-R902</synonym>
        <synonym>mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902</synonym>
        <rdfs:label>Sapecmeran Autogene</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C157247 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C157247">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663"/>
        <code>C157247</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle encapsulating mRNAs encoding for the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), the pro-inflammatory cytokines interleukin-23 (IL-23) and interleukin-36gamma (IL-36gamma), with potential immunomodulatory and anti-tumor activities. Upon intratumoral (IT) injection of the lipid nanoparticle encapsulated mRNAs encoding human OX40L/IL-23/IL-36gamma mRNA-2752, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNAs into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes against the nearby tumor cells. The co-administration of IL-23 and IL-36gamma further stimulates anti-tumor immune responses. Altogether, this may enhance T-cell mediated anti-tumor immune responses thereby killing of the tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. IL-36gamma activates innate immune cells and promotes T-helper 1 (Th1) responses, whereas IL-23 has been implicated in Th1/Th17 immunity as well as in the modulation of antigen-presenting cells (APCs).</definition>
        <name>Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Lipid Nanoparticle Encapsulated OX40L/IL-23/IL-36gamma mRNAs mRNA-2752</synonym>
        <synonym>Lipid Nanoparticle Encapsulated mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752</synonym>
        <synonym>Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752</synonym>
        <synonym>mRNA 2752</synonym>
        <synonym>mRNA-2752</synonym>
        <synonym>mRNA2752</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C157499 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C157499">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <code>C157499</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A preparation of self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles containing an as of yet undisclosed payload with potential immunostimulating and antineoplastic activities. Upon intravenous administration, NCP nanoparticle formulation CPI-100 delivers its payload to tumor cells, which may lead to enhanced immune-mediated killing and regression of tumor cells.</definition>
        <name>Nanoscale Coordination Polymer Nanoparticles CPI-100</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CPI 100</synonym>
        <synonym>CPI-100</synonym>
        <synonym>CPI100</synonym>
        <synonym>NCP Nanoparticles CPI-100</synonym>
        <synonym>Nanoscale Coordination Polymer Nanoparticles CPI-100</synonym>
        <rdfs:label>Nanoscale Coordination Polymer Nanoparticles CPI-100</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C157771 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C157771">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177175"/>
        <code>C157771</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A spherical nucleic acid (SN)-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, cavrotolimod targets and is able to enter various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and B cells, through endocytosis. Within the endosome, it binds to and activates TLR9. TLR9 activation induces immune signaling pathways and activates various immune cells, including B-cells, pDCs, NKs, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response as well as a cytotoxic T-lymphocyte (CTL)-based immune response against tumor cells. This results in an inhibition of tumor cell proliferation. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate and adaptive immune responses. The SNA is a dense, radial arrangement of nucleic acids (DNA) on the surface of liposomal nanoparticles, providing a 3D-construct, that has a high cellular uptake and an increased presentation of the DNA for TLR9 agonism. It also protects against breakdown by nucleases and increases the half-life of the construct compared to linear oligonucleotides that are not in SNA format.</definition>
        <name>Cavrotolimod</name>
        <semanticType>Nucleic Acid, Nucleoside, or Nucleotide</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>AST 008</synonym>
        <synonym>AST-008</synonym>
        <synonym>AST008</synonym>
        <synonym>CAVROTOLIMOD</synonym>
        <synonym>Cavrotolimod</synonym>
        <synonym>SNA AST-008</synonym>
        <synonym>TLR9 Agonist AST-008</synonym>
        <synonym>Toll-like Receptor 9 Activator AST-008</synonym>
        <rdfs:label>Cavrotolimod</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C158083 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C158083">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129822"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C133878"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1742"/>
        <code>C158083</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.</definition>
        <name>Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Immunologic Factor</semanticType>
        <synonym>Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide</synonym>
        <synonym>Cetuximab-loaded Polymeric Nanoparticles Decorated With Octreotide</synonym>
        <synonym>Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Octreotide</synonym>
        <rdfs:label>Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1590 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1590">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2842"/>
        <code>C1590</code>
        <definition>An antineoplastic agent that replaces hydrogen atom(s) in nucleophilic moieties with alky radical(s), hindering proper function. Alkylating agents exhibit cytotoxic effects through the alkylation of DNA, resulting in strand cross-linking, ultimately inhibiting DNA replication and cancer cell growth.</definition>
        <name>Antineoplastic Alkylating Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Antineoplastic Alkylating Agent</synonym>
        <synonym>Chemotherapy Alkylating Agents</synonym>
        <synonym>Chemotherapy Alkylators</synonym>
        <rdfs:label>Antineoplastic Alkylating Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1594 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1594">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1968"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2115"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C259"/>
        <code>C1594</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.</definition>
        <name>Anthracycline Antineoplastic Antibiotic</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Anthracycline Antineoplastic Antibiotic</synonym>
        <synonym>Anthracyclines</synonym>
        <synonym>Chemotherapy, Cancer, Anthracyclines</synonym>
        <synonym>anthracycline</synonym>
        <rdfs:label>Anthracycline Antineoplastic Antibiotic</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C159408 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C159408">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C63358"/>
        <code>C159408</code>
        <conceptInSubset>HemOnc Regimen Terminology</conceptInSubset>
        <conceptInSubset>Multi-agent Therapeutic Regimens</conceptInSubset>
        <conceptInSubset>Pharmacotherapy Regimens</conceptInSubset>
        <definition>A regimen consisting of atezolizumab and nab-paclitaxel that may be used in the treatment of programmed cell death 1 ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).</definition>
        <name>Atezolizumab/Nab-paclitaxel Regimen</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Atezolizumab-Nab-paclitaxel</synonym>
        <synonym>Atezolizumab/Albumin-bound Paclitaxel</synonym>
        <synonym>Atezolizumab/Nab-paclitaxel</synonym>
        <synonym>Atezolizumab/Nab-paclitaxel Regimen</synonym>
        <synonym>Atezolizumab/Nanoparticle Albumin-bound Paclitaxel</synonym>
        <synonym>Tecentriq/Abraxane</synonym>
        <synonym>nab-Paclitaxel and Atezolizumab</synonym>
        <rdfs:label>Atezolizumab/Nab-paclitaxel Regimen</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C160824 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C160824">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C15670"/>
        <code>C160824</code>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>A procedure for the focal treatment of solid tumors. Magnetic nanoparticles of iron oxide are introduced either directly into the tumor or into the resection cavity wall. These particles are subjected to an alternating magnetic field that causes the particles to generate heat and kill the cancer cells by thermal ablation.</definition>
        <name>NanoTherm Therapy</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>MagForce NanoTherm Therapy System</synonym>
        <synonym>NanoTherm</synonym>
        <synonym>NanoTherm Therapy</synonym>
        <synonym>NanoTherm Therapy System</synonym>
        <rdfs:label>NanoTherm Therapy</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C160867 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C160867">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431"/>
        <code>C160867</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticle encapsulated messenger RNA (mRNA) encoding human interleukin-12 subunit beta (IL-12B; IL-12 subunit p40) and interleukin-12 subunit alpha (IL-12A; IL-12 subunit p35) with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon intratumoral injection, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the IL-12A and IL-12B mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce a single-chain fusion protein of IL-12B and IL-12A subunits, which is secreted into the local tumor microenvironment (TME). Secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.</definition>
        <name>Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>LNP Encapsulated Human IL-12A/IL-12B mRNAs MEDI-1191</synonym>
        <synonym>Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191</synonym>
        <synonym>MEDI-1191</synonym>
        <synonym>MEDI1191</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C16203 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C16203">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43431"/>
        <code>C16203</code>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any specific activity undertaken during the course of a clinical study or research protocol.</definition>
        <name>Clinical or Research Activity</name>
        <semanticType>Activity</semanticType>
        <synonym>Clinical or Research Activity</synonym>
        <rdfs:label>Clinical or Research Activity</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C162186 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C162186">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C181141"/>
        <code>C162186</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.</definition>
        <name>mRNA-derived KRAS-targeted Vaccine V941</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>V 941</synonym>
        <synonym>V941</synonym>
        <synonym>mRNA 5671</synonym>
        <synonym>mRNA-5671</synonym>
        <synonym>mRNA-5671 Vaccine</synonym>
        <synonym>mRNA-derived KRAS-targeted Vaccine V941</synonym>
        <rdfs:label>mRNA-derived KRAS-targeted Vaccine V941</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C162773 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C162773">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C162773</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A suspension composed of uncoated, stable, submicron particles of the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intra-tumoral administration of the submicron particle paclitaxel sterile suspension, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The submicron particle paclitaxel is produced through a specific proprietary method of submicron particle production without the need for coating agents or carriers and allows for prolonged retention and sustained release at the tumor site.</definition>
        <name>Submicron Particle Paclitaxel Sterile Suspension</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>NanoPac</synonym>
        <synonym>Sterile Nanoparticle-based Paclitaxel Suspension</synonym>
        <synonym>Sterile Nanoparticulate Paclitaxel</synonym>
        <synonym>Submicron Particle Paclitaxel</synonym>
        <synonym>Submicron Particle Paclitaxel Formulation</synonym>
        <synonym>Submicron Particle Paclitaxel Sterile Suspension</synonym>
        <rdfs:label>Submicron Particle Paclitaxel Sterile Suspension</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163758 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163758">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C163758</code>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>Any agent that specifically targets or interferes with the synthesis or function of a molecule that is expressed specifically in or on cells of the tumor and/or the tumor microenvironment (TME), such as immune cells or surrounding blood vessels. The targeted molecule is usually overexpressed or mutated in tumors but minimally or not expressed by normal, healthy tissues; additionally, expression is typically associated with tumor cell proliferation, progression and/or survival. By blocking the function or expression of the tumor-associated target, the targeted therapy agent may exert potential antineoplastic and/or immunomodulatory activities.</definition>
        <name>Targeted Therapy Agent</name>
        <semanticType>Classification</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-tumor Targeted Therapy Agent</synonym>
        <synonym>Molecularly Targeted Therapy Agent</synonym>
        <synonym>Targeted Agent</synonym>
        <synonym>Targeted Therapeutic Agent</synonym>
        <synonym>Targeted Therapy Agent</synonym>
        <rdfs:label>Targeted Therapy Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163952 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163952">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163758"/>
        <code>C163952</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>Any agent that targets the human epidermal growth factor receptor (EGFR).</definition>
        <name>EGFR-targeting Agent</name>
        <semanticType>Classification</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>EGFR-targeting Agent</synonym>
        <rdfs:label>EGFR-targeting Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C165263 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C165263">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C165263</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation consisting of polymeric micelles (PMs), made with poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) block polymers, encapsulating the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with potential antineoplastic activity. Upon intravenous administration of the docetaxel PMs, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor&apos;s vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site where it binds specifically to the beta-tubulin subunit of the microtubule, thereby stabilizing tubulin and inhibiting microtubule disassembly. This results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel&apos;s efficacy while avoiding systemic exposure, which minimizes its toxicity.</definition>
        <name>Docetaxel Polymeric Micelles</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Docetaxel Lipid Emulsion</synonym>
        <synonym>Docetaxel Polymeric Micelles</synonym>
        <synonym>Docetaxel-PM</synonym>
        <synonym>Docetaxel-loaded PM</synonym>
        <synonym>Docetaxel-loaded PMs</synonym>
        <synonym>Docetaxel-loaded Polymeric Micelles</synonym>
        <synonym>NANOXEL-M</synonym>
        <synonym>NanoxelM</synonym>
        <rdfs:label>Docetaxel Polymeric Micelles</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C166169 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C166169">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2124"/>
        <code>C166169</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, cyanine 5.5 (Cy5.5), and surrounded by polyethylene glycol (PEG) chains attached to a human prostate-specific membrane antigen (PSMA) inhibitor (PSMAi) and labeled with, via the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N&apos;,N&apos;&apos;-triacetic acid (NOTA), the radioisotope copper Cu 64, with potential tumor-selective diagnostic properties upon positron emission tomography (PET) imaging. Upon administration of the copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C&apos; dots, the PSMAi moiety selectively targets and binds to PSMA expressed on tumor cells. Upon PET imaging, PSMA-expressing tumor cells can be visualized and assessed. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells. The nanoparticle formulation may allow for enhanced uptake in PSMA-positive tumors.</definition>
        <name>Copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C&apos; Dots</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>(64Cu)-labeled PSMA-targeting -PEG Cy5.5-C&apos; Dots</synonym>
        <synonym>64Cu-NOTA-PSMA-PEG-Cy5.5-C&apos; Dot Tracer</synonym>
        <synonym>64Cu-NOTA-PSMA-PEG-Cy5.5-C&apos; Dots</synonym>
        <synonym>64Cu-NOTA-PSMAi-PEG-Cy5.5-C&apos; Dots</synonym>
        <synonym>Copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C&apos; Dots</synonym>
        <rdfs:label>Copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C&apos; Dots</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C923"/>
        <code>C1663</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <definition>A type of vaccine that prevents or treats cancer.</definition>
        <name>Antineoplastic Vaccine</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Antineoplastic Vaccine</synonym>
        <synonym>Cancer Vaccine</synonym>
        <synonym>Neoplasm Vaccine</synonym>
        <synonym>Tumor Vaccine</synonym>
        <synonym>cancer treatment vaccine</synonym>
        <synonym>cancer vaccine</synonym>
        <rdfs:label>Antineoplastic Vaccine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C166389 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C166389">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C63360"/>
        <code>C166389</code>
        <conceptInSubset>HemOnc Regimen Terminology</conceptInSubset>
        <conceptInSubset>Multi-agent Therapeutic Regimens</conceptInSubset>
        <conceptInSubset>Pharmacotherapy Regimens</conceptInSubset>
        <definition>A regimen consisting of atezolizumab, carboplatin and nab-paclitaxel that may be used in the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).</definition>
        <name>Atezolizumab/Carboplatin/Nab-paclitaxel Regimen</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Atezolizumab/Carboplatin/Albumin-bound Paclitaxel</synonym>
        <synonym>Atezolizumab/Carboplatin/Nab-paclitaxel</synonym>
        <synonym>Atezolizumab/Carboplatin/Nab-paclitaxel Regimen</synonym>
        <synonym>Atezolizumab/Carboplatin/Nanoparticle Albumin-bound Paclitaxel</synonym>
        <synonym>Atezolizumab/Carboplatin/Paclitaxel Protein-bound</synonym>
        <synonym>Carboplatin, nab-Paclitaxel, Atezolizumab</synonym>
        <synonym>Tecentriq/Carboplatin/Abraxane</synonym>
        <rdfs:label>Atezolizumab/Carboplatin/Nab-paclitaxel Regimen</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C167334 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C167334">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1904"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C203332"/>
        <code>C167334</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A pegylated conjugate of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon administration, the proprietary linker slowly releases SN-38 from the pegylated SN-38 conjugate PLX038. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Compared with irinotecan, this formulation allows higher accumulation in solid tumors due to its nanoparticle size and long half-life.</definition>
        <name>Pegylated SN-38 Conjugate PLX038</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>PLX 038</synonym>
        <synonym>PLX-038</synonym>
        <synonym>PLX038</synonym>
        <synonym>Pegylated SN-38 Conjugate PLX038</synonym>
        <synonym>Pegylated SN-38 PLX038</synonym>
        <rdfs:label>Pegylated SN-38 Conjugate PLX038</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C16847 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C16847">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43431"/>
        <code>C16847</code>
        <definition>A practiced and regimented skill or series of actions.</definition>
        <name>Technique</name>
        <semanticType>Activity</semanticType>
        <synonym>Method</synonym>
        <synonym>Methods</synonym>
        <synonym>Methods and Techniques</synonym>
        <synonym>Methods, Other</synonym>
        <synonym>Technical</synonym>
        <synonym>Technique</synonym>
        <synonym>Techniques</synonym>
        <rdfs:label>Technique</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C169048 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C169048">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C390"/>
        <code>C169048</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A contrast agent formulation composed of a polymeric core containing the paramagnetic contrast agent manganese chloride tetrahydrate (MnCl2 4H2O), in which the Mn2+ ions are chelated to phosphonate groups, and covered with a coating layer of covalently attached polyetyleneglycol (PEG)-polymers, that can potentially be used as a contrast enhancer during magnetic resonance imaging (MRI). Upon intravenous administration of the nanoparticle-based manganese-containing contrast agent SN132D, the nanoparticles enhance absorption of the poorly absorbable contrast agent manganese, and selectively accumulates in the tumor microenvironment (TME). Due to the retention of manganese in the TME and its paramagnetic properties, this contrast agent enhances the visualization and detection of tumor cells during MRI.</definition>
        <name>Nanoparticle-based Manganese-containing Contrast Agent SN132D</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>MRI Contrast Agent SN132D</synonym>
        <synonym>Manganese-based Macromolecular Contrast Agent SN132D</synonym>
        <synonym>Manganese-containing Nanoparticle Contrast Agent SN132D</synonym>
        <synonym>Nanoparticle-based Contrast Agent with Manganese SN132D</synonym>
        <synonym>Nanoparticle-based Manganese-containing Contrast Agent SN132D</synonym>
        <synonym>SN132D</synonym>
        <synonym>SpagoPix</synonym>
        <rdfs:label>Nanoparticle-based Manganese-containing Contrast Agent SN132D</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C17005 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C17005">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43359"/>
        <code>C17005</code>
        <conceptInSubset>CDISC Glossary Terminology</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <conceptInSubset>GDC Property Terminology</conceptInSubset>
        <definition>A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)</definition>
        <name>Population Group</name>
        <semanticType>Population Group</semanticType>
        <synonym>Group</synonym>
        <synonym>Population</synonym>
        <synonym>Population Group</synonym>
        <synonym>Subpopulation</synonym>
        <synonym>population</synonym>
        <synonym>population group</synonym>
        <synonym>population_group</synonym>
        <rdfs:label>Population Group</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C170743 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C170743">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1291"/>
        <code>C170743</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A liposomal-based nanoparticle composed of an uncharged P-ethoxy antisense oligodeoxynucleotide (ODN) targeting Bcl-2 mRNA and incorporated in liposomes, with potential antineoplastic activity. Upon administration of liposomal Bcl-2 antisense oligonucleotide BP1002, this agent targets and hybridizes with Bcl-2 mRNA and inhibits the expression of Bcl-2 protein. This may induce tumor cell apoptosis of Bcl2-overexpressing tumor cells and may decrease tumor cell proliferation. Bcl2, a protein involved in regulating programmed cell death, is overexpressed in a wide variety of tumors. It promotes cellular survival and inhibits apoptosis.</definition>
        <name>Liposomal Bcl-2 Antisense Oligonucleotide BP1002</name>
        <semanticType>Nucleic Acid, Nucleoside, or Nucleotide</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>BP 1002</synonym>
        <synonym>BP-100-1.02</synonym>
        <synonym>BP-1002</synonym>
        <synonym>BP1002</synonym>
        <synonym>L-Bcl-2 Antisense Oligonucleotide BP1002</synonym>
        <synonym>Liposomal Bcl-2 Antisense BP1002</synonym>
        <synonym>Liposomal Bcl-2 Antisense Oligonucleotide BP1002</synonym>
        <rdfs:label>Liposomal Bcl-2 Antisense Oligonucleotide BP1002</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C170753 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C170753">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201688"/>
        <code>C170753</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A biodegradable, lyophilized lipid nanoparticle (LNP) encapsulating small interfering ribonucleic acid (siRNA) directed against glutathione S-transferase P (GSTP), with potential antineoplastic activity. Upon administration of LNP encapsulating GSTP siRNA NBF-006, the LNP formulation delivers the siRNA particles to the tumor cells where the GSTP siRNA targets and binds to GSTP mRNA. This results in the inhibition of the translation and expression of GSTP and may inhibit proliferation of KRAS-overexpressing tumor cells. GSTP, an enzyme overexpressed in many tumor cell types, is involved in modulating MAP kinase-related cell-signaling pathways.</definition>
        <name>Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Lipid Nanoparticle Encapsulating GSTP siRNA NBF-006</synonym>
        <synonym>Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006</synonym>
        <synonym>NBF 006</synonym>
        <synonym>NBF-006</synonym>
        <synonym>NBF006</synonym>
        <synonym>siRNA-based LNP NBF-006</synonym>
        <synonym>siRNA-based Lipid Nanoparticle NBF-006</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1708 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1708">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20181"/>
        <code>C1708</code>
        <conceptInSubset>ICDC Node Terminology</conceptInSubset>
        <conceptInSubset>ICDC Terminology</conceptInSubset>
        <definition>An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.</definition>
        <name>Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Agent</synonym>
        <synonym>agent</synonym>
        <rdfs:label>Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C172787 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C172787">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C923"/>
        <code>C172787</code>
        <definition>A type of vaccine that is based on mRNA, which encodes the antigen of interest expressed by a pathogen or tumor cell. Upon cellular uptake by host cells, the translated protein is presented to the immune system and may induce a specific immune response against cells expressing the protein. mRNA-based dendritic cell (DC) vaccines are mRNA vaccines, in which the mRNA is introduced ex vivo.</definition>
        <name>mRNA Vaccine</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>mRNA Vaccine</synonym>
        <rdfs:label>mRNA Vaccine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C173879 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C173879">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129825"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2201"/>
        <code>C173879</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An orally bioavailable nanoparticle-based formulation composed of sub-micron particles of the macrolide antibiotic rapamycin incorporated into a pH-sensitive poly(methyl methacrylate) polymer, with potential immunomodulating and antineoplastic activities. Upon oral administration of the encapsulated rapamycin, the nanoparticle specifically delivers rapamycin at the tumor site. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR), a key regulatory kinase. This may suppress mTORC1 activity. In addition, inhibition of mTOR may modulate central memory CD8 T cells, CD3+/CD56+ natural killer (NK) cells and CD8 T-cell responses. This may kill tumor cells. Compared to the administration of rapamycin alone, this formulation improves oral bioavailability of rapamycin with more consistent rapamycin levels, thereby allowing for administration of lower rapamycin dosage, which improves and minimizes rapamycin&apos;s toxicity. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.</definition>
        <name>Encapsulated Rapamycin</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Encapsulated Rapamycin</synonym>
        <synonym>Encapsulated Sirolimus</synonym>
        <synonym>Microencapsulated Rapamycin</synonym>
        <synonym>eRapa (TM)</synonym>
        <rdfs:label>Encapsulated Rapamycin</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C174128 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C174128">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C28681"/>
        <code>C174128</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A preparation of autologous T-cells targeting several multiple myeloma (MM)-associated antigens, with potential immunomodulating and antineoplastic activities. Peripheral blood mononuclear cells (PBMC) from the patient are collected and ex vivo exposed to nanoparticles that mimic antigen-presenting cells (APCs) loaded with multiple MM-associated antigens, including Wilms&apos; tumor 1 (WT1), CD138 (syndecan-1; SDC1), cancer-testis antigen NY-ESO-1 and CS1 (CD319; CRACC; SLAMF7), and are further enriched and expanded ex-vivo before being re-introduced into the patient. Upon administration, the multi-antigen-directed autologous T-cells NEXI-002 are re-introduced into the patient, where they target and kill tumor cells expressing these antigens.</definition>
        <name>Multi-antigen-directed Autologous T-cells NEXI-002</name>
        <semanticType>Cell</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Autologous MM-associated Antigens Specific T Cells NEXI-002</synonym>
        <synonym>Multi-antigen-directed Autologous T-cells NEXI-002</synonym>
        <synonym>NEXI 002</synonym>
        <synonym>NEXI-002</synonym>
        <synonym>NEXI-002 T Cells</synonym>
        <synonym>NEXI002</synonym>
        <synonym>TAA Primed Antigen-specific CD8+ T Cells NEXI-002</synonym>
        <rdfs:label>Multi-antigen-directed Autologous T-cells NEXI-002</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1742 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1742">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C1742</code>
        <conceptInSubset>CPTAC Codelists Terminology</conceptInSubset>
        <conceptInSubset>CPTAC Terminology</conceptInSubset>
        <conceptInSubset>CPTAC Treatments Codelist</conceptInSubset>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>An agent or endogenous substance that inhibits the formation of capillaries from existing blood vessels. In cancer therapy, angiogenesis inhibitors preferentially target the new blood vessels that tumors require for oxygen and nutrition, thereby inhibiting the growth and spread of these tumors.</definition>
        <name>Angiogenesis Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Angiogenesis Antagonists</synonym>
        <synonym>Angiogenesis Blockers</synonym>
        <synonym>Angiogenesis Inhibitor</synonym>
        <synonym>Angiogenesis Inhibitors</synonym>
        <synonym>Anti-Angiogenic Agents</synonym>
        <synonym>Antiangiogenesis Agents</synonym>
        <synonym>Antiangiogenic Agent</synonym>
        <synonym>angiogenesis inhibitor</synonym>
        <synonym>antiangiogenic</synonym>
        <rdfs:label>Angiogenesis Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1748 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1748">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129825"/>
        <code>C1748</code>
        <definition>Any substance that inhibits topoisomerase, an enzyme that cleaves the DNA backbone to relieve torsional stress in a DNA molecule generated during replication, transcription, and other structural transformations. Inhibition of topoisomerase causes DNA damage, inhibition of DNA replication, and apoptosis.</definition>
        <name>Topoisomerase Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>DNA Topoisomerase Inhibitors</synonym>
        <synonym>Topoisomerase Inhibitor</synonym>
        <synonym>Topoisomerase Inhibitors</synonym>
        <synonym>topoisomerase inhibitor</synonym>
        <rdfs:label>Topoisomerase Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1752 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1752">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C923"/>
        <code>C1752</code>
        <definition>A vaccine based on a synthetic peptide or peptides produced from tissue samples or recombinant sources. Vaccination with peptide vaccines may elicit host immune responses against antigen-expressing cells.</definition>
        <name>Peptide Vaccine</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Peptide Vaccine</synonym>
        <rdfs:label>Peptide Vaccine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C175469 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C175469">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2201"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C804"/>
        <code>C175469</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An intravenous formulation composed of a phospholipid suspension of nanoparticles containing the synthetic retinoid derivative fenretinide, with potential antineoplastic activity. Upon intravenous administration, fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in susceptible tumor cell types. Fenretinide also binds to and inhibits the activity of mammalian target of rapamycin (mTOR), which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Independent of RAR activation and mTOR inhibition, this agent may also modulate gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS).</definition>
        <name>Fenretinide Phospholipid Suspension ST-001</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Fenretinide Phospholipid Suspension ST-001</synonym>
        <synonym>ST 001</synonym>
        <synonym>ST-001</synonym>
        <synonym>ST001</synonym>
        <synonym>nanoFenretinide ST-001</synonym>
        <rdfs:label>Fenretinide Phospholipid Suspension ST-001</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C175941 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C175941">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201688"/>
        <code>C175941</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A polypeptide nanoparticle (PNP)-based small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2), with potential antineoplastic activity. Upon intralesional administration, cotsiranib binds to both TGF-beta 1 and COX-2 messenger RNAs (mRNAs), preventing the translation and expression of TGF-beta 1 and COX-2 proteins. This inhibits TGF-beta 1-mediated signaling and abrogates TGF-beta 1-mediated immunosuppression, which may enhance anti-tumor immunity in the tumor microenvironment (TME) and promote a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. The inhibition of COX-2 prevents COX-2-mediated signaling, which may result in apoptosis and a reduction in tumor cell proliferation, tumor angiogenesis and metastasis.</definition>
        <name>Cotsiranib</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>COTSIRANIB</synonym>
        <synonym>Cotsiranib</synonym>
        <synonym>STP 705</synonym>
        <synonym>STP-705</synonym>
        <synonym>STP705</synonym>
        <rdfs:label>Cotsiranib</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C176017 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C176017">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163758"/>
        <code>C176017</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any agent that targets prostate-specific membrane antigen (PSMA).</definition>
        <name>PSMA-targeting Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>PSMA-targeting Agent</synonym>
        <rdfs:label>PSMA-targeting Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C176586 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C176586">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <code>C176586</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any agent that activates the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173).</definition>
        <name>STING Agonist</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>STING Agonist</synonym>
        <rdfs:label>STING Agonist</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177174 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177174">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2139"/>
        <code>C177174</code>
        <definition>Any agent that binds to and activates toll-like receptors (TLRs).</definition>
        <name>Toll-like Receptor Agonist</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>TLR Agonist</synonym>
        <synonym>Toll-like Receptor Agonist</synonym>
        <rdfs:label>Toll-like Receptor Agonist</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177175 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177175">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177174"/>
        <code>C177175</code>
        <definition>Any agent that binds to and activates toll-like receptor 9 (TLR9).</definition>
        <name>Toll-like Receptor 9 Agonist</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>TLR9 Agonist</synonym>
        <synonym>Toll-like Receptor 9 Agonist</synonym>
        <rdfs:label>Toll-like Receptor 9 Agonist</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177176 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177176">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177174"/>
        <code>C177176</code>
        <definition>Any agent that binds to and activates toll-like receptor 7 (TLR7).</definition>
        <name>Toll-like Receptor 7 Agonist</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>TLR7 Agonist</synonym>
        <synonym>Toll-like Receptor 7 Agonist</synonym>
        <rdfs:label>Toll-like Receptor 7 Agonist</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177430 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177430">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C177430</code>
        <definition>Any agent that targets any of the cancer cell metabolism pathways.</definition>
        <name>Agent Targeting Cancer Metabolism</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Agent Targeting Cancer Metabolism</synonym>
        <rdfs:label>Agent Targeting Cancer Metabolism</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C178643 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C178643">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1904"/>
        <code>C178643</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation consisting of double core-shell (DUCS) micelles containing 7-ethyl-10-hydroxy-camptothecin (SN-38), the active, hydrophobic metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon intravenous administration, nanoparticle SN-38-encapsulated micelle formulation SNB-101 diffuses into the tumor site and the SN-38 moiety binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication, and apoptosis. Compared to SN-38 alone, this formulation increases the water solubility of the poorly soluble drug SN-38, and due to the stability of this formulation, it has a much longer circulation time and reduces toxicity to normal, healthy tissues.</definition>
        <name>Nanoparticle SN-38-encapsulated Micelle Formulation SNB-101</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Nanoparticle Formulation SNB-101</synonym>
        <synonym>Nanoparticle SN-38-encapsulated Micelle Formulation SNB-101</synonym>
        <synonym>SN-38-containing Nano-particle SNB-101</synonym>
        <synonym>SN-38-containing Nano-sized Micelle Formulation SNB-101</synonym>
        <synonym>SNB 101</synonym>
        <synonym>SNB-101</synonym>
        <synonym>SNB101</synonym>
        <rdfs:label>Nanoparticle SN-38-encapsulated Micelle Formulation SNB-101</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179302 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179302">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663"/>
        <code>C179302</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A ferritin-based, nanoparticle vaccine consisting of the Epstein-Barr Virus (EBV) envelop glycoprotein gp350 and a saponin-based adjuvant, with potential immunizing activity against EBV. Upon intramuscular administration of EBV gp350-ferritin nanoparticle vaccine with saponin-based adjuvant, the EBV gp350 may activate both humoral and cellular immune responses which may result in protection against EBV infection. EBV, a ubiquitous human herpes virus, is associated with infectious mononucleosis and various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.</definition>
        <name>Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>EBV gp350-based Nanoparticle Vaccine</synonym>
        <synonym>EBV gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant</synonym>
        <synonym>EBV gp350-ferritin Vaccine</synonym>
        <synonym>EBV gp350-ferritin Vaccine/Matrix M1</synonym>
        <synonym>Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Matrix-M1 Adjuvant</synonym>
        <synonym>Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant</synonym>
        <rdfs:label>Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179581 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179581">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2189"/>
        <code>C179581</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A synthetic microRNA (miRNA) mimic of the endogenous tumor suppressor miR-193a-3p formulated in lipid nanoparticles (LNPs), with potential antineoplastic and immune-activating activities. Upon administration, miRNA-193a-3p mimic INT-1B3 targets tumor cells, binds to its target sequence in mRNA transcripts, which leads to translational repression or mRNA degradation. This inhibits protein expression encoded by that particular mRNA sequence. INT-1B3 is able to downregulate many oncogenic signaling pathways, such as the oncogenic PI3K/Akt and Ras/MAPK pathways, and upregulate the tumor suppressive PTEN pathway. INT-1B3 also modulates the expression of cyclin D1, Mcl-1, K-Ras, c-Kit and TIM-3. In addition, INT-1B3 is able to modulate the tumor microenvironment (TME) through inhibition of CD39/CD73 and by downregulating the adenosine-A2A receptor pathway. This leads to a decrease in immunosuppressive FoxP3/Lag3 regulatory T cells and monocytic myeloid-derived suppressor cells (mMDSCs), increases the maturation of dendritic cells (DCs) and induces a T cell-mediated anti-tumor immune response. Altogether, this may induce cell cycle arrest and apoptosis, increase cell senescence, and decrease tumor cell proliferation, survival, migration and metastasis.</definition>
        <name>miRNA 193a-3p Mimic INT-1B3</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>INT 1B3</synonym>
        <synonym>INT-1B3</synonym>
        <synonym>INT1B3</synonym>
        <synonym>Lipid Nanoparticle Encapsulating miR-193a-3p Mimic INT-1B3</synonym>
        <synonym>miRNA 193a-3p Mimic INT-1B3</synonym>
        <synonym>microRNA 193a-3p Mimic INT-1B3</synonym>
        <rdfs:label>miRNA 193a-3p Mimic INT-1B3</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179607 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179607">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1752"/>
        <code>C179607</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An immunomodulating agent and nanovaccine composed of the invariant natural killer T cell (iNKT) agonist, dendritic cell (DC) transactivator, and an alpha-galactosylceramide (a-GalCer) analog threitolceramide-6 (ThrCer6, IMM60) and immunogenic peptides derived from the tumor-associated antigen (TAA) New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles, with potential immunomodulating and antineoplastic activities. Upon administration of NY-ESO-1 peptides/ThrCer6-loaded nanoparticles PORT-3, ThrCer6 targets and binds to the T-cell receptor on iNKTs, thereby activating the iNKTs. The activated iNKTs activate DCs, resulting in the secretion of a large amount of pro-inflammatory cytokines. The NY-ESO-1 peptides are processed and presented by DCs. Altogether, this induces antigen-specific CD4 and CD8 T cell, and B cell responses, and leads to the induction of a cytotoxic T-lymphocyte (CTL)-mediated immune response against NY-ESO-1-expressing tumor cells. Encapsulating antigens and adjuvants together within the same biodegradable polymeric nanoparticle can enhance T cell responses. NY-ESO-1 is a cancer-testis antigen normally expressed in testicular germ cells and trophoblasts of the placenta and overexpressed in a variety of cancers.</definition>
        <name>NY-ESO-1 Peptides/Threitolceramide-6-loaded Nanoparticles PORT-3</name>
        <semanticType>Immunologic Factor</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>NY-ESO-1 Peptides/ThrCer6-loaded Nanoparticles PORT-3</synonym>
        <synonym>NY-ESO-1 Peptides/Threitolceramide-6-encapsulating Nanoparticles PORT-3</synonym>
        <synonym>NY-ESO-1 Peptides/Threitolceramide-6-loaded Nanoparticles PORT-3</synonym>
        <synonym>Nanoparticles PORT-3</synonym>
        <synonym>PLGA Nanoparticles Loaded with NY-ESO-1 Peptides/IMM60</synonym>
        <synonym>PORT 3</synonym>
        <synonym>PORT-3</synonym>
        <synonym>PORT3</synonym>
        <rdfs:label>NY-ESO-1 Peptides/Threitolceramide-6-loaded Nanoparticles PORT-3</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179620 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179620">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179676"/>
        <code>C179620</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding for a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, mRNA-encoded anti-claudin18.2 monoclonal antibody BNT141 binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the anti-CLDN18.2 monoclonal antibody. The antibody specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.</definition>
        <name>mRNA-encoded Anti-Claudin18.2 Monoclonal Antibody BNT141</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-CLDN18.2 mRNA-encoded Antibody BNT141</synonym>
        <synonym>BNT 141</synonym>
        <synonym>BNT-141</synonym>
        <synonym>BNT141</synonym>
        <synonym>RiboMab BNT141</synonym>
        <synonym>mRNA-encoded Anti-Claudin18.2 Monoclonal Antibody BNT141</synonym>
        <synonym>mRNA-encoded Antibody BNT141</synonym>
        <synonym>rMAB BNT141</synonym>
        <rdfs:label>mRNA-encoded Anti-Claudin18.2 Monoclonal Antibody BNT141</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179638 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179638">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C587"/>
        <code>C179638</code>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticles (LNPs) encapsulating nucleoside-modified messenger RNA (mRNA) encoding the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating activity. Upon administration, ribocytokine IL-2 BNT153 is taken up by cells and the expressed IL-2 targets and binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells.</definition>
        <name>Ribocytokine IL-2 BNT153</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Immunologic Factor</semanticType>
        <synonym>BNT 153</synonym>
        <synonym>BNT-153</synonym>
        <synonym>BNT-153 MRNA</synonym>
        <synonym>BNT153</synonym>
        <synonym>Human Interleukin-2 mRNA-encoded BNT153</synonym>
        <synonym>Ribocytokine IL-2 BNT153</synonym>
        <rdfs:label>Ribocytokine IL-2 BNT153</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179639 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179639">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C592"/>
        <code>C179639</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticles (LNPs) encapsulating nucleoside-modified messenger RNA (mRNA) encoding the endogenous cytokine interleukin-7 (IL-7), with potential immunostimulating activity. Upon administration, ribocytokine IL-7 BNT152 is taken up by cells and the expressed IL-7 targets and binds to the IL-7 receptor (IL7R). The binding of IL-7 to IL7R activates IL7/IL7R-mediated signaling, which activates B- and T- lymphocytes, may improve immune recovery and activation, and may enhance anti-tumor immune responses.</definition>
        <name>Ribocytokine IL-7 BNT152</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Immunologic Factor</semanticType>
        <synonym>BNT 152</synonym>
        <synonym>BNT-152</synonym>
        <synonym>BNT-152 MRNA</synonym>
        <synonym>BNT152</synonym>
        <synonym>Human Interleukin-7 mRNA-encoded BNT152</synonym>
        <synonym>Ribocytokine IL-7 BNT152</synonym>
        <rdfs:label>Ribocytokine IL-7 BNT152</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179676 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179676">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129822"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200250"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20401"/>
        <code>C179676</code>
        <definition>Any monoclonal antibody that is directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18).</definition>
        <name>Anti-claudin18.2 Monoclonal Antibody</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-CLDN18.2 Monoclonal Antibody</synonym>
        <synonym>Anti-claudin18.2 Monoclonal Antibody</synonym>
        <rdfs:label>Anti-claudin18.2 Monoclonal Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179685 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C179685">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213366"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431"/>
        <code>C179685</code>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) and a retinoic acid-inducible gene I protein (RIG-I; DDX58) activating moiety encapsulated in dually derivatized chitosan (DDX) nanoparticles, with potential immunostimulating and antineoplastic activities. Upon intravesical administration of detalimogene voraplasmid, the DDX nanoparticles deliver the IL-12 and RIG-I activating DNA plasmid to the bladder urothelium. This leads to local expression of IL-12 and a RIG-I activating moiety. The increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-lymphocyte (CTL) responses against tumor cells. The RIG-I activating moiety activates the cytosolic RNA receptor RIG-I and induces RIG-I-mediated signaling. This upregulates interferon-alpha (IFN-a) and beta (IFN-b), and induces a potent IFN-mediated innate immune response against the tumor cells. This further induces the activation of NKs and CTLs and induces apoptosis in cancer cells.</definition>
        <name>Detalimogene Voraplasmid</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>DDX Nanoparticles-encapsulated IL-12 and RIG-I Activating DNA Plasmid EG-70</synonym>
        <synonym>DETALIMOGENE VORAPLASMID</synonym>
        <synonym>Detalimogene Voraplasmid</synonym>
        <synonym>Dually Derivatized Chitosan Nanoparticles-encapsulated IL-12 and RIG-I Activating DNA Plasmid EG-70</synonym>
        <synonym>EG 70</synonym>
        <synonym>EG-70</synonym>
        <synonym>EG70</synonym>
        <rdfs:label>Detalimogene Voraplasmid</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C180409 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C180409">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2198"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C267"/>
        <code>C180409</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A sub-micron spray containing a nanoparticle water soluble equimolar solution composed of delta-9-tetrahydrocannabinol (delta-9-THC; d9-THC), an analogue of tetrahydrocannabinol (THC) and the primary form of THC found in the Cannabis sativa L. plant, and cannabidiol (CBD), a phytocannabinoid derived from Cannabis species, with potential analgesic activity. Upon administration to the oro-buccal membrane, d9-THC/CBD combination agent binds to and activates the cannabinoid G-protein coupled receptor (CBR) located in the central nervous system (CNS). This activates the inwardly rectifying potassium channels, which decrease presynaptic neuron firing, and inhibits voltage-sensitive calcium channels that decrease neurotransmitter release. This inhibits excitatory postsynaptic neuronal transmission, and inhibits the release of pro-inflammatory mediators. This provides an analgesic effect.</definition>
        <name>delta9-Tetrahydrocannabinol/Cannabidiol Combination Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>MDCNB-01</synonym>
        <synonym>NanaBis</synonym>
        <synonym>d9-THC/CBD Nanoparticle-based Combination Agent</synonym>
        <synonym>delta9-Tetrahydrocannabinol/Cannabidiol Combination Agent</synonym>
        <rdfs:label>delta9-Tetrahydrocannabinol/Cannabidiol Combination Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C180674 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C180674">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C587"/>
        <code>C180674</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticles (LNPs) encapsulating nucleoside-modified messenger RNA (mRNA) encoding the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating activity. Upon administration, ribocytokine IL-2 BNT153 is taken up by cells and the expressed IL-2 targets and binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells.</definition>
        <name>CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Immunologic Factor</semanticType>
        <synonym>ANV 419</synonym>
        <synonym>ANV-419</synonym>
        <synonym>ANV419</synonym>
        <synonym>Antibody-like Fusion Protein ANV419</synonym>
        <synonym>CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419</synonym>
        <synonym>CD122-selective IL-2/Anti-IL-2Ra Antibody Fusion Protein ANV419</synonym>
        <rdfs:label>CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C180692 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C180692">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177176"/>
        <code>C180692</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A micelle nanoparticle formulation composed of the Toll-Like receptor 7 (TLR7) agonist phospholipid conjugate 1v270 encapsulated within 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)-polyethylene glycol (PEG)-2000, with potential immunostimulating activity. Upon intravenous administration of the nanoparticles encapsulating TLR7 agonist 1v270 MBS8, the TLR7 agonist targets, binds to and activates TLR7, thereby stimulating dendritic cells (DCs) and neutrophils, and enhancing natural killer cell (NK) cytotoxicity. This activation results in the production of pro-inflammatory cytokines, including interferon alpha. MBS8 may activate cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses leading to tumor cell lysis. In addition, MBS8 is able to stimulate immune memory T-cells to further recognize and eliminate cancer cells. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and the activation of innate immunity. The micelle formulation was engineered to reduce systemic cytokine production which may lower systemic toxicity. production which may lower systemic toxicity.</definition>
        <name>Nanoparticles Encapsulating TLR7 Agonist 1v270 MBS8</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>DOPE-PEG2000/1v270 Micelles MBS8</synonym>
        <synonym>MBS 8</synonym>
        <synonym>MBS-8</synonym>
        <synonym>MBS8</synonym>
        <synonym>MBS8(1V270)</synonym>
        <synonym>Nanoparticles Encapsulating TLR7 Agonist 1v270 MBS8</synonym>
        <synonym>TLR7 Agonist 1v270-containing Micelles MBS8</synonym>
        <rdfs:label>Nanoparticles Encapsulating TLR7 Agonist 1v270 MBS8</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C181141 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C181141">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C172787"/>
        <code>C181141</code>
        <definition>Any mRNA-based cancer vaccine.</definition>
        <name>mRNA Cancer Vaccine</name>
        <semanticType>Nucleic Acid, Nucleoside, or Nucleotide</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>mRNA Antineoplastic Vaccine</synonym>
        <synonym>mRNA Cancer Vaccine</synonym>
        <synonym>mRNA-based Cancer Vaccine</synonym>
        <synonym>mRNA-derived Cancer Vaccine</synonym>
        <rdfs:label>mRNA Cancer Vaccine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C184380 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C184380">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C184380</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A polypeptide nanoparticle (PNP)-based therapeutic comprised of two small interfering RNA (siRNA) oligonucleotides directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-TGF-beta 1/anti-COX-2 siRNAs STP707 binds to both TGF-beta 1 and COX-2 messenger RNAs (mRNAs), preventing the translation and expression of TGF-beta 1 and COX-2 proteins. This inhibits TGF-beta 1-mediated signaling and abrogates TGF-beta 1-mediated immunosuppression, which may enhance anti-tumor immunity in the tumor microenvironment (TME) and promote a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. The inhibition of COX-2 prevents COX-2-mediated signaling, which may result in apoptosis and a reduction in tumor cell proliferation, tumor angiogenesis and metastasis.</definition>
        <name>Anti-TGF-beta 1/Anti-COX-2 siRNAs STP707</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-TGF-beta 1/Anti-COX-2 siRNA Oligonucleotides STP707</synonym>
        <synonym>Anti-TGF-beta 1/Anti-COX-2 siRNAs STP707</synonym>
        <synonym>Anti-TGF-beta 1/COX-2 siRNAs STP707</synonym>
        <synonym>STP 707</synonym>
        <synonym>STP-707</synonym>
        <synonym>STP707</synonym>
        <rdfs:label>Anti-TGF-beta 1/Anti-COX-2 siRNAs STP707</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C185869 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C185869">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C181141"/>
        <code>C185869</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A vaccine consisting of a lipid nanoparticle (LNP) encapsulating four messenger RNAs (mRNAs) encoding the Epstein-Barr Virus (EBV) envelope glycoproteins gp42, gp220, gH and gL, with potential immunizing activity against EBV. Upon intramuscular administration of LNP-encapsulated EBV mRNA vaccine mRNA-1189, the LNP binds to the plasma membrane of cells and releases the mRNAs into the cells. The mRNAs are then translated by ribosomes to produce the EBV envelope glycoproteins. This may activate both humoral and cellular immune responses which may result in protection against EBV infection. EBV, a ubiquitous human herpes virus, is associated with infectious mononucleosis and various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.</definition>
        <name>Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-EBV mRNA Vaccine mRNA-1189</synonym>
        <synonym>LNP-encapsulated EBV mRNA Vaccine mRNA-1189</synonym>
        <synonym>LNP-encapsulated mRNA-based EBV Vaccine mRNA-1189</synonym>
        <synonym>Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189</synonym>
        <synonym>mRNA 1189</synonym>
        <synonym>mRNA-1189</synonym>
        <synonym>mRNA1189</synonym>
        <rdfs:label>Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C186664 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C186664">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C186664</code>
        <definition>Any chemotherapeutic agent that is cytotoxic in nature and non-specifically kills rapidly proliferating cells, including tumor cells. This includes cytotoxic agents that are modified or formulated in such a way as to more specifically target tumor cells but for which the fundamental cytotoxic mechanism of action (MoA) has not changed. Targeted therapy agents that have antineoplastic MoAs are not included.</definition>
        <name>Cytotoxic Chemotherapeutic Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Antineoplastic Cytotoxic Agent</synonym>
        <synonym>Cytotoxic Antineoplastic Agent</synonym>
        <synonym>Cytotoxic Chemotherapeutic Agent</synonym>
        <synonym>Cytotoxic Chemotherapy Agent</synonym>
        <rdfs:label>Cytotoxic Chemotherapeutic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187021 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187021">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200114"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2843"/>
        <code>C187021</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A conjugate composed of folic acid analogs and exatecans covalently bound by linkers to the ultrasmall silica-based nanoparticle carrier C&apos;Dot, with potential antineoplastic activity. Upon administration, pasifolate exatecan targets and binds to the human folate receptor 1 (FOLR1; FR-alpha) on FR-alpha-expressing tumor cells. Upon internalization, the camptothecin analog exatecan is released via proteolytic cleavage of the linker and inhibits DNA topoisomerase 1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing FR-alpha. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; it is overexpressed in various cancer cell types.</definition>
        <name>Pasifolate Exatecan</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>EC112002</synonym>
        <synonym>ELU 001</synonym>
        <synonym>ELU-001</synonym>
        <synonym>ELU001</synonym>
        <synonym>FA-CDC ELU001</synonym>
        <synonym>FR-alpha-targeting CDC ELU001</synonym>
        <synonym>FR-alpha-targeting Ultrasmall Silica Nanoparticle-drug Conjugate ELU001</synonym>
        <synonym>Folate-receptor Alpha-targeting C&apos;Dot-drug Conjugate ELU001</synonym>
        <synonym>Folate-receptor Alpha-targeting Ultrasmall Silica Nanoparticle-drug Conjugate ELU001</synonym>
        <synonym>Folic-acid Functionalized C&apos;Dot-drug-conjugate ELU001</synonym>
        <synonym>PASIFOLATE EXATECAN</synonym>
        <synonym>Pasifolate Exatecan</synonym>
        <rdfs:label>Pasifolate Exatecan</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187033 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187033">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1291"/>
        <code>C187033</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle preparation of archexin, a 20-mer antisense (AS) oligodeoxynucleotide (ODN) against the proto-oncogene Akt, with potential antineoplastic activity. Upon administration of AS ODN WGI-0301, archexin binds to Akt-1 mRNA, inhibiting translation of the transcript. Suppression of Akt-1 expression may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated signaling. This may inhibit proliferation and induce apoptosis of tumor cells in which Akt-1 is overexpressed. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.</definition>
        <name>Akt-1 Antisense Oligonucleotide WGI-0301</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Akt-1 AS ODN WGI-0301</synonym>
        <synonym>Akt-1 Antisense ODN WGI-0301</synonym>
        <synonym>Akt-1 Antisense Oligonucleotide WGI-0301</synonym>
        <synonym>WGI 0301</synonym>
        <synonym>WGI-0301</synonym>
        <synonym>WGI0301</synonym>
        <rdfs:label>Akt-1 Antisense Oligonucleotide WGI-0301</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187083 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187083">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C177430"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C29726"/>
        <code>C187083</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation composed of a nanoscale coordination polymer (NCP) complex containing two as of yet undisclosed anti-tumor agents, with potential antineoplastic activities. Upon intravenous administration, nanoparticle formulation CPI-300 delivers the anti-tumor agents to tumor cells, which may lead, through as of yet undisclosed mechanism of actions (MoAs), to specific tumor cell killing and inhibition of proliferation of tumor cells.</definition>
        <name>Nanoparticle Formulation CPI-300</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CPI 300</synonym>
        <synonym>CPI-300</synonym>
        <synonym>CPI300</synonym>
        <synonym>NCP Platform-based CPI-300</synonym>
        <synonym>Nanoparticle Formulation CPI-300</synonym>
        <synonym>Nanoscale Coordination Polymer-based Formulation CPI-300</synonym>
        <rdfs:label>Nanoparticle Formulation CPI-300</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187116 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187116">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2843"/>
        <code>C187116</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A polymeric nanoparticle formulation of the topoisomerase I inhibitor camptothecin (CPT), an alkaloid isolated from the Chinese tree Camptotheca acuminata, covalently conjugated, via a linker, to a biocompatible polymer scaffold, with potential antineoplastic activity. Upon intravenous administration of polymeric nanoparticle-conjugated CPT DAN-222, the nanoparticles accumulate in tumor tissue and CPT is released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, CPT selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to CPT alone, the nanoparticle formulation has a prolonged half-life and greatly improves the biodistribution of CPT resulting in an accumulation of CPT at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects.</definition>
        <name>Polymeric Nanoparticle-conjugated Camptothecin DAN-222</name>
        <semanticType>Organic Chemical</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>DAN 222</synonym>
        <synonym>DAN-222</synonym>
        <synonym>DAN222</synonym>
        <synonym>Polymeric Nanoparticle-conjugated Camptothecin DAN-222</synonym>
        <synonym>Polymeric Nanoparticle-containing Camptothecin DAN-222</synonym>
        <synonym>Polymeric Nanoparticles DAN-222</synonym>
        <rdfs:label>Polymeric Nanoparticle-conjugated Camptothecin DAN-222</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187124 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C187124">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129822"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201282"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211959"/>
        <code>C187124</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle (LNP) encapsulating nucleoside-modified messenger RNA (mRNA) encoding for bispecific antibody directed against the tumor-associated antigen (TAA) Claudin 6 (CLDN6; CLDN-6) and the human T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, mRNA-encoded anti-CD3/anti-CLDN6 bispecific antibody BNT142 binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is translated and the anti-CD3/anti-CLDN6 bispecific antibody binds to both CD3-expressing T-cells and CLDN6-expressing cancer cells, thereby crosslinking CLDN6-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN6-expressing tumor cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.</definition>
        <name>mRNA-encoded Anti-CD3/Anti-CLDN6 Bispecific Antibody BNT142</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-CD3/Anti-CLDN6 mRNA-encoded Antibody BNT142</synonym>
        <synonym>BNT 142</synonym>
        <synonym>BNT-142</synonym>
        <synonym>BNT142</synonym>
        <synonym>CD3 x CLDN6 mRNA-encoded Antibody BNT142</synonym>
        <synonym>CD3xCLDN6 RiboMAB-encoding mRNA BNT142</synonym>
        <synonym>RiboMab BNT142</synonym>
        <synonym>mRNA-encoded Anti-CD3/Anti-CLDN6 Bispecific Antibody BNT142</synonym>
        <synonym>rMAB BNT142</synonym>
        <rdfs:label>mRNA-encoded Anti-CD3/Anti-CLDN6 Bispecific Antibody BNT142</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1892 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1892">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C1892</code>
        <definition>A natural or synthetic substance, such as a drug, vitamin, hormone, plant product or food supplement, that may reduce the risk of developing or recurrence of tumor formation. Chemopreventive agent may work at different stages and may inhibit the initiation, promotion, transformation, and/or progression of the malignant process.</definition>
        <name>Chemopreventive Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Chemopreventive Agent</synonym>
        <rdfs:label>Chemopreventive Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C190153 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C190153">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C190153</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle (LNP)-based formulation consisting of a biscistronic mRNA that encodes two independent epigenomic controllers targeting the proto-oncogene MYC (c-Myc), with potential antineoplastic activity. Upon administration of LNP encapsulated MYC-targeting mRNA-based agent OTX-2002, the lipid formulation promotes the uptake by tumor cells. The biscistronic mRNA is then translated by the cellular protein translation machinery to produce two independent epigenomic controllers consisting of a DNA binding domain and an epigenetic effector protein. The two epigenomic controllers bind to regulatory regions on the MYC insulated genomic domain (IGD), a DNA loop bound by CTCF (CCCTC-binding factor). This downregulates MYC expression pre-transcriptionally, which may inhibit proliferation in susceptible tumor cells. MYC, a proto-oncogene overexpressed in a variety of cancers, plays a role in the regulation of transcription and cell proliferation.</definition>
        <name>Lipid Nanoparticle Encapsulated MYC-targeting mRNA-based Agent OTX-2002</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>LNP Encapsulated MYC-targeting mRNA-based Agent OTX-2002</synonym>
        <synonym>Lipid Nanoparticle Encapsulated MYC-targeting mRNA-based Agent OTX-2002</synonym>
        <synonym>OTX 2002</synonym>
        <synonym>OTX-2002</synonym>
        <synonym>OTX2002</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulated MYC-targeting mRNA-based Agent OTX-2002</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C190391 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C190391">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431"/>
        <code>C190391</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticle (LNP) encapsulating self-replicating RNA (srRNA) encoding human interleukin-12 (IL-12), with potential immunomodulatory and antineoplastic activities. Upon intratumoral injection of LNP encapsulated srRNA encoding human IL-12 JCXH-211, the LNPs bind to the plasma membrane of nearby tumor cells and release srRNA encoding IL-12 into the tumor cells. The srRNA amplifies within the tumor cells, and is translated by the cellular protein translation machinery to produce IL-12, which is secreted into the local tumor microenvironment (TME). The secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may enhance immune-mediated destruction of tumor cells and decrease tumor cell proliferation. In addition, the virus-based RNA replicon may trigger anti-viral innate immune responses, further killing tumor cells.</definition>
        <name>Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>JCXH 211</synonym>
        <synonym>JCXH-211</synonym>
        <synonym>JCXH211</synonym>
        <synonym>LNP Encapsulated srRNA Encoding Human IL-12 JCXH-211</synonym>
        <synonym>Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 JCXH-211</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1904 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1904">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1748"/>
        <code>C1904</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any substance that inhibits topoisomerase-I, a topoisomerase that relieves torsional stress in a DNA molecule by cutting only one strand of the DNA double helix. Inhibition of topoisomerase-I causes DNA damage, inhibition of DNA replication, and apoptosis.</definition>
        <name>Topoisomerase-I Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Topoisomerase-I Inhibitor</synonym>
        <synonym>Topoisomerase-I Inhibitors</synonym>
        <rdfs:label>Topoisomerase-I Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1907 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1907">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C1907</code>
        <definition>Any drug derived from microorganisms, plants, or animals; also, synthesized versions of these substances or their derivatives.</definition>
        <name>Drug, Natural Product</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Drug Derived from Natural Products</synonym>
        <synonym>Drug, Natural Product</synonym>
        <rdfs:label>Drug, Natural Product</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C190739 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C190739">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C190739</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, complexed with danburstotug, a human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential antineoplastic activity. Upon administration of nab-paclitaxel/danburstotug complex AP160, the danburstotug moiety specifically binds to PD-L1 and targets this formulation to PD-L1-positive tumor cells. In turn, paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of PD-L1-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and targeting by the danburstotug moiety allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types.</definition>
        <name>Nab-paclitaxel/Danburstotug Complex AP160</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>AP 160</synonym>
        <synonym>AP-160</synonym>
        <synonym>AP160</synonym>
        <synonym>Nab-paclitaxel/Danburstotug Complex AP160</synonym>
        <synonym>Nab-paclitaxel/STI-3031 Complex AP160</synonym>
        <rdfs:label>Nab-paclitaxel/Danburstotug Complex AP160</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1908 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1908">
        <owl:disjointWith rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20181"/>
        <owl:disjointWith rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43431"/>
        <code>C1908</code>
        <definition>An organic or inorganic substance, element, isotope, food or other materials derived from microorganism, plant, or animal sources. They can be used for the prevention, diagnosis, treatment or research of disease states, for industrial purposes, or for the promotion or maintenance of organism viability or health.</definition>
        <name>Drug, Food, Chemical or Biomedical Material</name>
        <semanticType>Classification</semanticType>
        <synonym>Drug, Food, Chemical or Biomedical Material</synonym>
        <rdfs:label>Drug, Food, Chemical or Biomedical Material</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1908"/>
        <code>C1909</code>
        <conceptInSubset>BRIDG Class Terminology</conceptInSubset>
        <conceptInSubset>BRIDG Terminology</conceptInSubset>
        <conceptInSubset>CDISC Glossary Terminology</conceptInSubset>
        <conceptInSubset>CDISC Protocol Terminology</conceptInSubset>
        <conceptInSubset>CDISC SDTM Intervention Type Terminology</conceptInSubset>
        <conceptInSubset>CDISC SDTM Terminology</conceptInSubset>
        <conceptInSubset>CRF4 Treatment Chemotherapy Table</conceptInSubset>
        <conceptInSubset>CRF4 Treatment Steroids during Radiation Table</conceptInSubset>
        <conceptInSubset>CRF4 Treatment Steroids during Re-Irradiation Table</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <conceptInSubset>GDC Property Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>NICHD Terminology</conceptInSubset>
        <conceptInSubset>Pediatric Immunization Terminology</conceptInSubset>
        <definition>Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.</definition>
        <name>Pharmacologic Substance</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Agent</synonym>
        <synonym>DRUG</synonym>
        <synonym>Drug</synonym>
        <synonym>Drug Substance</synonym>
        <synonym>Pharmaceutical Agent</synonym>
        <synonym>Pharmaceuticals</synonym>
        <synonym>Pharmacologic Agent</synonym>
        <synonym>Pharmacologic Substance</synonym>
        <synonym>Pharmacological Substance</synonym>
        <synonym>Therapeutic Agent</synonym>
        <synonym>drug</synonym>
        <synonym>therapeutic agents</synonym>
        <synonym>therapeutic_agents</synonym>
        <rdfs:label>Pharmacologic Substance</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1913 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1913">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1908"/>
        <code>C1913</code>
        <definition>Substances that are grouped or classified by chemical composition.</definition>
        <name>Drug or Chemical by Structure</name>
        <semanticType>Classification</semanticType>
        <synonym>Drug or Chemical by Structure</synonym>
        <rdfs:label>Drug or Chemical by Structure</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1916 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1916">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C718"/>
        <code>C1916</code>
        <definition>Organic or inorganic compounds that contain nitrogen as an integral part of the molecule.</definition>
        <name>Nitrogen Compound</name>
        <semanticType>Chemical Viewed Structurally</semanticType>
        <semanticType>Organic Chemical</semanticType>
        <synonym>Nitrogen Compound</synonym>
        <rdfs:label>Nitrogen Compound</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1931 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1931">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1907"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C1931</code>
        <definition>Plant-derived compound used to treat cancer.</definition>
        <name>Antineoplastic Plant Product</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Antineoplastic Plant Product</synonym>
        <rdfs:label>Antineoplastic Plant Product</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1932 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1932">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1908"/>
        <code>C1932</code>
        <definition>A chemical that influences the properties of another chemical or biological function. (NCI)</definition>
        <name>Chemical Modifier</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Chemical Modifier</synonym>
        <synonym>Modifier</synonym>
        <rdfs:label>Chemical Modifier</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1934 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1934">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2122"/>
        <code>C1934</code>
        <definition>An agent that induces the differentiation or maturation of cells, specifically neoplastic cells, resulting in decreases in tumor growth and metastasis. (NCI04)</definition>
        <name>Differentiation Inducer</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Differentiating Agents</synonym>
        <synonym>Differentiation Agents</synonym>
        <synonym>Differentiation Inducer</synonym>
        <rdfs:label>Differentiation Inducer</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1937 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1937">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C802"/>
        <code>C1937</code>
        <definition>Any reagent that is used in vitro or in vivo for detection or screening of a particular disease or any health-related issue.</definition>
        <name>Diagnostic Reagent</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Diagnostic Reagent</synonym>
        <rdfs:label>Diagnostic Reagent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1941 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1941">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1283"/>
        <code>C1941</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A recombinant therapeutic agent which is chemically identical to or similar to one of a number of endogenous tumor necrosis factor (TNF) proteins. TNF family cytokines bind to and activate specific cell-surface receptors, thereby mediating inflammatory processes, cell proliferation, immunity, angiogenesis, and tumor cell cytotoxicity. One primary antitumor effect of TNFs involves stimulation of T cell-mediated antitumor cytotoxicity.</definition>
        <name>Recombinant Tumor Necrosis Factor Family Protein</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Recombinant Tumor Necrosis Factor Family Protein</synonym>
        <synonym>TNF</synonym>
        <synonym>Tumor Necrosis Factor Family Protein</synonym>
        <synonym>Tumor Necrosis Factors</synonym>
        <synonym>tumor necrosis factor</synonym>
        <rdfs:label>Recombinant Tumor Necrosis Factor Family Protein</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1946 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1946">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C471"/>
        <code>C1946</code>
        <definition>Any substance that inhibits histone deacetylase, an enzyme that catalyzes the removal of acetyl groups from core histones. Inhibition of histone deacetylase can result in hyperacetylation of histones, with an effect on gene expression and cell differentiation.</definition>
        <name>Histone Deacetylase Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>HDAC Agent</synonym>
        <synonym>HDAC inhibitor</synonym>
        <synonym>Histone Deacetylase Inhibitor</synonym>
        <synonym>histone deacetylase inhibitor</synonym>
        <rdfs:label>Histone Deacetylase Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <code>C1962</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>DNA constructs or co-administered agents used in gene therapy. Gene therapy constructs are used in delivery of genetic material into cells in order to permanently correct an inherited disease or an acquired disease such as cancer.</definition>
        <name>Gene Therapy Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Gene Therapy</synonym>
        <synonym>Gene Therapy Agent</synonym>
        <rdfs:label>Gene Therapy Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1966 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1966">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C802"/>
        <code>C1966</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>A compound that enables or improves the visualization of body structures or functions for medical imaging.</definition>
        <name>Imaging Agent</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Image Enhancement Agent</synonym>
        <synonym>Imaging Agent</synonym>
        <rdfs:label>Imaging Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1968 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1968">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1748"/>
        <code>C1968</code>
        <definition>Any substance that inhibits topoisomerase-II, a topoisomerase that relieves torsional stress in a DNA molecule by cutting both strands of the DNA double helix. A topoisomerase II inhibitor can either stabilize the DNA-protein complex or inhibit the catalytic activity of the enzyme. Inhibition of topoisomerase-II causes DNA damage, inhibition of DNA replication, and apoptosis.</definition>
        <name>Topoisomerase-II Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Topoisomerase-II Inhibitor</synonym>
        <synonym>Topoisomerase-II Inhibitors</synonym>
        <rdfs:label>Topoisomerase-II Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19711 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19711">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C17005"/>
        <code>C19711</code>
        <conceptInSubset>BRIDG Class Terminology</conceptInSubset>
        <conceptInSubset>BRIDG Terminology</conceptInSubset>
        <conceptInSubset>CDISC DDF Entities Terminology</conceptInSubset>
        <conceptInSubset>CDISC DDF Terminology</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <definition>A formal group of people that exists to further a particular profession.</definition>
        <name>Professional Organization or Group</name>
        <semanticType>Professional or Occupational Group</semanticType>
        <synonym>ORG</synonym>
        <synonym>Organization</synonym>
        <synonym>Organizational</synonym>
        <synonym>Other Agency or Organization</synonym>
        <synonym>Outside Bodies</synonym>
        <synonym>Professional Organization or Group</synonym>
        <rdfs:label>Professional Organization or Group</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19729 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19729">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19980"/>
        <code>C19729</code>
        <definition>NCI-designated Comprehensive Cancer Centers conduct research and provide services directly to cancer patients. These facilities must demonstrate expertise in each of three areas: laboratory, clinical, and behavioral and population-based research. Comprehensive Cancer Centers are expected to initiate and conduct early-phase, innovative clinical trials and to participate in the NCI&apos;s cooperative groups by providing leadership and recruiting patients for trials. Comprehensive Cancer Centers must also conduct activities in outreach and education, and provide information on advances in health care for both health care professionals and the public.</definition>
        <name>NCI-Designated Comprehensive Cancer Center</name>
        <semanticType>Health Care Related Organization</semanticType>
        <synonym>Comprehensive Cancer Center</synonym>
        <synonym>NCI-Designated Comprehensive Cancer Center</synonym>
        <rdfs:label>NCI-Designated Comprehensive Cancer Center</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C198655 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C198655">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1511"/>
        <code>C198655</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A radioconjugate composed of macrophage-targeted polyglucose nanoparticle, labeled with the radioisotope copper Cu 64, with potential use as a tracer for macrophages including tumor-associated macrophages (TAMs) during positron emission tomography (PET). Upon administration of copper Cu 64-labeled macrophage-targeted nanoparticle, the macrophage-targeted nanoparticle is taken up by macrophages, including TAMs in the tumor microenvironment (TME). Upon PET imaging, the macrophages can be detected. The accumulation of macrophages is present in various inflammatory diseases and tumors.</definition>
        <name>Copper 64 Cu-labeled Macrophage-targeted Nanoparticle</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>64Cu-Macrin</synonym>
        <synonym>64Cu-labeled Macrin</synonym>
        <synonym>Copper 64 Cu-labeled Macrin</synonym>
        <synonym>Copper 64 Cu-labeled Macrophage-targeted Nanoparticle</synonym>
        <synonym>[64]Cu-Macrin</synonym>
        <rdfs:label>Copper 64 Cu-labeled Macrophage-targeted Nanoparticle</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C199143 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C199143">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19711"/>
        <code>C199143</code>
        <definition>A formalized group of individuals focused on aspect(s) of healthcare.</definition>
        <name>Professional Healthcare Organization or Group</name>
        <semanticType>Professional or Occupational Group</semanticType>
        <synonym>Professional Healthcare Organization or Group</synonym>
        <rdfs:label>Professional Healthcare Organization or Group</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19975 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19975">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C199143"/>
        <code>C19975</code>
        <definition>Groups of scientists who link their expertise and resources in collaborative efforts to address important questions of shared interest.</definition>
        <name>Consortium or Network</name>
        <semanticType>Professional or Occupational Group</semanticType>
        <synonym>Centers, Networks, and Consortia</synonym>
        <synonym>Consortium</synonym>
        <synonym>Consortium or Network</synonym>
        <synonym>NCI Consortium or Network</synonym>
        <synonym>Network</synonym>
        <rdfs:label>Consortium or Network</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19980 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19980">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19975"/>
        <code>C19980</code>
        <definition>Facilities designated Cancer Centers generally conduct a combination of basic, population sciences, and clinical research, and are encouraged to stimulate collaborative research involving more than one field of study. Several of these centers conduct only laboratory research and do not provide patient care. The NCI-designated Cancer Centers that do provide patient care are also expected to conduct early-phase, innovative clinical trials and to participate in the NCI Cooperative Group Program.</definition>
        <name>NCI-Designated Cancer Center</name>
        <semanticType>Health Care Related Organization</semanticType>
        <semanticType>Professional or Occupational Group</semanticType>
        <synonym>Cancer Center</synonym>
        <synonym>Cancer Centers</synonym>
        <synonym>NCI-Designated Cancer Center</synonym>
        <rdfs:label>NCI-Designated Cancer Center</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200114 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200114">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163758"/>
        <code>C200114</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any agent targeting folate receptor alpha (FRa; FolRa; FOLR1).</definition>
        <name>FOLR1-targeting Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>FOLR1-targeting Agent</synonym>
        <synonym>FRa-targeting Agent</synonym>
        <synonym>Folate Receptor Alpha-targeting Agent</synonym>
        <rdfs:label>FOLR1-targeting Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200250 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200250">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163758"/>
        <code>C200250</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any agent that targets claudin 18.2 (CLDN18.2; A2 isoform of claudin-18).</definition>
        <name>CLDN18.2-targeting Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CLDN18.2-targeting Agent</synonym>
        <synonym>Claudin 18.2-targeting Agent</synonym>
        <rdfs:label>CLDN18.2-targeting Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200369 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C200369">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2124"/>
        <code>C200369</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A radioconjugate comprised of the microRNA-10b (miR-10b)-inhibitor TTX-MC138, which consists of an anti-miR10b antagomir conjugated to ultrasmall iron oxide nanoparticles, chelated with 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA) and radiolabeled with the radiotracer copper Cu 64, that may be used as an imaging agent for miR-10b-overexpressing tumor cells upon positron emission tomography (PET)-magnetic resonance imaging (PET-MRI). Upon administration of copper Cu 64 NODAGA-TTX-MC138, the TTX-MC138 moiety targets and binds to miR-10b inside tumor cells. This allows for visualization of miR-10b-overexpressing tumor cells upon imaging with PET-MRI. miR-10b, a mRNA that is highly expressed in a variety of metastatic tumor cells, plays a key role in tumor cell migration, invasion and metastasis.</definition>
        <name>Copper Cu 64 NODAGA-TTX-MC138</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>64Cu-NODAGA-TTX-MC138</synonym>
        <synonym>Copper Cu 64 NODAGA-TTX-MC138</synonym>
        <synonym>Cu-64 labeled TTX-MC138</synonym>
        <synonym>TTX-MC138-NODAGA-Cu64</synonym>
        <rdfs:label>Copper Cu 64 NODAGA-TTX-MC138</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201282 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201282">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C203828"/>
        <code>C201282</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any bispecific antibody that simultaneously binds to the CD3 subunit within the T-cell receptor (TCR) complex expressed on T-cells and a tumor-associated antigen (TAA) expressed on tumor cells.</definition>
        <name>T-cell Engaging Bispecific Antibody</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <synonym>T-cell Engaging Bispecific Antibody</synonym>
        <synonym>T-cell-engaging Bispecific Antibody</synonym>
        <synonym>TCE BsAb</synonym>
        <rdfs:label>T-cell Engaging Bispecific Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201688 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201688">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <code>C201688</code>
        <definition>Any agent that is based on small interfering RNA (siRNA).</definition>
        <name>siRNA Therapeutic Agent</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Short Interfering RNA Therapeutic</synonym>
        <synonym>Small Interfering RNA Therapeutic</synonym>
        <synonym>siRNA Therapeutic Agent</synonym>
        <synonym>siRNA-based Agent</synonym>
        <rdfs:label>siRNA Therapeutic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20181 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20181">
        <owl:disjointWith rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43431"/>
        <code>C20181</code>
        <definition>An organizational header for concepts representing mostly abstract entities.</definition>
        <name>Conceptual Entity</name>
        <semanticType>Classification</semanticType>
        <synonym>Conceptual Entity</synonym>
        <rdfs:label>Conceptual Entity</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201982 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201982">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C176586"/>
        <code>C201982</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation consisting of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173)-activating, pH-sensitive, polymeric micelles PC7A, loaded with the endogenous STING agonist cGAMP, with potential immunoactivating and antineoplastic activities. Upon intratumoral administration of dual-activating polyvalent STING agonist ONM-501, both the polymer PC7A and the encapsulated cGAMP target and bind to STING, thereby activating the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.</definition>
        <name>Dual-activating Polyvalent STING Agonist ONM-501</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Dual-activating Polyvalent STING Agonist ONM-501</synonym>
        <synonym>ONM 501</synonym>
        <synonym>ONM-501</synonym>
        <synonym>ONM501</synonym>
        <synonym>PC7A-encapsulated STING Agonist ONM-501</synonym>
        <synonym>PC7A-encapsulated cGAMP ONM-501</synonym>
        <synonym>STING-activating Polymer-encapsulated STING Agonist ONM-501</synonym>
        <rdfs:label>Dual-activating Polyvalent STING Agonist ONM-501</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C202248 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C202248">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431"/>
        <code>C202248</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) encoding human single-chain interleukin-12 (scIL-12), with potential immunomodulatory and antineoplastic activities. Upon intratumoral injection, the LNP moiety binds to the plasma membrane of nearby cells and releases the scIL-12 mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce scIL-12, which is secreted into the local tumor microenvironment (TME). IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.</definition>
        <name>Lipid Nanoparticle Encapsulated mRNA Encoding Human Single-chain IL-12 ABO2011</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ABO 2011</synonym>
        <synonym>ABO-2011</synonym>
        <synonym>ABO2011</synonym>
        <synonym>ABOD 2011</synonym>
        <synonym>ABOD-2011</synonym>
        <synonym>ABOD2011</synonym>
        <synonym>LNP-encapsulated mRNA Encoding IL-12 ABO2011</synonym>
        <synonym>Lipid Nanoparticle Encapsulated mRNA Encoding Human Single-chain IL-12 ABO2011</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulated mRNA Encoding Human Single-chain IL-12 ABO2011</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C202862 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C202862">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C202862</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel that are coated with the bladder cancer-targeting ligand PLZ4, a cyclic peptide with amino acid sequence of QDGRMGF, with potential antineoplastic activity. Upon administration of the PLZ4-coated paclitaxel-loaded micelle formulation, the PLZ4 moiety specifically targets and binds to bladder cancer cells while avoiding normal, healthy cells. This specifically delivers paclitaxel to bladder cancer cells and, due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micelle formulation and the addition of PLZ4 may allow for the delivery of higher doses of paclitaxel to bladder cancer cells while minimizing systemic toxicity.</definition>
        <name>PLZ4-coated Paclitaxel-loaded Micelle Formulation</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>PLZ4-coated Paclitaxel-loaded Micelle Formulation</synonym>
        <synonym>PLZ4-coated Paclitaxel-loaded Micelles</synonym>
        <synonym>PPM</synonym>
        <synonym>PPMs</synonym>
        <rdfs:label>PLZ4-coated Paclitaxel-loaded Micelle Formulation</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C203332 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C203332">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1748"/>
        <code>C203332</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any topoisomerase inhibitor in a pegylated formulation.</definition>
        <name>Pegylated Topoisomerase Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Pegylated Topoisomerase Inhibitor</synonym>
        <rdfs:label>Pegylated Topoisomerase Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20368 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20368">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C16847"/>
        <code>C20368</code>
        <definition>Technique used in the laboratory for scientific research.</definition>
        <name>Research Technique</name>
        <semanticType>Laboratory Procedure</semanticType>
        <synonym>Research Technique</synonym>
        <rdfs:label>Research Technique</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C203828 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C203828">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C112883"/>
        <code>C203828</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any antibody that simultaneously binds to the CD3 subunit within the T-cell receptor (TCR) complex expressed on T-cells and at least one tumor-associated antigen (TAA) expressed on tumor cells.</definition>
        <name>T-cell Engaging Antibody</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <synonym>T Cell Engager</synonym>
        <synonym>T-cell Engaging Antibody</synonym>
        <synonym>T-cell-engaging Antibody</synonym>
        <synonym>TCE</synonym>
        <rdfs:label>T-cell Engaging Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20401 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20401">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C20401</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.</definition>
        <name>Monoclonal Antibody</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <synonym>MAb</synonym>
        <synonym>MoAB</synonym>
        <synonym>Monoclonal Antibodies</synonym>
        <synonym>Monoclonal Antibody</synonym>
        <synonym>Monoclonal Antibody Therapy</synonym>
        <synonym>monoclonal antibody</synonym>
        <rdfs:label>Monoclonal Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C204213 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C204213">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1450"/>
        <code>C204213</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A nano-engineered intraoperative system containing a liquid permeation enhancer (PE) and a patch composed of nanoparticles loaded with the inorganic platinum agent cisplatin, with potential antineoplastic and immunomodulating activities. Immediately following surgical tumor resection, the cisplatin nano-engineered intraoperative system PRV211 is applied intraoperatively; the PE is brushed onto the resected tumor bed and then the cisplatin patch is applied onto the same tumor site. Upon subsequent long-lasting and controlled release from the patch and penetration into the tumor bed, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells. Cisplatin may reach regional lymph nodes and may trigger anti-tumor immune responses. Administration of PRV211 may eliminate any remaining micro metastases or close margins that could not be fully resected while avoiding system circulation. This may prevent systemic side effect and cancer recurrence.</definition>
        <name>Cisplatin Nano-engineered Intraoperative System PRV211</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Cisplatin Nano-engineered Formulation PRV211</synonym>
        <synonym>Cisplatin Nano-engineered Intraoperative Formulation PRV211</synonym>
        <synonym>Cisplatin Nano-engineered Intraoperative System PRV211</synonym>
        <synonym>Cisplatin Nanoparticles-containing Intraoperative Formulation PRV211</synonym>
        <synonym>Intraoperative Cisplatin System PRV211</synonym>
        <synonym>Nano-engineered Hydrogel PRV211</synonym>
        <synonym>Nano-engineered Polymeric Patch PRV211</synonym>
        <synonym>PRV 211</synonym>
        <synonym>PRV-211</synonym>
        <synonym>PRV211</synonym>
        <rdfs:label>Cisplatin Nano-engineered Intraoperative System PRV211</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C204794 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C204794">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C181141"/>
        <code>C204794</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An mRNA-based, personalized cancer vaccine consisting of total tumor RNA (TTRNA) derived from autologous tumor cells, formulated in DOTAP lipid nanoparticles, with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous total tumor mRNA loaded liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs). The expressed epitopes are then presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient&apos;s cancer cells that express these tumor antigens.</definition>
        <name>Autologous Total Tumor mRNA Loaded Liposome Vaccine</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Autologous Total Tumor mRNA Loaded DOTAP Liposome Vaccine</synonym>
        <synonym>Autologous Total Tumor mRNA Loaded Liposome Vaccine</synonym>
        <synonym>Autologous Total Tumor mRNA-NP Vaccine</synonym>
        <synonym>Autologous Total Tumor mRNA-nanoparticle Vaccine</synonym>
        <rdfs:label>Autologous Total Tumor mRNA Loaded Liposome Vaccine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C204942 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C204942">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <code>C204942</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A lipid nanoparticle (LNP) formulation encapsulating messenger RNA (mRNA) encoding the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9) protein and a single guide RNA targeting transthyretin (TTR), that may decrease serum TTR concentration. Upon administration of LNP encapsulating mRNA encoding Cas9 protein and TTR-targeting single guide RNA NTLA-2001, the LNP moiety binds to the plasma membrane of nearby cells and releases the Cas9 mRNA and the TTR-targeting single guide RNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce Cas9, which gene-edits the TTR gene in vivo, thereby lowering the levels of misfolded TTR in the blood. This may reduce the accumulation of misfolded TTR protein in the tissues.</definition>
        <name>Lipid Nanoparticle Encapsulating mRNA Encoding Cas9 Protein and TTR-targeting Single Guide RNA NTLA-2001</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>LNP Encapsulating mRNA Encoding Cas9 Protein and TTR-targeting Single Guide RNA NTLA-2001</synonym>
        <synonym>Lipid Nanoparticle Encapsulating mRNA Encoding Cas9 Protein and TTR-targeting Single Guide RNA NTLA-2001</synonym>
        <synonym>NTLA 2001</synonym>
        <synonym>NTLA-2001</synonym>
        <synonym>NTLA2001</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulating mRNA Encoding Cas9 Protein and TTR-targeting Single Guide RNA NTLA-2001</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C205639 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C205639">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431"/>
        <code>C205639</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticle (LNP) encapsulating self-replicating RNA (srRNA) encoding human interleukin-12 (IL-12), with potential immunomodulatory and antineoplastic activities. Upon intratumoral injection of LNP encapsulated srRNA encoding human IL-12 STX-001, the LNPs bind to the plasma membrane of nearby tumor cells and release srRNA encoding IL-12 into the tumor cells. The srRNA amplifies within the tumor cells, and is translated by the cellular protein translation machinery to produce IL-12, which is secreted into the local tumor microenvironment (TME). The secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may enhance immune-mediated destruction of tumor cells and decrease tumor cell proliferation.</definition>
        <name>Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 STX-001</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>LNP Encapsulated srRNA Encoding Human IL-12 STX-001</synonym>
        <synonym>LNP-formulated Self-replicating RNA Encoding IL-12 STX-001</synonym>
        <synonym>Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 STX-001</synonym>
        <synonym>STX 001</synonym>
        <synonym>STX-001</synonym>
        <synonym>STX001</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulated Self-replicating RNA Encoding Human IL-12 STX-001</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C208191 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C208191">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <code>C208191</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>A preparation of one or more cell type(s) that is meant to be administered to a patient for a specific therapeutic effect.</definition>
        <name>Cell Therapy Agent</name>
        <semanticType>Cell</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Cell Therapy Agent</synonym>
        <synonym>Cell-based Agent</synonym>
        <rdfs:label>Cell Therapy Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C208344 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C208344">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2196"/>
        <code>C208344</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation containing an antagomir and oligonucleotide targeting microRNA-10b (miR-10b) encapsulated within a nanoparticle consisting of an iron oxide core that is coated with dextran, with potential antineoplastic activity. Upon administration of microRNA-10b antagomir-iron oxide/dextran-based nanoparticle TTX-MC138, the anti-miR-10b moiety targets and binds to miR-10b inside tumor cells. This inhibits miR-10b and kills miR-10b-overexpressing tumor cells. This may inhibit tumor progression and metastasis. miR-10b, a non-coding RNA that is highly expressed in a variety of metastatic tumor cells, plays a key role in tumor cell migration, invasion and metastasis. The dextran coated iron oxide nanoparticles allow for an increased half-life, decreased clearance and increased tumor cell uptake.</definition>
        <name>MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-miR-10b Nanoparticle TTX-MC138</synonym>
        <synonym>MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138</synonym>
        <synonym>MicroRNA-10b Inhibitor TTX-MC138</synonym>
        <synonym>MicroRNA-10b-targeted Nanoparticle-based Formulation TTX-MC138</synonym>
        <synonym>TTX MC138</synonym>
        <synonym>TTX-MC138</synonym>
        <synonym>TTXMC138</synonym>
        <synonym>miR-10b Antagomir-containing Iron Oxide-based Nanoparticle TTX-MC138</synonym>
        <synonym>miR-10b Inhibitor TTX-MC138</synonym>
        <rdfs:label>MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20985 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20985">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C49236"/>
        <code>C20985</code>
        <conceptInSubset>CDISC SDTM Procedure Terminology</conceptInSubset>
        <conceptInSubset>CDISC SDTM Terminology</conceptInSubset>
        <conceptInSubset>CPTAC Codelists Terminology</conceptInSubset>
        <conceptInSubset>CPTAC Terminology</conceptInSubset>
        <conceptInSubset>CPTAC Treatments Codelist</conceptInSubset>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <definition>Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by surgery, chemical destruction, morbid process, or noxious substance.</definition>
        <name>Ablation Therapy</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>ABLATION</synonym>
        <synonym>Ablation</synonym>
        <synonym>Ablation Therapy</synonym>
        <synonym>Ablation, NOS</synonym>
        <synonym>Catheter Ablation</synonym>
        <synonym>Local Ablation Therapy</synonym>
        <synonym>Local Ablative Therapy</synonym>
        <synonym>ablation</synonym>
        <rdfs:label>Ablation Therapy</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C210897 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C210897">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201688"/>
        <code>C210897</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation consisting of lipid nanoparticle (LNP)-encapsulated small interfering ribonucleic acid (siRNA) targeting beta-catenin, with potential antineoplastic activity. Upon administration of LNP encapsulating beta-catenin siRNA ALN-BCAT, the LNP formulation delivers the siRNA particles to the tumor cells where the beta-catenin siRNA targets and binds to beta-catenin mRNA. This results in the inhibition of the translation and expression of beta-catenin. This disrupts beta-catenin-dependent oncogenic signaling and prevents the transcription of Wnt target genes that regulate the proliferation, migration, invasion, and the metastatic potential of tumor cells, as well as genes regulating the immunosuppression of the tumor microenvironment (TME). Dysregulation of the Wnt/beta-catenin signaling pathway is found in a variety of tumors and drives oncogenesis.</definition>
        <name>Lipid Nanoparticle Encapsulating Beta-catenin siRNA ALN-BCAT</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ALN BCAT</synonym>
        <synonym>ALN-BCAT</synonym>
        <synonym>ALNBCAT</synonym>
        <synonym>Beta-catenin-targeting RNA Interference Therapeutic ALN-BCAT</synonym>
        <synonym>Beta-catenin-targeting RNAi Therapeutic ALN-BCAT</synonym>
        <synonym>LNP Encapsulating Beta-catenin siRNA ALN-BCAT</synonym>
        <synonym>Lipid Nanoparticle Encapsulating Beta-catenin siRNA ALN-BCAT</synonym>
        <rdfs:label>Lipid Nanoparticle Encapsulating Beta-catenin siRNA ALN-BCAT</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2114 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2114">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1590"/>
        <code>C2114</code>
        <definition>A blistering agent primarily containing sulfur and chlorine groups that alkylates DNA to form DNA crosslinks, causing inhibition of DNA synthesis.</definition>
        <name>Mustard Agent</name>
        <semanticType>Classification</semanticType>
        <synonym>Mustard Agent</synonym>
        <rdfs:label>Mustard Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2115 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2115">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2161"/>
        <code>C2115</code>
        <definition>An antineoplastic agent that either covalently or noncovalently binds to the minor groove of DNA, causing inhibition of DNA synthesis. (NCI)</definition>
        <name>DNA Minor Groove Binding Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>DNA Minor Groove Binding Agent</synonym>
        <rdfs:label>DNA Minor Groove Binding Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211533 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211533">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1892"/>
        <code>C211533</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An orally bioavailable nanoparticle-based formulation containing curcumin, a poorly water-soluble phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties, including antineoplastic, chemopreventive, antioxidant, anti-angiogenic, neuroprotective and anti-inflammatory activities. Upon oral administration, nanocurcumin blocks the formation of reactive-oxygen species (ROS), neutralizes free radicals, and prevents oxidative stress and DNA damage. Curcumin possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation, and inhibits the activity of nuclear factor-kappa B (NF-kB), and the NF-kB-mediated signaling pathway. This decreases the production of inflammatory mediators, such as interferon-gamma (IFNg). It disrupts various cell signal transduction pathways involved in carcinogenesis and prevents the expression of many transcription factors, and modulates the expression of many genes and proteins involved in tumor cell proliferation, invasion and angiogenesis. It also induces tumor cell apoptosis. It may also modulate the immune system, enhance an immune response against tumor cells, and may decrease regulatory T-cells (Tregs). This may prevent and/or inhibit tumor cell formation and proliferation. Compared to the very poorly absorbed curcumin alone, this nanoformulation may have greater bioavailability, an improved pharmacokinetic profile and increased efficacy.</definition>
        <name>Nanocurcumin</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Curcumin Nanoformulation</synonym>
        <synonym>Curcumin-based Nanoformulation</synonym>
        <synonym>Nanocurcumin</synonym>
        <rdfs:label>Nanocurcumin</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211940 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211940">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C163758"/>
        <code>C211940</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any agent that targets claudin 6 (CLDN6).</definition>
        <name>CLDN6-targeting Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CLDN6-targeting Agent</synonym>
        <synonym>Claudin 6-targeting Agent</synonym>
        <rdfs:label>CLDN6-targeting Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211959 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211959">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C211940"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C28227"/>
        <code>C211959</code>
        <definition>A bispecific antibody targeting both the tumor-associated antigen (TAA) claudin-6 (CLDN6) and the T-cell surface antigen CD3.</definition>
        <name>Anti-CLDN6/Anti-CD3 Bispecific Antibody</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Anti-CD3/Anti-CLDN6 Monoclonal Antibody</synonym>
        <synonym>Anti-CLDN6 x Anti-CD3 Bispecific Antibody</synonym>
        <synonym>Anti-CLDN6/Anti-CD3 Bispecific Antibody</synonym>
        <synonym>Anti-CLDN6/CD3 Bispecific Antibody</synonym>
        <synonym>Anti-Claudin-6/Anti-CD3 Bispecific Antibody</synonym>
        <synonym>CLDN6 x CD3 Bispecific Antibody</synonym>
        <synonym>CLDN6/CD3 Bispecific Antibody</synonym>
        <synonym>CLDN6/CD3-directed Bispecific Antibody</synonym>
        <rdfs:label>Anti-CLDN6/Anti-CD3 Bispecific Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2122 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2122">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C2122</code>
        <definition>An agent that either induces or inhibits the differentiation or maturation of cells, specifically neoplastic cells, resulting in decreases in tumor growth and metastasis. (NCI04)</definition>
        <name>Cell Differentiating Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Cell Differentiating Agent</synonym>
        <rdfs:label>Cell Differentiating Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2124 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2124">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1446"/>
        <code>C2124</code>
        <definition>Compounds comprised of a radioactive agent linked to a pharmacological substance to be used to prevent, diagnose, or treat various diseases, including cancer. (NCI)</definition>
        <name>Radioconjugate</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Radio Conjugates</synonym>
        <synonym>Radioconjugate</synonym>
        <rdfs:label>Radioconjugate</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213366 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213366">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <code>C213366</code>
        <definition>Any gene therapy agent that uses plasmid to carry genes into host cells.</definition>
        <name>Plasmid-based Gene Therapy Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Plasmid DNA-based Gene Therapy Agent</synonym>
        <synonym>Plasmid Vector-based Gene Therapy Agent</synonym>
        <synonym>Plasmid-based Gene Therapy Agent</synonym>
        <rdfs:label>Plasmid-based Gene Therapy Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C213431</code>
        <definition>Any agent that contains, expresses or produces any form of the cytokine interleukin-12 (IL12; IL-12).</definition>
        <name>IL-12-based Therapeutic Agent</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>IL-12-based Agent</synonym>
        <synonym>IL-12-based Therapeutic Agent</synonym>
        <synonym>Interleukin-12-based Agent</synonym>
        <rdfs:label>IL-12-based Therapeutic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2139 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2139">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C2139</code>
        <definition>Substances that stimulate the immune system.</definition>
        <name>Immunostimulant</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Immunostimulant</synonym>
        <synonym>Immunostimulating Agent</synonym>
        <synonym>immunostimulant</synonym>
        <rdfs:label>Immunostimulant</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2150 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2150">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C471"/>
        <code>C2150</code>
        <definition>Any substance that inhibits ribonucleotide reductase, an enzyme that catalyzes the conversion of ribonucleoside diphosphates to deoxyribonucleotide diphosphate precursors for de novo DNA synthesis. Inhibition of ribonucleotide reductase can cause inhibition of DNA synthesis and cell growth.</definition>
        <name>Ribonucleotide Reductase Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Ribonucleotide Reductase Inhibitor</synonym>
        <rdfs:label>Ribonucleotide Reductase Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2161 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2161">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2842"/>
        <code>C2161</code>
        <definition>An agent that binds covalently or non-covalently in the major or minor groove of DNA and can disrupt DNA replication.</definition>
        <name>DNA Groove Binding Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>DNA Groove Binding Agent</synonym>
        <rdfs:label>DNA Groove Binding Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2163 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2163">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2842"/>
        <code>C2163</code>
        <definition>An agent capable of attaching to DNA with a covent bond. DNA adduct forming agents cause disruption of DNA replication and mitosis.</definition>
        <name>DNA Adduct Forming Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>DNA Adduct Forming Agent</synonym>
        <rdfs:label>DNA Adduct Forming Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2189 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2189">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C2189</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>A substance that inhibits kinase enzymes and other proteins involved in signal transduction pathways to prevent tumor cell growth and induce apoptosis.</definition>
        <name>Signal Transduction Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Signal Transduction Inhibitor</synonym>
        <synonym>signal transduction inhibitor</synonym>
        <rdfs:label>Signal Transduction Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2196 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2196">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C2196</code>
        <definition>An agent that prevents or impairs tumor metastasis.</definition>
        <name>Antimetastatic Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Antimetastatic Agent</synonym>
        <rdfs:label>Antimetastatic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2198 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2198">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C241"/>
        <code>C2198</code>
        <definition>Nonopioid agents that produce an analgesic effect, such as NSAIDs.</definition>
        <name>Nonnarcotic Analgesic</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Nonnarcotic Analgesic</synonym>
        <synonym>nonopioid</synonym>
        <rdfs:label>Nonnarcotic Analgesic</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2201 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2201">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61074"/>
        <code>C2201</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any substance that inhibits mammalian target of rapamycin (mTOR or FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)), a serine/threonine protein kinase that is active in the control of cell growth, cell proliferation, and cell motility. Inhibition of mTOR can inhibit cell proliferation.</definition>
        <name>mTOR Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>mTOR Inhibitor</synonym>
        <rdfs:label>mTOR Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C221 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C221">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1916"/>
        <code>C221</code>
        <definition>A family or group of nitrogen-containing base compounds primarily derived from plant and animal sources. Many alkaloids are used medicinally, including cancer therapy.</definition>
        <name>Alkaloid</name>
        <semanticType>Organic Chemical</semanticType>
        <synonym>Alkaloid</synonym>
        <synonym>Alkaloids</synonym>
        <synonym>alkaloid</synonym>
        <rdfs:label>Alkaloid</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C241 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C241">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C78272"/>
        <code>C241</code>
        <definition>Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.</definition>
        <name>Analgesic Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Analgesic Agent</synonym>
        <synonym>Analgesic Drugs</synonym>
        <synonym>Analgesics</synonym>
        <synonym>Anodynes</synonym>
        <synonym>Antinociceptive Agents</synonym>
        <synonym>Pain-relief Medication</synonym>
        <synonym>analgesic</synonym>
        <rdfs:label>Analgesic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C25218 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C25218">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C16203"/>
        <code>C25218</code>
        <conceptInSubset>BRIDG Attribute Terminology</conceptInSubset>
        <conceptInSubset>BRIDG Terminology</conceptInSubset>
        <conceptInSubset>CDISC Glossary Terminology</conceptInSubset>
        <conceptInSubset>CDISC MRCT Center Clinical Research Glossary</conceptInSubset>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <conceptInSubset>GDC Property Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>ICDC Property Terminology</conceptInSubset>
        <conceptInSubset>ICDC Terminology</conceptInSubset>
        <conceptInSubset>NICHD Terminology</conceptInSubset>
        <conceptInSubset>Neonatal Research Network Terminology</conceptInSubset>
        <conceptInSubset>Operational Ontology for Radiation Oncology Prostate Cancer Terminology</conceptInSubset>
        <definition>An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.</definition>
        <name>Intervention or Procedure</name>
        <semanticType>Health Care Activity</semanticType>
        <synonym>Clinical Intervention or Procedure</synonym>
        <synonym>Intervention</synonym>
        <synonym>Intervention Strategies</synonym>
        <synonym>Intervention or Procedure</synonym>
        <synonym>Interventional</synonym>
        <synonym>Interventional Procedure Type</synonym>
        <synonym>Procedure</synonym>
        <synonym>intervention</synonym>
        <synonym>interventionDescription</synonym>
        <synonym>procedure</synonym>
        <synonym>study intervention</synonym>
        <synonym>treatment type</synonym>
        <synonym>treatment_type</synonym>
        <rdfs:label>Intervention or Procedure</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C259 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C259">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C186664"/>
        <code>C259</code>
        <definition>An antibiotic, or its derivative, that can kill or inhibit the growth of tumor cells. Antineoplastic antibiotics can interfere with the normal function of cellular nucleic acids and proteins.</definition>
        <name>Antineoplastic Antibiotic</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Anticancer Antibiotic</synonym>
        <synonym>Anticancer Antibiotics</synonym>
        <synonym>Antineoplastic Antibiotic</synonym>
        <synonym>Antineoplastic Antibiotics</synonym>
        <synonym>Antitumor Antibiotic</synonym>
        <synonym>Antitumor Antibiotics</synonym>
        <synonym>anticancer antibiotic</synonym>
        <synonym>antineoplastic antibiotics</synonym>
        <synonym>antitumor antibiotics</synonym>
        <rdfs:label>Antineoplastic Antibiotic</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C25974 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C25974">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C273"/>
        <code>C25974</code>
        <definition>Any agent that binds to tubulin molecules and interferes with the microtubule assembly and disassembly dynamic. A tubulin binding agent impedes cell division and can be used to treat a variety of cancers.</definition>
        <name>Tubulin Binding Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Tubulin Binding Agent</synonym>
        <synonym>Tubulin Binding Agents</synonym>
        <synonym>antimicrotubule agent</synonym>
        <rdfs:label>Tubulin Binding Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C26170 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C26170">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C26170</code>
        <definition>A class of agents used in prophylactic or curative therapy to attenuate the negative side effects of toxins or drugs. Protective agents belong to various chemical classes, acting through various pharmacological mechanisms. They may neutralize exogenous poisons, coat mucosa for protection against physical or chemical damage, offer antioxidant protection against free radicals or ionizing radiation, or induce endogenous detoxifying enzymes. (NCI04)</definition>
        <name>Protective Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Protective Agent</synonym>
        <synonym>Protective Drug</synonym>
        <rdfs:label>Protective Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C267 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C267">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C78272"/>
        <code>C267</code>
        <definition>A pharmacological agent that prevents nausea and/or vomiting.</definition>
        <name>Antiemetic Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Anti-emetic Agent</synonym>
        <synonym>Antiemetic Agent</synonym>
        <synonym>Antiemetic Drugs</synonym>
        <synonym>Antiemetics</synonym>
        <synonym>antiemetic</synonym>
        <rdfs:label>Antiemetic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2688 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2688">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C2688</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>HemOnc Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.</definition>
        <name>Nab-paclitaxel</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ABI 007</synonym>
        <synonym>ABI-007</synonym>
        <synonym>ABI007</synonym>
        <synonym>Abraxane</synonym>
        <synonym>Albumin-Stabilized Nanoparticle Paclitaxel</synonym>
        <synonym>Albumin-bound Paclitaxel</synonym>
        <synonym>Nab-paclitaxel</synonym>
        <synonym>Nanoparticle Albumin-bound Paclitaxel</synonym>
        <synonym>Nanoparticle Paclitaxel</synonym>
        <synonym>Naveruclif</synonym>
        <synonym>Paclitaxel Albumin</synonym>
        <synonym>Paclitaxel Nanoparticle Albumin-bound</synonym>
        <synonym>Paclitaxel Protein-Bound</synonym>
        <synonym>Paclitaxel nanoparticle albumin-bound</synonym>
        <synonym>Protein-bound Paclitaxel</synonym>
        <synonym>nanoparticle paclitaxel</synonym>
        <synonym>paclitaxel albumin-stabilized nanoparticle formulation</synonym>
        <synonym>protein-bound paclitaxel</synonym>
        <rdfs:label>Nab-paclitaxel</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C272 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C272">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C186664"/>
        <code>C272</code>
        <definition>An antineoplastic agent with a structural similarity to a natural substance that can replace that substance in a normal biochemical pathway and interfere with the normal metabolic processes of cells.</definition>
        <name>Antimetabolite</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Antimetabolite</synonym>
        <synonym>Antimetabolites</synonym>
        <synonym>antimetabolite</synonym>
        <rdfs:label>Antimetabolite</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C273 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C273">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C186664"/>
        <code>C273</code>
        <definition>An agent that inhibits tumor growth by interfering with mitotic processes or the assembly of the mitotic machinery.</definition>
        <name>Antimitotic Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Antimitotic Agent</synonym>
        <synonym>Antimitotic Drugs</synonym>
        <synonym>Antimitotics</synonym>
        <synonym>Microtubular Function Inhibitors</synonym>
        <synonym>Mitosis Inhibitor Agents</synonym>
        <synonym>Mitosis Inhibitor Drugs</synonym>
        <synonym>Mitosis Inhibitors</synonym>
        <synonym>Mitotic Inhibitor Agents</synonym>
        <synonym>Mitotic Inhibitor Drugs</synonym>
        <synonym>Mitotic Inhibitors</synonym>
        <synonym>mitotic inhibitor</synonym>
        <rdfs:label>Antimitotic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C274</code>
        <conceptInSubset>AML Total Dose Table</conceptInSubset>
        <conceptInSubset>AML Variable Terminology</conceptInSubset>
        <conceptInSubset>GCT Total Dose Table</conceptInSubset>
        <conceptInSubset>GCT Variable Terminology</conceptInSubset>
        <conceptInSubset>HL Total Dose Table</conceptInSubset>
        <conceptInSubset>HL Variable Terminology</conceptInSubset>
        <conceptInSubset>OS Total Dose Table</conceptInSubset>
        <conceptInSubset>OS Variable Terminology</conceptInSubset>
        <conceptInSubset>Operational Ontology for Radiation Oncology Prostate Cancer Terminology</conceptInSubset>
        <definition>A substance that inhibits the maturation, growth or spread of tumor cells.</definition>
        <name>Antineoplastic Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>ANTINEOPLASTIC_AGENT</synonym>
        <synonym>Anti-Cancer Agents</synonym>
        <synonym>Anti-Tumor Agents</synonym>
        <synonym>Anti-Tumor Drugs</synonym>
        <synonym>Antineoplastic Agent</synonym>
        <synonym>Antineoplastic Drug</synonym>
        <synonym>Antineoplastic Drugs</synonym>
        <synonym>Antineoplastics</synonym>
        <synonym>Antiproliferative Agents</synonym>
        <synonym>Antiproliferative Drugs</synonym>
        <synonym>Cancer Drug</synonym>
        <synonym>Chemotherapeutic Agents, Neoplastic Disease</synonym>
        <synonym>Tumor-Specific Treatment Agents</synonym>
        <synonym>antineoplastic</synonym>
        <synonym>chemotherapeutic agent</synonym>
        <rdfs:label>Antineoplastic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C275 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C275">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C26170"/>
        <code>C275</code>
        <conceptInSubset>PQ/CMC Excipient Function Terminology</conceptInSubset>
        <definition>A group of organic or inorganic substances capable of preventing the genotoxic and carcinogenic effects of free-radical compounds. Antioxidants bind to and neutralize (&apos;scavenge&apos;) free radicals, thereby transforming them into non-toxic compounds and blocking their genotoxic and carcinogenic effects. This class of agents includes the vitamins C and E, the carotenoids, and selenium. Organic antioxidants are found in high concentrations in fruits, seeds and vegetables.</definition>
        <name>Antioxidant</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Antioxidant</synonym>
        <synonym>antioxidant</synonym>
        <rdfs:label>Antioxidant</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C28227 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C28227">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1454"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20401"/>
        <code>C28227</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any monoclonal antibody that targets two different antigens. A bispecific monoclonal antibody is made up of two different monoclonal antibodies or antibody fragments and contains two different antigen-binding sites.</definition>
        <name>Bispecific Monoclonal Antibody</name>
        <semanticType>Classification</semanticType>
        <synonym>Bispecific Monoclonal Antibody</synonym>
        <synonym>bispecific monoclonal antibody</synonym>
        <rdfs:label>Bispecific Monoclonal Antibody</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2842 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2842">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C186664"/>
        <code>C2842</code>
        <definition>DNA binding molecules regulate mechanisms central to cellular function, including DNA replication and gene expression. Many small molecules that mimic or block these processes offer potential therapeutic agents. Understanding how complexation affects both the structural and mechanical properties of DNA is an important step towards understanding the functional mechanisms of binding agents, and may also provide a key to more rational drug design. There are three major classes of binding modes: intercalation, groove binding and covalent crosslinking.</definition>
        <name>DNA Binding Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>DNA Binding Agent</synonym>
        <rdfs:label>DNA Binding Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2843 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2843">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1904"/>
        <code>C2843</code>
        <definition>Any substance based on the structure of camptothecin that stabilizes topoisomerase I-DNA covalent complexes, thereby causing DNA damage and apoptosis.</definition>
        <name>Camptothecin Analogue</name>
        <semanticType>Chemical Viewed Structurally</semanticType>
        <synonym>Camptothecin Analog</synonym>
        <synonym>Camptothecin Analogue</synonym>
        <synonym>camptothecin analogue</synonym>
        <rdfs:label>Camptothecin Analogue</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C28681 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C28681">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C142078"/>
        <code>C28681</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A population of lymphocytes isolated from an individual, altered in vitro, and returned to the same individual for therapeutic purposes. (NCI04)</definition>
        <name>Therapeutic Autologous Lymphocytes</name>
        <semanticType>Cell</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Autologous T-cells</synonym>
        <synonym>Therapeutic Autologous Lymphocytes</synonym>
        <rdfs:label>Therapeutic Autologous Lymphocytes</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C29726 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C29726">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <code>C29726</code>
        <definition>Synthetic enzyme or mixture of enzymes used to replace or supplement enzymes to treat enzyme deficiency or to promote healthy body functions.</definition>
        <name>Enzyme Replacement or Supplement Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Enzyme Replacement Agent</synonym>
        <synonym>Enzyme Replacement or Supplement Agent</synonym>
        <rdfs:label>Enzyme Replacement or Supplement Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C307</code>
        <conceptInSubset>BRIDG Class Terminology</conceptInSubset>
        <conceptInSubset>BRIDG Terminology</conceptInSubset>
        <conceptInSubset>CDISC Glossary Terminology</conceptInSubset>
        <conceptInSubset>CDISC Protocol Terminology</conceptInSubset>
        <conceptInSubset>CDISC SDTM Intervention Type Terminology</conceptInSubset>
        <conceptInSubset>CDISC SDTM Terminology</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <conceptInSubset>NICHD Terminology</conceptInSubset>
        <conceptInSubset>Pediatric Rheumatology Terminology</conceptInSubset>
        <definition>Biotechnology-derived pharmaceutical agents made from living organisms or their products. Includes recombinant proteins, monoclonal antibodies, and nucleic acids.</definition>
        <name>Biological Agent</name>
        <semanticType>Classification</semanticType>
        <synonym>BIOLOGIC</synonym>
        <synonym>Biologic</synonym>
        <synonym>Biological Agent</synonym>
        <synonym>Biological Drug</synonym>
        <synonym>Biological Products</synonym>
        <synonym>Biologicals</synonym>
        <synonym>Biologics</synonym>
        <synonym>Biopharmaceuticals</synonym>
        <synonym>Immunologic, Immunochemical</synonym>
        <synonym>Immunologics</synonym>
        <synonym>biologic agent</synonym>
        <synonym>biological agent</synonym>
        <synonym>biological drug</synonym>
        <synonym>biological product</synonym>
        <rdfs:label>Biological Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C308</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>Operational Ontology for Radiation Oncology Prostate Cancer Terminology</conceptInSubset>
        <definition>Any substance that induces, enhances, restores or suppresses the host&apos;s immune system, or an agent that utilizes or is derived from a component of the immune system.</definition>
        <name>Immunotherapeutic Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>BRM</synonym>
        <synonym>Biological Response Modifier</synonym>
        <synonym>Biomodulators</synonym>
        <synonym>Immune Mediators</synonym>
        <synonym>Immune Modulators</synonym>
        <synonym>Immune Regulators</synonym>
        <synonym>Immunomodulating Agent</synonym>
        <synonym>Immunomodulators</synonym>
        <synonym>Immunomodulatory Agent</synonym>
        <synonym>Immunopotentiators</synonym>
        <synonym>Immunotherapeutic Agent</synonym>
        <synonym>Immunotherapeutic Drug</synonym>
        <synonym>Immunotherapy</synonym>
        <synonym>Immunotherapy Agent</synonym>
        <rdfs:label>Immunotherapeutic Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C360 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C360">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1932"/>
        <code>C360</code>
        <conceptInSubset>PQ/CMC Excipient Function Terminology</conceptInSubset>
        <definition>An inorganic or organic molecule which binds metal ions. Metal chelators are frequently polydentate, indicating that they form multiple bonds with the metal ion, resulting in more stable coordination complexes.</definition>
        <name>Chelating Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Chelating Agent</synonym>
        <synonym>Chelating agent</synonym>
        <synonym>Chelators</synonym>
        <synonym>Metal Chelant</synonym>
        <synonym>Metal Chelating Agent</synonym>
        <synonym>Metal Chelator</synonym>
        <synonym>chelating agent</synonym>
        <rdfs:label>Chelating Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C38140 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C38140">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C390"/>
        <code>C38140</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A synthetic ultrasmall superparamagnetic iron oxide composed of dextran-coated iron oxide nanoparticles (also known as &apos;ultrasmall particulate iron oxides&apos; or USPIO). Ferumoxtran-10, which accumulates in non-cancerous lymphatic tissue, is used as a molecular resonance imaging (MRI) contrast agent. (NCI04)</definition>
        <name>Ferumoxtran-10</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Combidex</synonym>
        <synonym>Ferumoxtran-10</synonym>
        <synonym>USPIO</synonym>
        <synonym>Ultrasmall Particulate Iron Oxide</synonym>
        <synonym>ferumoxtran-10</synonym>
        <rdfs:label>Ferumoxtran-10</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C390 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C390">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1966"/>
        <code>C390</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NICHD Terminology</conceptInSubset>
        <conceptInSubset>Newborn Screening Terminology</conceptInSubset>
        <definition>Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue.</definition>
        <name>Contrast Agent</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Contrast</synonym>
        <synonym>Contrast Agent</synonym>
        <synonym>Contrast Drugs</synonym>
        <synonym>Contrast Medium</synonym>
        <synonym>contrast material</synonym>
        <rdfs:label>Contrast Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C39438 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C39438">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C19729"/>
        <code>C39438</code>
        <definition>The Jonsson Comprehensive Cancer Center conducts basic, clinical, and cancer prevention research, while providing the latest treatments to patients, while training the next generation of medical researchers. The Center is developing new technologies for early detection and classification of cancers, combining nanotechnology, systems biology, and molecular imaging. It is affiliated with University of California, Los Angeles and was designated as an NCI comprehensive cancer center in 1974.</definition>
        <name>Jonsson Comprehensive Cancer Center</name>
        <semanticType>Health Care Related Organization</semanticType>
        <synonym>JCCC</synonym>
        <synonym>Jonsson Comprehensive Cancer Center</synonym>
        <synonym>Jonsson Comprehensive Cancer Center of University of California Los Angeles</synonym>
        <synonym>The UCLA&apos;s Jonsson Comprehensive Cancer Center</synonym>
        <rdfs:label>Jonsson Comprehensive Cancer Center</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43359 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43359">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20181"/>
        <code>C43359</code>
        <definition>Any number of entities (members) considered as a unit.</definition>
        <name>Group</name>
        <semanticType>Group</semanticType>
        <synonym>Group</synonym>
        <synonym>Panel</synonym>
        <rdfs:label>Group</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43431 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C43431">
        <code>C43431</code>
        <conceptInSubset>BRIDG Class Terminology</conceptInSubset>
        <conceptInSubset>BRIDG Terminology</conceptInSubset>
        <conceptInSubset>MD Anderson Symptom Inventory - Head and Neck</conceptInSubset>
        <definition>An active process; excludes processes and mechanisms which fulfill biological functions.</definition>
        <name>Activity</name>
        <semanticType>Activity</semanticType>
        <synonym>Activity</synonym>
        <synonym>General activity</synonym>
        <rdfs:label>Activity</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C45678 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C45678">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1908"/>
        <code>C45678</code>
        <definition>Natural or synthetic substances that are used in various industries or in laboratories for a broad range of applications. This group includes, but is not limited to, pharmaceutical excipients, research/diagnostic agents, agricultural agents, and other non-edible products that may have human health implication.</definition>
        <name>Industrial Aid</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Industrial Additive</synonym>
        <synonym>Industrial Aid</synonym>
        <rdfs:label>Industrial Aid</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C471 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C471">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C471</code>
        <definition>A pharmacological agent that inhibits the catalytic activity of an enzyme.</definition>
        <name>Enzyme Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Enzyme Antagonist</synonym>
        <synonym>Enzyme Inhibitor</synonym>
        <synonym>Enzyme Inhibitor Agent</synonym>
        <synonym>Enzyme Inhibitor Drug</synonym>
        <rdfs:label>Enzyme Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C48203 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C48203">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1708"/>
        <code>C48203</code>
        <definition>A complex consisting of a therapeutic entity coupled to a nanoparticle entity that has an external coating designed to deliver the therapeutic to a precise location in the body. This complex is useful because of the ability to deliver drugs in a controlled fashion to a specific site of interest. Conjugates such as this are also utilized as imaging and contrast agents for MRI and other imaging studies.</definition>
        <name>Nanoparticle-targeted Drug</name>
        <semanticType>Conceptual Entity</semanticType>
        <synonym>Nanoparticle-targeted Drug</synonym>
        <rdfs:label>Nanoparticle-targeted Drug</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C48415 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C48415">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C48415</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A biodegradable poly(ethylene glycol)-poly(D,L-lactide) copolymer micelle nanoparticle-entrapped formulation of paclitaxel with antineoplastic activity. Paclitaxel promotes microtubule assembly and prevents depolymerization, thus interfering with normal mitosis. The copolymer residue increases the water-solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone.</definition>
        <name>Paclitaxel-Loaded Polymeric Micelle</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Cynviloq TM</synonym>
        <synonym>Genexol PM</synonym>
        <synonym>IG-001</synonym>
        <synonym>Paclitaxel-Loaded Polymeric Micelle</synonym>
        <synonym>paclitaxel-loaded polymeric micelle</synonym>
        <rdfs:label>Paclitaxel-Loaded Polymeric Micelle</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C48803 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C48803">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1913"/>
        <code>C48803</code>
        <conceptInSubset>FDA Structured Product Labeling Terminology</conceptInSubset>
        <conceptInSubset>PQ/CMC Substance Classification Terminology</conceptInSubset>
        <conceptInSubset>SPL Substance Indexing Terminology</conceptInSubset>
        <definition>A substance made up of variable numbers of repeating structural units linked through covalent bonds.</definition>
        <name>Polymer</name>
        <semanticType>Chemical Viewed Structurally</semanticType>
        <synonym>POLYMER SUBSTANCE</synonym>
        <synonym>Polymer</synonym>
        <synonym>Polymeric</synonym>
        <synonym>Polymeric Macromolecules</synonym>
        <synonym>Polymers</synonym>
        <synonym>polymer</synonym>
        <rdfs:label>Polymer</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C49178 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C49178">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213366"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213431"/>
        <code>C49178</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based formulation composed of a non-viral plasmid DNA vector encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) encapsulated in a biodegradable, biocompatible lipoplex composed of polyethylene glycol (PEG), polyethylenimine (PEI), and cholesterol, with potential immunoactivating and antineoplastic activities. Upon intraperitoneal (IP) delivery of the PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector IMNN-001, the lipoplex is endocytosed by nearby cells, and the plasmid DNA is transported into the nucleus, which leads to local expresssion of IL-12. In turn, the increased IL-12 production at the tumor site activates the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and promoting cytotoxic T-cell responses against tumor cells.</definition>
        <name>PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>GEN 1</synonym>
        <synonym>GEN-1</synonym>
        <synonym>GEN1</synonym>
        <synonym>IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer</synonym>
        <synonym>IMNN 001</synonym>
        <synonym>IMNN-001</synonym>
        <synonym>IMNN001</synonym>
        <synonym>Nanoparticle-encased IL-12 DNA Plasmid Vector</synonym>
        <synonym>PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001</synonym>
        <synonym>phIL-12-005</synonym>
        <rdfs:label>PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C49236 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C49236">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C25218"/>
        <code>C49236</code>
        <conceptInSubset>Breast Cancer Treatment Outcomes Scale-Cosmetic Status</conceptInSubset>
        <conceptInSubset>CDISC Glossary Terminology</conceptInSubset>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>Canine Glioma Project Property Terminology</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <conceptInSubset>GDC Property Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>ICDC Property Terminology</conceptInSubset>
        <conceptInSubset>ICDC Terminology</conceptInSubset>
        <conceptInSubset>NICHD Terminology</conceptInSubset>
        <conceptInSubset>Newborn Screening Terminology</conceptInSubset>
        <conceptInSubset>Operational Ontology for Radiation Oncology Prostate Cancer Terminology</conceptInSubset>
        <definition>Medical care intended to treat or cure a condition or lessen its symptoms. This includes the administration of drugs, surgical procedures, physical or psychotherapy, or the use of therapeutic devices.</definition>
        <name>Therapeutic Procedure</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>TREAT</synonym>
        <synonym>TX</synonym>
        <synonym>Therapeutic</synonym>
        <synonym>Therapeutic Interventions</synonym>
        <synonym>Therapeutic Method</synonym>
        <synonym>Therapeutic Procedure</synonym>
        <synonym>Therapeutic Technique</synonym>
        <synonym>Therapy</synonym>
        <synonym>Treatment</synonym>
        <synonym>any therapy</synonym>
        <synonym>any_therapy</synonym>
        <synonym>therapy</synonym>
        <synonym>treatment</synonym>
        <synonym>treatment or therapy</synonym>
        <synonym>treatment_or_therapy</synonym>
        <rdfs:label>Therapeutic Procedure</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C574 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C574">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C574</code>
        <conceptInSubset>GDC Property Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <name>Immunosuppressant</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Immunosuppressant</synonym>
        <synonym>Immunosuppressive Agents</synonym>
        <synonym>immunosuppressant</synonym>
        <synonym>immunosuppressive</synonym>
        <synonym>immunosuppressive treatment type</synonym>
        <synonym>immunosuppressive_treatment_type</synonym>
        <rdfs:label>Immunosuppressant</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C587 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C587">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C593"/>
        <code>C587</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.</definition>
        <name>Recombinant Interleukin-2</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>HUMAN INTERLEUKIN-2</synonym>
        <synonym>IL-2</synonym>
        <synonym>Interleukin II</synonym>
        <synonym>Interleukin-2</synonym>
        <synonym>Lymphocyte Mitogenic Factor</synonym>
        <synonym>Mitogenic Factor</synonym>
        <synonym>Recombinant Interleukin-2</synonym>
        <synonym>Recombinant interleukin-2</synonym>
        <synonym>Ro-236019</synonym>
        <synonym>T-Cell Growth Factor</synonym>
        <synonym>TCGF</synonym>
        <synonym>TSF</synonym>
        <synonym>Thymocyte Stimulating Factor</synonym>
        <synonym>interleukin-2</synonym>
        <rdfs:label>Recombinant Interleukin-2</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C592 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C592">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C593"/>
        <code>C592</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A recombinant protein which is chemically identical to or similar to endogenous interleukin-7 (IL-7) with hematopoietic and immunopotentiating properties. Produced by bone marrow, thymic stromal, and spleen cells, the cytokine interleukin-7 is a hematopoietic growth factor for progenitor B cells and T cells and stimulates proliferation and differentiation of mature T-cells and Natural Killer cells. (NCI05)</definition>
        <name>Recombinant Interleukin-7</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CYT 99 007</synonym>
        <synonym>IL-7</synonym>
        <synonym>Lymphopoietin-1</synonym>
        <synonym>Recombinant Human Interleukin-7</synonym>
        <synonym>Recombinant Interleukin-7</synonym>
        <rdfs:label>Recombinant Interleukin-7</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C593 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C593">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1283"/>
        <code>C593</code>
        <definition>Formulated therapeutic analogs of one of a number of endogenous cytokine interleukins. Produced by T cells, macrophages, and other cells, interleukins bind to a specific surface receptor on immunohematopoietic cells, thereby inducing a multitude of biologic effects including stimulation of growth, differentiation, and proliferation of lymphocytes and eosinophils; activation of lymphocytes and macrophages; enhancement of mast cell activity; activation of the acute phase response; and stimulation of hematopoiesis. Some interleukins may enhance the host&apos;s immune response to malignant cells by stimulating lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL), which are capable of lysing some tumor cells. (NCI04)</definition>
        <name>Recombinant Interleukin</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Interleukins</synonym>
        <synonym>Recombinant Interleukin</synonym>
        <rdfs:label>Recombinant Interleukin</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61074 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61074">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1404"/>
        <code>C61074</code>
        <definition>Any substance that inhibits serine/threonine protein kinase, an enzyme that phosphorylates the hydroxyl group of serine or threonine on various proteins in various signaling cascades. Inhibition of serine/threonine protein kinase can inhibit cell proliferation and induce apoptosis.</definition>
        <name>Serine/Threonine Kinase Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Serine/Threonine Kinase Inhibitor</synonym>
        <rdfs:label>Serine/Threonine Kinase Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C61078</code>
        <definition>Any formulation containing paclitaxel, an antimitotic taxane.</definition>
        <name>Paclitaxel Preparation</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Paclitaxel Preparation</synonym>
        <rdfs:label>Paclitaxel Preparation</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62308 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62308">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1913"/>
        <code>C62308</code>
        <definition>A small, stable particle whose size is measured in nanometers. These particles are used in various biomedical applications in which they can be utilized as drug carriers or imaging agents. Various targeting agents, such as antibodies, drugs, imaging agents, and reporters can be attached to the surface of a nanoparticle.</definition>
        <name>Nanoparticle</name>
        <semanticType>Physical Object</semanticType>
        <synonym>Nanoparticle</synonym>
        <synonym>nanoparticle</synonym>
        <rdfs:label>Nanoparticle</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62309 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62309">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C20368"/>
        <code>C62309</code>
        <definition>The utilization of small (&lt;100 nm), stable particles in a variety of technologies. Based on an understanding of chemical, biological and physical phenomena at the nanoscale level, processes are employed to create new nanoparticle technologies.</definition>
        <name>Nanoparticle Application</name>
        <semanticType>Activity</semanticType>
        <synonym>Nanoparticle Application</synonym>
        <rdfs:label>Nanoparticle Application</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62310 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62310">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62309"/>
        <code>C62310</code>
        <definition>The use of nanoparticles for therapeutic applications in a clinical setting.</definition>
        <name>Clinical Nanoparticle Application</name>
        <semanticType>Activity</semanticType>
        <synonym>Clinical Nanoparticle Application</synonym>
        <rdfs:label>Clinical Nanoparticle Application</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62311 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62311">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62310"/>
        <code>C62311</code>
        <definition>This method entails the attachment of a drug to the surface of nanoparticles. The role of the nanoparticle is to facilitate delivery of the drug to a cellular target that it would not reach in its free form.</definition>
        <name>Nanoparticle-Mediated Drug Delivery</name>
        <semanticType>Activity</semanticType>
        <synonym>Nano Drug Delivery</synonym>
        <synonym>Nanoparticle Mediated Drug Delivery</synonym>
        <synonym>Nanoparticle-Mediated Drug Delivery</synonym>
        <rdfs:label>Nanoparticle-Mediated Drug Delivery</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62312 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62312">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62364"/>
        <code>C62312</code>
        <definition>Nanoscale hollow polymeric vessels that have the potential to be utilized to selectively deliver hydrophobic drugs to specific sites within individual cells.</definition>
        <name>Nanocontainer</name>
        <semanticType>Manufactured Object</semanticType>
        <synonym>Nanocontainer</synonym>
        <rdfs:label>Nanocontainer</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62358 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62358">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C360"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C390"/>
        <code>C62358</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <definition>A coordination complex consisting of a gadolinium ion bound to a hexadentate organic chelating agent such as diethylenetriaminepentaacetic acid. Chelates of gadolinium are frequently utilized as magnetic resonance imaging (MRI) contrast agents and can be used to track nanoparticle-mediated drug delivery.</definition>
        <name>Gadolinium-Chelate</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Gadolinium Coordination Complex</synonym>
        <synonym>Gadolinium-Chelant Complex</synonym>
        <synonym>Gadolinium-Chelate</synonym>
        <synonym>Gadolinium-based Contrast Agent</synonym>
        <rdfs:label>Gadolinium-Chelate</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62364 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62364">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1913"/>
        <code>C62364</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>A nanoparticle bound to another moiety of interest via a chemical or physical interaction.</definition>
        <name>Nanoparticle Complex</name>
        <semanticType>Classification</semanticType>
        <synonym>Nanoparticle Complex</synonym>
        <rdfs:label>Nanoparticle Complex</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62366 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62366">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62364"/>
        <code>C62366</code>
        <definition>A functional macromolecule composed of nanoscale components.</definition>
        <name>Nanodevice</name>
        <semanticType>Classification</semanticType>
        <synonym>Nano-device</synonym>
        <synonym>Nanodevice</synonym>
        <rdfs:label>Nanodevice</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62367 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62367">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62366"/>
        <code>C62367</code>
        <definition>An explosive device comprised of carbon nanotubes. These nanoscale devices have desirable optical and thermal properties that can be exploited for novel cancer therapeutics. The ability to manipulate these properties facilitates a controlled, localized activation and clearance mechanism of diseased or abnormal cells.</definition>
        <name>Nanobomb</name>
        <semanticType>Classification</semanticType>
        <synonym>Nanobomb</synonym>
        <rdfs:label>Nanobomb</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62375 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62375">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62364"/>
        <code>C62375</code>
        <definition>A nanoparticle composed of a metallic shell surrounding a semiconductor. When nanoshells reach a target cancer cell, they can be irradiated with near-infrared light or excited with a magnetic field; either of these exposures will cause the nanoshell to become hot, thereby killing the cancer cell. The metal spheres can absorb or scatter light at several wavelengths, making them well-suited for several clinical applications.</definition>
        <name>Nanoshell</name>
        <semanticType>Classification</semanticType>
        <synonym>Nanoshell</synonym>
        <rdfs:label>Nanoshell</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62379 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62379">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62308"/>
        <code>C62379</code>
        <definition>The classification of discrete nanoparticle entities.</definition>
        <name>Nanoparticle Type</name>
        <semanticType>Classification</semanticType>
        <synonym>Kind of nanoparticle</synonym>
        <synonym>Nanoparticle Type</synonym>
        <rdfs:label>Nanoparticle Type</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62384 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62384">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C48803"/>
        <code>C62384</code>
        <definition>A microscopic vesicle consisting of one or more phospholipid layers surrounding an aqueous core. Liposomes can be utilized to facilitate the delivery of nanoparticles with attached therapeutic agents to biological targets such as specific cells or organs.</definition>
        <name>Liposome Vesicle</name>
        <semanticType>Chemical Viewed Structurally</semanticType>
        <synonym>LV</synonym>
        <synonym>Liposome Vesicle</synonym>
        <synonym>MLV</synonym>
        <synonym>Multilamellar Liposome Vesicles</synonym>
        <synonym>SUV</synonym>
        <synonym>Small Unilamellar Vesicles</synonym>
        <rdfs:label>Liposome Vesicle</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62388 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62388">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62379"/>
        <code>C62388</code>
        <definition>Self-assembling durable silica spheres that fit inside each other. These spheres range in size from 2 to 50 nanometers and form within seconds. They are small enough to be introduced into the body and have uniform pores that facilitate the controlled release of drugs. The spheres also have the capability to absorb both organic and inorganic substances. For example, nanoparticles can absorb small particles of iron, thereby allowing magnetic control. Thus, the contents of nanospheres can be released upon activation.</definition>
        <name>Nanosphere</name>
        <semanticType>Classification</semanticType>
        <synonym>Nanosphere</synonym>
        <rdfs:label>Nanosphere</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62538 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62538">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1941"/>
        <code>C62538</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle delivery system for recombinant human tumor necrosis factor (TNF) consisting of recombinant TNF bound to pegylated colloidal gold nanoparticles with potential antineoplastic activity. Upon intravenous administration, colloidal gold-bound recombinant human TNF travels through the bloodstream, avoiding immune detection and uptake by the reticuloendothelial system because of nanoparticle pegylation. Due to their size, the colloidal gold nanoparticles exit the circulatory system only at hyperpermeable tumor neovasculature sites; TNF then binds to and activates tumor cell TNF receptors, which may result in an increase in tumor cell apoptosis and a reduction in tumor cell proliferation. Compared to the administration of unbound TNF, colloidal gold-bound TNF may improve the efficacy and safety of TNF administration by delivering TNF specifically to tumor tissue.</definition>
        <name>Colloidal Gold-Bound Tumor Necrosis Factor</name>
        <semanticType>Amino Acid, Peptide, or Protein</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Aurimmune</synonym>
        <synonym>CYT-6091</synonym>
        <synonym>Colloidal Gold-Bound Recombinant Human Tumor Necrosis Factor</synonym>
        <synonym>Colloidal Gold-Bound Tumor Necrosis Factor</synonym>
        <synonym>TNF-bound colloidal gold</synonym>
        <synonym>colloidal gold-bound TNF</synonym>
        <synonym>colloidal gold-bound rhTNF</synonym>
        <synonym>colloidal gold-bound tumor necrosis factor</synonym>
        <rdfs:label>Colloidal Gold-Bound Tumor Necrosis Factor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62597 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62597">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1752"/>
        <code>C62597</code>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A peptide vaccine, containing nanoparticles of cholesteryl hydrophobized pullulan (CHP) complexed with the tumor-associated antigen HER-2/neu (ErbB-2), with potential antineoplastic activity. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumors, including breast, ovarian, and gastric cancers. Vaccination with CHP-HER-2 peptide vaccine may stimulate the host immune system to mount a humoral as well as a cytotoxic T-cell response against tumor cells expressing the HER-2/neu antigen. This results in an inhibition of tumor cell proliferation and tumor cell death. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water.</definition>
        <name>CHP-HER-2 Peptide Vaccine</name>
        <semanticType>Immunologic Factor</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CHP-HER-2 Peptide Vaccine</synonym>
        <synonym>Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146</synonym>
        <rdfs:label>CHP-HER-2 Peptide Vaccine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62598 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62598">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1663"/>
        <code>C62598</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A peptide cancer vaccine containing nanoparticles of cholesteryl hydrophobized pullulan (CHP) complexed with the cancer-testis antigen NY-ESO-1 protein, with potential immunostimulating and antineoplastic activities. Upon administration, CHP-NY-ESO-1 peptide vaccine IMF-001 may stimulate the host immune system to mount a humoral and cytotoxic T-cell response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water. NY-ESO-1, an antigen found in normal testis, is upregulated in various cancers, including bladder, breast, hepatocellular, melanoma, and prostate cancers.</definition>
        <name>CHP-NY-ESO-1 Peptide Vaccine IMF-001</name>
        <semanticType>Immunologic Factor</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CHP-NY-ESO-1 Peptide Vaccine IMF-001</synonym>
        <synonym>Cholesteryl Pullulan-NY-ESO-1 Vaccine IMF-001</synonym>
        <synonym>IMF-001</synonym>
        <rdfs:label>CHP-NY-ESO-1 Peptide Vaccine IMF-001</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62634 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62634">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C12218"/>
        <code>C62634</code>
        <definition>Any regimen that can be used for the treatment of cancer and non-neoplastic disease.</definition>
        <name>Chemo/immuno/hormone Therapy Regimen</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Chemo/immuno/hormone Therapy Regimen</synonym>
        <rdfs:label>Chemo/immuno/hormone Therapy Regimen</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C63358 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C63358">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62634"/>
        <code>C63358</code>
        <definition>Any regimen that can be used for the treatment of breast cancer.</definition>
        <name>Regimen Used to Treat Breast Carcinoma</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Regimen Used to Treat Breast Carcinoma</synonym>
        <rdfs:label>Regimen Used to Treat Breast Carcinoma</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C63360 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C63360">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62634"/>
        <code>C63360</code>
        <definition>Any regimen that can be used for the treatment of non-small cell lung carcinoma (NSCLC).</definition>
        <name>Regimen Used to Treat Non-Small Cell Lung Carcinoma</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Chemo(immuno)therapy Regimen Used to Treat NSCLC</synonym>
        <synonym>Chemotherapy Regimen Used to Treat Non-Small Cell Lung Cancer</synonym>
        <synonym>Regimen Used to Treat Non-Small Cell Lung Carcinoma</synonym>
        <rdfs:label>Regimen Used to Treat Non-Small Cell Lung Carcinoma</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C66943 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C66943">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67422"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C932"/>
        <code>C66943</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An emulsion containing the tartrate salt of the semisynthetic vinca alkaloid vinorelbine with antineoplastic activity. Vinorelbine binds to tubulin, inhibiting tubulin polymerization into microtubules; cell division is prevented, the cell cycle is arrested metaphase and cell death ensues. In this formulation vinorelbine is emulsified in a homogeneous suspension of nanoparticles, which protects the venous endothelium from coming into direct contact with the active ingredient, potentially reducing vinorelbine-associated venous toxicity at the venous injection site.</definition>
        <name>Vinorelbine Tartrate Emulsion</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ANX-530</synonym>
        <synonym>Vinorelbine Tartrate Emulsion</synonym>
        <synonym>Vinorelbine Tartrate Injectable Emulsion</synonym>
        <rdfs:label>Vinorelbine Tartrate Emulsion</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67422 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67422">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C25974"/>
        <code>C67422</code>
        <definition>Any of a class of anti-mitotic compounds that bind to the vinca site of the beta tubulin subunit, a region located within the middle domain of the tubulin structure and corresponding with a residue sequence approximating 177-215. The agent binds to the vinca site to produce a conformational change in the protofilament structure and at high concentrations, to induce the formation of spirals and crystal aggregates; these changes impair the polymerization of tubulin dimers and thereby, prevent the assembly of microtubules. The subsequent decrease in the amount of formed microtubules causes disassembly of the mitotic spindle resulting from instability of the structure during the mitotic interphase, eventually leading to cell cycle arrest and/or apoptosis. Vinca-site binding agents include natural compounds isolated from the periwinkle (Catharanthus roseus, formally, Vinca roseus) plant and synthetic compounds.</definition>
        <name>Vinca-Domain Binding Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Vinca-Domain Binding Agent</synonym>
        <synonym>Vinca-Domain Binding Agents</synonym>
        <synonym>Vinca-Site Binding Agent</synonym>
        <synonym>Vinca-Site Binding Agents</synonym>
        <rdfs:label>Vinca-Domain Binding Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C25974"/>
        <code>C67437</code>
        <definition>Any of a class of anti-mitotic compounds that bind to the taxane site of the beta-tubulin subunit, a region described as a binding pocket located within the middle domain and corresponding to an approximate residue sequence of 217-231. Specifically, these agents bind to a cysteine residue within the pocket, which is also the binding site for GTP. Agents binding at the taxane site promote the polymerization of dimers to form a very rigid and stable microtubule structure which is not readily disassembled. By interfering with microtubule dynamics these agents inhibit the normal turnover process essential during mitosis, thereby causing cell-cycle arrest and/or apoptosis.</definition>
        <name>Taxane-Pocket Binding Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Taxane-Pocket Binding Agent</synonym>
        <synonym>Taxane-Site Binding Agent</synonym>
        <rdfs:label>Taxane-Pocket Binding Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67502 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67502">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1594"/>
        <code>C67502</code>
        <definition>A compound drug containing doxorubicin as an active ingredient.</definition>
        <name>Doxorubicin Preparation</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Doxorubicin Preparation</synonym>
        <rdfs:label>Doxorubicin Preparation</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C68566 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C68566">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C62379"/>
        <code>C68566</code>
        <definition>Nanoparticles that have been functionalized with chemical amine groups and dextran. These particles have been utilized as magnetic resonance imaging agents and as probes to investivate thrombosis and tumor vasculature in conjunction with a CREKA peptide (cys-arg-glu-lys-ala).</definition>
        <name>SPIO Nanoparticle</name>
        <semanticType>Physical Object</semanticType>
        <synonym>Amino Dextran-Coated Iron Oxide Particle</synonym>
        <synonym>SPIO</synonym>
        <synonym>SPIO Nanoparticle</synonym>
        <rdfs:label>SPIO Nanoparticle</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C697 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C697">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2114"/>
        <code>C697</code>
        <definition>A mustard agent containing nitrogen and chlorine atoms.</definition>
        <name>Nitrogen Mustard Compound</name>
        <semanticType>Classification</semanticType>
        <synonym>Nitrogen Mustard Compound</synonym>
        <rdfs:label>Nitrogen Mustard Compound</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C71696 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C71696">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1742"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C71696</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle albumin-bound formulation of the taxane docetaxel with antineoplastic activity. Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. This nanoparticle albumin-bound formulation solubilizes docetaxel without the use of the nonionic solubilizer Cremophor ELP, permitting the administration of larger doses of docetaxel while avoiding Cremophor ELP-associated toxicity.</definition>
        <name>Nanoparticle Albumin-Bound Docetaxel</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ABI-008</synonym>
        <synonym>CPO 100</synonym>
        <synonym>CPO-100</synonym>
        <synonym>CPO100</synonym>
        <synonym>DTX-HSA</synonym>
        <synonym>Docetaxel Albumin-bound</synonym>
        <synonym>Nab-Docetaxel</synonym>
        <synonym>Nanoparticle Albumin-Bound Docetaxel</synonym>
        <rdfs:label>Nanoparticle Albumin-Bound Docetaxel</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C718 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C718">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1913"/>
        <code>C718</code>
        <definition>Molecule that contains atoms of the element carbon, usually combined with itself and with atoms of one or more other element such as hydrogen, oxygen, nitrogen, sulfur, phosphorus, chlorine, or fluorine. Excludes carbides, carbonates and carbon oxides.</definition>
        <name>Organic Chemical</name>
        <semanticType>Classification</semanticType>
        <semanticType>Organic Chemical</semanticType>
        <synonym>Organic Chemical</synonym>
        <rdfs:label>Organic Chemical</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C74065 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C74065">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1742"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2201"/>
        <code>C74065</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>HemOnc Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.</definition>
        <name>Sirolimus Albumin-bound Nanoparticles</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ABI 009</synonym>
        <synonym>ABI-009</synonym>
        <synonym>ABI009</synonym>
        <synonym>Albumin-bound Sirolimus</synonym>
        <synonym>Fyarro</synonym>
        <synonym>Nab-Rapamycin</synonym>
        <synonym>Nab-sirolimus</synonym>
        <synonym>Nanoparticle Albumin-Bound Rapamycin</synonym>
        <synonym>Nanoparticle Albumin-bound Sirolimus</synonym>
        <synonym>Sirolimus Albumin-bound Nanoparticles</synonym>
        <synonym>Sirolimus Albumin-bound Particles</synonym>
        <synonym>Sirolimus Protein-bound Particles</synonym>
        <synonym>Sirolimus protein-bound particles</synonym>
        <rdfs:label>Sirolimus Albumin-bound Nanoparticles</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C74526 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C74526">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129824"/>
        <code>C74526</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>Any agent that inhibits functions of heat shock proteins (Hsp). Hsps are a group of homodimeric molecular chaperones that interact with a diverse group of proteins, assisting in their folding and in the elimination of any misfolded or damaged molecules. Although transiently expressed during cell cycle in normal cells, Hsps are constitutively elevated in various types of cancer which raises the apoptosis threshold of these tumor cells and provides protection against cytotoxic agents. Hsp inhibitors may destabilize, and facilitate degradation of proto-oncoproteins leading to reversal of apoptosis regulation and cell death.</definition>
        <name>Heat Shock Protein Inhibitor</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Heat Shock Protein Inhibitor</synonym>
        <synonym>Hsp Inhibitor</synonym>
        <rdfs:label>Heat Shock Protein Inhibitor</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C78272 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C78272">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1909"/>
        <code>C78272</code>
        <definition>An agent that exerts a physiologic effect on neurotransmission or on any anatomic entity that is part of the nervous system, including the central nervous system (CNS) and peripheral nervous system (PNS).</definition>
        <name>Agent Affecting Nervous System</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Agent Affecting Nervous System</synonym>
        <rdfs:label>Agent Affecting Nervous System</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C78450 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C78450">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C201688"/>
        <code>C78450</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A proprietary transferrin receptor-targeted nanoparticle preparation of a non-chemically modified small-interfering RNA (siRNA) directed against the M2 subunit of ribonucleotide reductase (RRM2) with potential antineoplastic activity. Upon administration, transferrin receptor-targeted anti-RRM2 siRNA CALAA-01 binds to transferrin receptors (TfRs), releasing anti-RRM2 siRNA after endocytosis; anti-RRM2 siRNA silences the expression of RRM2 via the RNAi pathway, impeding the assembly of the holoenzyme ribonucleotide reductase (RR) which catalyzes the production of deoxyribonucleotides. As a result, inhibition of cellular proliferation may occur in cells expressing TfR, a cell surface protein overexpressed on various cancer cell types.</definition>
        <name>Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>CALAA-01</synonym>
        <synonym>Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01</synonym>
        <rdfs:label>Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C798 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C798">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C274"/>
        <code>C798</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <definition>An agent that makes tumor cells more sensitive to radiation therapy.</definition>
        <name>Radiosensitizing Agent</name>
        <semanticType>Chemical Viewed Functionally</semanticType>
        <synonym>Radiation Sensitizers</synonym>
        <synonym>Radiation-Sensitizing Agents</synonym>
        <synonym>Radiation-Sensitizing Drugs</synonym>
        <synonym>Radiosensitizers</synonym>
        <synonym>Radiosensitizing Agent</synonym>
        <synonym>Radiosensitizing Drugs</synonym>
        <synonym>radiosensitizer</synonym>
        <rdfs:label>Radiosensitizing Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C802 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C802">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C45678"/>
        <code>C802</code>
        <definition>Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance.</definition>
        <name>Reagent</name>
        <semanticType>Indicator, Reagent, or Diagnostic Aid</semanticType>
        <synonym>Reagent</synonym>
        <synonym>reagent</synonym>
        <rdfs:label>Reagent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C804 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C804">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129820"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1934"/>
        <code>C804</code>
        <definition>A group of agents that includes retinol (Vitamin A) and related compounds with potential antineoplastic and/or chemopreventive activities. A retinoic acid agent binds to and/or activates specific nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), thereby modulating transcription of genes responsible for cell differentiation and proliferation. A retinoic acid agent may exhibit immunomodulatory and anti-inflammatory properties and may inhibit ornithine decarboxylase, resulting in a decrease in polyamine synthesis and keratinization. (NCI04)</definition>
        <name>Retinoic Acid Agent</name>
        <semanticType>Classification</semanticType>
        <synonym>Retinoic Acid Agent</synonym>
        <synonym>Retinoic Acid and Derivatives</synonym>
        <synonym>Retinoic Acids</synonym>
        <synonym>Retinoid</synonym>
        <synonym>Retinoids</synonym>
        <synonym>retinoid</synonym>
        <rdfs:label>Retinoic Acid Agent</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C82391 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C82391">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1742"/>
        <code>C82391</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A lipid nanoparticle formulation containing two small interfering RNAs (siRNAs) for kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF) with potential antitumor activity. Upon intravenous administration, the siRNAs in KSP/VEGF siRNAs ALN-VSP02ALN bind to both KSP and VEGF messenger RNAs (mRNAs), preventing translation of KSP and VEGF proteins; this may result in growth inhibition of tumor cells that overexpress KSP and VEGF. VEGF and KSP are upregulated in many tumor cells and play an important role in tumor proliferation and survival.</definition>
        <name>Anti-KSP/Anti-VEGF siRNAs ALN-VSP02</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ALN-VSP02</synonym>
        <synonym>Anti-KSP/Anti-VEGF siRNAs ALN-VSP02</synonym>
        <rdfs:label>Anti-KSP/Anti-VEGF siRNAs ALN-VSP02</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C82676 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C82676">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C2843"/>
        <code>C82676</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>HemOnc Agent Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A liposomal dispersion formulated with the semisynthetic camptothecin analogue irinotecan, provided as the hydrochloride trihydrate form, which is encapsulated and entrapped within liposomes in a gelated or precipitated state as the irinotecan sucrose octasulfate (sucrosulfate) salt form, with potential antineoplastic activity. Upon administration of the liposomes containing irinotecan sucrosulfate, irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. During the S-phase, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell, extends the circulation of irinotecan, and prolongs the duration of active therapy at the site of tumor to inhibit tumor growth.</definition>
        <name>Irinotecan Sucrosofate</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>IRINOTECAN SUCROSOFATE</synonym>
        <synonym>Irinotecan Liposome</synonym>
        <synonym>Irinotecan Sucrosofate</synonym>
        <synonym>Irinotecan Sucrosofate Liposome</synonym>
        <synonym>Irinotecan Sucrosofate-containing Pegylated Liposomal Formulation</synonym>
        <synonym>Irinotecan liposome</synonym>
        <synonym>MM 398</synonym>
        <synonym>MM-398</synonym>
        <synonym>MM398</synonym>
        <synonym>Nanoliposomal Irinotecan</synonym>
        <synonym>Nanoliposomal Irinotecan as Sucrosofate</synonym>
        <synonym>Nanoparticle Liposome Formulation of Irinotecan</synonym>
        <synonym>Onivyde</synonym>
        <synonym>PEP 02</synonym>
        <synonym>PEP-02</synonym>
        <synonym>PEP02</synonym>
        <synonym>inotecan Hydrochloride as Sucrosulfate Salt Form Liposomal Formulation</synonym>
        <synonym>nal-IRI</synonym>
        <rdfs:label>Irinotecan Sucrosofate</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C82691 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C82691">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C156880"/>
        <code>C82691</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>An orally bioavailable nanoparticle albumin-bound inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AB-010 selectively binds to Hsp90, inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This agent may inhibit the growth of a wide variety of cancer cell types; the incorporation of albumin into its formulation may facilitate its endothelial transcytosis through the gp60-regulated albumin transport pathway. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding and degradation of many oncogenic signaling proteins.</definition>
        <name>Hsp90 Inhibitor AB-010</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>AB-010</synonym>
        <synonym>Heat Shock Protein 90 Inhibitor AB-010</synonym>
        <synonym>Hsp90 Inhibitor AB-010</synonym>
        <rdfs:label>Hsp90 Inhibitor AB-010</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C85476 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C85476">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1450"/>
        <code>C85476</code>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based prodrug formulation consisting of polymeric micelles incorporating the inorganic platinum agent cisplatin with potential antineoplastic activity. In demplatin pegraglumer, cisplatin forms a polymer-metal complex with hydrophilic polyethylene glycol poly(glutamic acid) block copolymers by attaching to the micelle inner core consisting of the hydrophobic polyamino acids. Upon cell entry and release from the polymer-metal complex, cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-linking, DNA-protein cross-linking and, subsequently, tumor cell apoptosis and growth inhibition. Due to the hydrophilic nature of polyethylene glycol, this formulation increases the water-solubility of cisplatin and decreases the nephrotoxicity and neurotoxicity associated with the administration of cisplatin alone.</definition>
        <name>Demplatin Pegraglumer</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>DEMPLATIN PEGRAGLUMER</synonym>
        <synonym>Demplatin Pegraglumer</synonym>
        <synonym>NC-6004</synonym>
        <synonym>Nanoplatin</synonym>
        <rdfs:label>Demplatin Pegraglumer</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C88264 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C88264">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1962"/>
        <code>C88264</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation composed of DOTAP:cholesterol liposome nanoparticles complexed with the plasmid C-VISA BiKDD, with potential antineoplastic activity. C-VISA BikDD: liposome consists of a pancreatic-cancer-specific expression vector VISA (VP16-GAL4-WPRE integrated systemic amplifier) and a pancreatic-cancer-specific promoter CCKAR (cholecystokinin type A receptor) (CCKAR-VISA or C-VISA) which drives expression of the gene BikDD, a mutant form of the potent proapoptotic gene Bik (Bcl-2 interacting killer). Upon administration and transduction into pancreatic tumor cells, expression of BikDD by C-VISA BikDD:liposome may induce pancreatic tumor cell apoptosis and suppress pancreatic tumor cell proliferation. BikDD binds with greater affinity to anti-apoptotic proteins bcl-2, bcl-xl, bcl-w and Mcl-1 and is more potent than wild-type Bik. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at molar ratio of 1:1.</definition>
        <name>C-VISA BikDD:Liposome</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>C-VISA BikDD Plasmid: DOTAP:Cholesterol Liposome-Based Nanoparticle</synonym>
        <synonym>C-VISA BikDD:Liposome</synonym>
        <rdfs:label>C-VISA BikDD:Liposome</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C90534 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C90534">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1742"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C90534</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation containing protein-stabilized liposome nanoparticles encapsulating the poorly water-soluble, second-generation taxane analog docetaxel with antineoplastic activity. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Compared to the use of toxic carriers to increase solubilization of docetaxel, protein-stabilized liposomal docetaxel improves drug solubility while avoiding carrier-associated toxicity.</definition>
        <name>Protein Stabilized Liposomal Docetaxel Nanoparticles</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>ATI-1123</synonym>
        <synonym>Protein Stabilized Liposomal Docetaxel Nanoparticles</synonym>
        <rdfs:label>Protein Stabilized Liposomal Docetaxel Nanoparticles</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C91074 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C91074">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1450"/>
        <code>C91074</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle formulation containing N-glutaryl phosphatidylethanolamine (NGPE)-liposomes encapsulating oxaliplatin and conjugated to the human transferrin (Tf) ligand, with potential antineoplastic activity. Upon infusion of oxaliplatin-encapsulated transferrin-conjugated NGPE liposomes, the transferrin moiety targets and binds to the Tf receptor, which is overexpressed on a variety of human cancer cells. Upon binding and internalization, oxaliplatin is released and its active derivatives alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which results in an inhibition of DNA replication and transcription. By extending the circulation time and specifically targeting transferrin receptors, this formulation may improve the efficacy and safety of oxaliplatin therapy, compared to administration of oxaliplatin alone. NGPE, a reactive phospholipid, is used as a linker to attach the Tf ligand, to the liposome.</definition>
        <name>Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>MBP-426</synonym>
        <synonym>Oxaliplatin-Encapsulated Tf-Conjugated NGPE-Liposome</synonym>
        <synonym>Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome</synonym>
        <rdfs:label>Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C91087 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C91087">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C91087</code>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A polymeric nanoparticle (PNP) formulation containing the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the PNP formulation may enhance stability and improve delivery.</definition>
        <name>Docetaxel-PNP</name>
        <semanticType>Organic Chemical</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>Docetaxel-PNP</synonym>
        <synonym>PNP-DTX</synonym>
        <rdfs:label>Docetaxel-PNP</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C91708 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C91708">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C213366"/>
        <code>C91708</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A formulation composed of DOTAP:cholesterol liposomal nanoparticles complexed with a plasmid expression cassette encoding human FUS1 protein, with potential antineoplastic activity. Upon administration, DOTAP:chol-Fus1 liposome complex accumulates mainly in the lungs and particularly in cancer cells. Upon transfer of the Fus1 gene into tumor cells, the expression of Fus1 may induce tumor cell apoptosis and suppress tumor cell proliferation. Fus1, a potent tumor-suppressor protein, is present in normal, healthy cells but often absent in certain cancer cells. DOTAP:cholesterol liposome is composed of cationic lipid dioleoyl-trimethylammonium propane (DOTAP) and cholesterol at a molar ratio of 1:1.</definition>
        <name>Quaratusugene Ozeplasmid</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>GPX 001</synonym>
        <synonym>GPX-001</synonym>
        <synonym>GPX001</synonym>
        <synonym>INGN 401</synonym>
        <synonym>QUARATUSUGENE OZEPLASMID</synonym>
        <synonym>Quaratusugene Ozeplasmid</synonym>
        <synonym>Reqorsa</synonym>
        <rdfs:label>Quaratusugene Ozeplasmid</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C923 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C923">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C307"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C308"/>
        <code>C923</code>
        <conceptInSubset>CDISC Glossary Terminology</conceptInSubset>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>Clinical Data Interchange Standards Consortium Terminology</conceptInSubset>
        <conceptInSubset>NICHD Terminology</conceptInSubset>
        <conceptInSubset>Pediatric Immunization Terminology</conceptInSubset>
        <definition>Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.</definition>
        <name>Vaccine</name>
        <semanticType>Classification</semanticType>
        <synonym>Vaccine</synonym>
        <synonym>Vaccine Therapy</synonym>
        <synonym>vaccine</synonym>
        <rdfs:label>Vaccine</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C932 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C932">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C1931"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C221"/>
        <code>C932</code>
        <name>Vinca Alkaloid Compound</name>
        <semanticType>Chemical Viewed Structurally</semanticType>
        <synonym>Vinca Alkaloid Compound</synonym>
        <synonym>Vinca Alkaloids</synonym>
        <synonym>vinca alkaloid</synonym>
        <rdfs:label>Vinca Alkaloid Compound</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C94625 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C94625">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C49236"/>
        <code>C94625</code>
        <conceptInSubset>CTRP Intervention Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <definition>A form of treatment in which heat is applied/generated through any mechanism for the purpose of treating an injury or illness.</definition>
        <name>Thermotherapy</name>
        <semanticType>Therapeutic or Preventive Procedure</semanticType>
        <synonym>Heat Therapy</synonym>
        <synonym>Thermotherapy</synonym>
        <synonym>thermotherapy</synonym>
        <rdfs:label>Thermotherapy</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C95892 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C95892">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C176017"/>
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C67437"/>
        <code>C95892</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane antigen (PSMA), with antineoplastic activity. PSMA-targeted docetaxel nanoparticles BIND-014 carry docetaxel within a matrix of polylactic acid covered with a coating of polyethylene glycol; embedded on the surface of the polyethylene glycol coating are ligands targeted to PSMA. BIND-014 allows gradual release of docetaxel upon degradation of the polylactic acid, and the PEG encapsulation escapes the host immune response while PSMA ligands on the surface restrict the cytotoxic effect to PSMA-expressing cells. Docetaxel binds to and stabilizes the beta-tubulin subunit, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. PSMA is a cell-surface antigen that is abundantly present on the surface of cancer cells and on the neovasculature that feeds a wide variety of tumor types.</definition>
        <name>PSMA-targeted Docetaxel Nanoparticles BIND-014</name>
        <semanticType>Organic Chemical</semanticType>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>BIND-014</synonym>
        <synonym>PSMA-targeted Docetaxel Nanoparticles BIND-014</synonym>
        <rdfs:label>PSMA-targeted Docetaxel Nanoparticles BIND-014</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C96037 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C96037">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C61078"/>
        <code>C96037</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A nanoparticle-based injectable concentrate containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon reconstitution and administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and allows for administration of higher doses resulting in higher concentrations of paclitaxel at the tumor site, and an increased safety profile.</definition>
        <name>Paclitaxel Injection Concentrate for Nanodispersion</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>PICN</synonym>
        <synonym>Paclitaxel Injection Concentrate for Nanodispersion</synonym>
        <synonym>SPARC1023</synonym>
        <synonym>SPARC1028</synonym>
        <synonym>SPARC1210</synonym>
        <rdfs:label>Paclitaxel Injection Concentrate for Nanodispersion</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C98280 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C98280">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129819"/>
        <code>C98280</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>FDA Established Names and Unique Ingredient Identifier Codes Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A suspension of nanoparticles containing inert inorganic hafnium oxide (HfO2) crystals with potential antineoplastic activity. Upon injection of NBTXR3 in the tumor, the hafnium oxide-containing nanoparticles accumulate into the tumor cells. Subsequent application of radiation beams to the tumor tissue causes HfO2 particles to emit huge amounts of electrons. This results in the formation of free radicals within the tumor cells, which in turn causes targeted destruction of the cancer cells. Compared to standard radiotherapy, because of the inert nature of NBTXR3, this agent emits electrons only during its exposure to radiation which improves radiotherapy efficiency.</definition>
        <name>Hafnium Oxide-containing Nanoparticles NBTXR3</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>HAFNIUM OXIDE</synonym>
        <synonym>Hafnium Oxide-containing Nanoparticles NBTXR3</synonym>
        <synonym>NBTXR3</synonym>
        <rdfs:label>Hafnium Oxide-containing Nanoparticles NBTXR3</rdfs:label>
    </owl:Class>
    


    <!-- http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C98288 -->

    <owl:Class rdf:about="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C98288">
        <rdfs:subClassOf rdf:resource="http://www.semanticweb.org/daniel/ontologies/2025/9/ontologia_tfg#C129821"/>
        <code>C98288</code>
        <conceptInSubset>CTRP Agent Terminology</conceptInSubset>
        <conceptInSubset>CTRP Terminology</conceptInSubset>
        <conceptInSubset>GDC Terminology</conceptInSubset>
        <conceptInSubset>GDC Therapeutic Agent Terminology</conceptInSubset>
        <conceptInSubset>GDC Value Terminology</conceptInSubset>
        <conceptInSubset>NCI Drug Dictionary Terminology</conceptInSubset>
        <conceptInSubset>NCIt Antineoplastic Agent Terminology</conceptInSubset>
        <definition>A colloidal mixture of nanoparticles consisting of small interfering RNA (siRNA) targeting the native eukaryotic translation initiation factor 5A (eIF5A), plasmids expressing a pro-apoptotic mutant of elF5A under the control of a B-cell specific promoter (B29), and a synthetic cationic polymer polyethylenimine (PEI) as a delivery vehicle, with potential antineoplastic activity. Upon administration, the siRNA component of SNS01-T suppresses elF5A expression, thereby interfering with translation of eIF5A and reducing levels of hypusinated elF5A in cancer cells. In turn, this inhibits activation of the transcription factor NF-kB and induces apoptosis. In addition, the B-cell specific plasmid component expresses an arginine substituted form of eIF5A, eIF5AK50R, which can not be hypusinated, thus leads to a selective induction of apoptosis in B-cells. The native unhypusinated form of eIF5A is pro-apoptotic and can be modified at the lysine residue, by deoxyhypusine synthase (DHS) and subsequently deoxyhypusine hydroxylase (DHH), to the anti-apoptotic hypusinated form which is associated with tumor cell growth and survival. The delivery vehicle protects the siRNA and plasmid from degradation.</definition>
        <name>SNS01-T Nanoparticles</name>
        <semanticType>Pharmacologic Substance</semanticType>
        <synonym>SNS01-T</synonym>
        <synonym>SNS01-T Nanoparticles</synonym>
        <rdfs:label>SNS01-T Nanoparticles</rdfs:label>
    </owl:Class>
</rdf:RDF>



<!-- Generated by the OWL API (version 4.5.29.2024-05-13T12:11:03Z) https://github.com/owlcs/owlapi -->

